IN THE MATTER OF

CDK GLOBAL, INC., CDK GLOBAL, LLC, AUTO/MATE, INC., ROBERT EUSTACE, ELSA EUSTACE, G. LARRY COLSON, JR., MICHAEL ESPOSITO, AND GLEN EUSTACE

COMPLAINT AND FINAL ORDER IN REGARD TO ALLEGED VIOLATIONS OF SECTION 5 OF THE FEDERAL TRADE COMMISSION ACT AND SECTION 7 OF THE CLAYTON ACT

Docket No. 9382; File No. 171 0156 Complaint, March 19, 2018 – Decision, March 26, 2018

This case addresses the \$190 million acquisition by CDK Global, Inc. of certain assets of Auto/Mate, Inc. The complaint alleges that the acquisition, if consummated, would violate Section 7 of the Clayton Act and Section 5 of the FTC Act by restraining competition in the market for dealer management systems business software ("DMS") to franchise automotive dealerships in the United States. The order dismisses the Complaint on the grounds that the Respondents terminated their Stock Purchase Agreement and withdrew the Hart-Scott-Rodino Notification and Report Forms which they filed for the acquisition.

Participants

For the Commission: James Abell, Stephen Antonio, Peggy Bayer Femenella, Michael Blevins, Alicia Burns-Wright, Maria Cirincione, Michael Franchak, Matthew Gessesse, and Janet Kim.

For the Respondents: Aidan Synnott, Paul, Weiss, Rifkind, Wharton & Garrison LLP; Lee Van Voorhis, Jenner & Block LLP.

COMPLAINT


Pursuant to the provisions of the Federal Trade Commission Act ("FTC Act"), and by virtue of the authority vested in it by the FTC Act, the Federal Trade Commission ("Commission"), having reason to believe that Respondents CDK Global, Inc. and CDK Global, LLC (collectively "CDK") and Auto/Mate, Inc. ("Auto/Mate"), Robert Eustace, Elsa Eustace, G. Larry Colson, Jr., Michael Esposito, and Glen Eustace have executed an acquisition agreement in violation of Section 5 of the FTC Act, as amended, 15 U.S.C. § 45, which if consummated would violate Section 7 of the Clayton Act, as amended, 15 U.S.C. § 18, and Section 5 of the FTC Act, and it appearing to the Commission that a proceeding by it in respect thereof would be in the public interest, hereby issues its complaint pursuant to Section 5(b) of the FTC Act, 15 U.S.C. § 45(b), and Section 11(b) of the Clayton Act, 15 U.S.C. § 21(b), stating its charges as follows:

I. NATURE OF THE CASE

- 1. Respondents are providers of dealer management systems ("DMS") for franchise (new car) dealerships. The DMS is mission-critical business software used by dealerships to manage nearly every aspect of their business, including accounting, payroll, parts and vehicle inventory, service repair scheduling, and vehicle financing. Franchise DMS providers must also obtain car manufacturer ("OEM") certifications so that the DMS can share information between the franchise dealerships and OEMs, including information about new car sales, warranty services, parts, financial performance, and labor time.
- 2. CDK and Reynolds & Reynolds ("Reynolds") are the two largest franchise DMS providers in the United States. They are also the highest priced, and have similar business models, which include long-term contracts and significant initial and monthly fees for third-party applications (app) vendors to integrate with their respective DMS.
- 3. Auto/Mate is an innovative, disruptive challenger to the two market leaders. It offers franchise dealerships a distinct value proposition, including strong functionality, low pricing, an

agnostic platform for third-party applications, extensive OEM certifications, short contracts, free software upgrades and training, and a reputation for high-quality customer service. In recent years, Auto/Mate has grown as a competitive threat in the franchise DMS market, including by specifically targeting CDK customers. Auto/Mate has consistently expanded its customer base and revenues through both aggressive pricing and adapting its differentiated product to match the preferences of many franchise dealers, placing pressure on CDK's pricing and margins. It has also developed features attractive to larger franchise dealerships and as a result, became an increasing threat to take more customers from CDK. CDK identified Auto/Mate as a current and emerging threat and responded aggressively by discounting and offering more flexible and better terms to customers.

4. In the fall of 2016 when Auto/Mate placed itself up for sale, CDK concluded that it could eliminate a strong current competitor, which was threatening to become an even more disruptive rival, by simply purchasing the company. However, CDK's plan to rid itself of a significant and growing competitive threat hit a roadblock: during the bidding process, CDK suspected that other well-financed, credible bidders recognized Auto/Mate's competitive strengths and were seriously interested in buying the company. CDK recognized that if Auto/Mate fell into the hands of a well-financed buyer willing to invest additional resources, Auto/Mate would become an even more aggressive and effective competitor. CDK was so concerned about this possibility that it



- 6. CDK's post-merger plans for Auto/Mate provide substantial additional support for the conclusion that this Acquisition will reduce competition. Post-merger, CDK plans to substantially downgrade prices, and prevent CDK's larger customers from migrating
- 7. Today, competition from Auto/Mate yields a myriad of substantial benefits to franchise dealers. Auto/Mate's presence in this market means lower prices, greater innovation, more flexible contract terms, and better service. If consummated, the Acquisition would eliminate the considerable and growing competition between CDK and Auto/Mate. It would also eliminate competition between Auto/Mate and other DMS providers, and thereby cause significant and pervasive harm to franchise dealers.
- 8. The Acquisition would entrench CDK's share of the relevant market and would significantly increase market concentration. Post-Acquisition, CDK would control approximately 47% of the franchise DMS market. Reynolds would possess approximately of the relevant market. Under the 2010 U.S. Department of Justice and Federal Trade Commission Horizontal Merger Guidelines Guidelines"), a post-merger market-concentration level above 2500 points, as measured by the Herfindahl-Hirschman Index ("HHI"), and an increase in market concentration of more than 200 points renders a merger presumptively unlawful. Acquisition market concentration would be more than 2500, and the Acquisition would increase HHIs in an already concentrated market by well over 200 points. Thus, the Acquisition is presumptively unlawful.
- 9. New entry or repositioning by existing producers would not be timely, likely, or sufficient to counteract the anticompetitive effects of the Acquisition. *De novo* entrants face considerable barriers including substantial and lengthy up-front investments in product development and OEM certification, with a high risk of failure. Similarly, existing DMS providers face substantial challenges in order to reposition to replace Auto/Mate's competitive significance, including but not limited

to, a poor or non-existent reputation among customers, software with limited functionality, limited or non-existent OEM certifications, poor service levels, constrained capacity, and high prices. In brief, the remaining firms in this market are not likely to replace the unique, substantial, and growing competitive significance of Auto/Mate in a timely way, either collectively or individually.


10. Respondents cannot show cognizable efficiencies that would offset the likely and substantial competitive harm from the Acquisition.

II. JURISDICTION

- 11. Respondents are, and at all relevant times have been, engaged in commerce or in activities affecting "commerce" as defined in Section 4 of the FTC Act, 15 U.S.C. § 44, and Section 1 of the Clayton Act, 15 U.S.C. § 12.
- 12. The Acquisition constitutes an acquisition subject to Section 7 of the Clayton Act, 15 U.S.C. § 18.

III. RESPONDENTS

13. CDK is the largest provider of franchise DMS in the United States. CDK is a publicly traded company, headquartered in Hoffman Estates, Illinois. CDK had 2017 global revenues of over \$2 billion. In the United States, CDK has DMS customers with more than franchise dealership locations (or "rooftops," the industry's preferred term).



franchise dealership rooftops. Since 2012, Auto/Mate has grown rapidly, significantly increasing its customer base year-over-year. Auto/Mate is now the fifth largest franchise DMS provider in the United States with approximately market share.

IV. THE ACQUISITION

15. Pursuant to a Stock Purchase Agreement, dated April 28, 2017, CDK proposes to acquire 100% of the shares of Auto/Mate for approximately in cash.

V. MARKET PARTICIPANTS AND INDUSTRY DYNAMICS

- 16. The United States franchise DMS market is highly concentrated with CDK and Reynolds controlling approximately 70% of the market. Dealertrack, Auto/Mate, and Autosoft round out the top five franchise DMS providers in the United States. Each of the remaining franchise DMS providers accounts for a much smaller share of the market.
- 17. CDK and Reynolds have similar business models both offer a broad set of features and OEM certifications, but both also charge relatively high prices, and both regularly require their customers to sign long-term contracts. In addition to these issues, both companies tend to charge relatively high fees for integrating third party applications, and CDK has a reputation for relatively poor customer service. Despite such business practices that frustrate some of their customers, the two market leaders have maintained dominant positions in this market.
- 18. Customers frustrated with CDK's and Reynolds's business practices have faced significant challenges in switching DMS suppliers and, historically, a lack of good alternatives to the two market leaders. In order to change DMS suppliers, franchise dealers need to spend a significant number of hours training their staff, while dealing with losses in productivity that can lead to lower sales during the transition period. Because the DMS touches essentially every aspect of a dealer's business, there is considerable risk associated with switching to a DMS that does not perform adequately. This makes customers understandably

wary of DMS suppliers without an established track record of success.

- 19. Auto/Mate is a low price, innovative company that has posted consistent, double-digit growth in recent years. A significant portion of Auto/Mate's wins in recent years have come at CDK's expense. Auto/Mate's value proposition includes but is not limited to, low prices, an ample and growing set of features, month-to-month contracts, the choice of on-site or cloud server deployment, a full roster of major OEM certifications, a low-cost agnostic platform for third-party applications, a strong reputation, and excellent customer service.
- 20. Today, no other DMS offers Auto/Mate's combination of low prices, high functionality, and strong customer service. These attributes position Auto/Mate well to effectively challenge the market leadership of CDK and Reynolds. According to its internal business documents, Auto/Mate plans to grow its market share both by continuing to aggressively court and win small franchise dealership customers as well as by continuing to expand on its recent successes in winning larger franchise dealership customers. In 2016, Auto/Mate stated it could grow
- 21. Compared to Auto/Mate, each remaining DMS provider, including Dealertrack and Autosoft, lacks important features or value, including but not limited to, low pricing, important software functionalities, important OEM certifications, month-to-month contracts, or a strong reputation. Many of these DMS providers have failed to show significant growth or have stagnated or contracted in the last several years. Many of the remaining DMS providers have significant limitations on their capacity to add and support new customers.

VI. RELEVANT MARKET

22. The relevant market is the sale of DMS for franchise dealers in the United States ("Relevant Market" or "U.S. Franchise DMS Market"). A hypothetical monopolist of the sale of all franchise DMS in the United States would find it profit-

maximizing to impose at least a small but significant and non-transitory increase in price ("SSNIP").

A. Relevant Product Market

- 23. The relevant product market in which to assess the effects of the proposed Acquisition is DMS for franchise dealers.
- 24. The DMS is a mission-critical business software that serves as the backbone of the dealer's information technology systems. Within a dealership, the DMS is used to manage nearly every aspect of the business, including accounting, payroll, parts and vehicle inventory, service repair scheduling, and vehicle financing. Much of the technology needed to run a dealership, including internet connectivity, telephones, website management, inventory, service scheduling, finance and insurance, and accounting is run or connected through the DMS. The DMS is also necessary for sharing information between the dealerships and OEMs like Ford, Audi, or Honda. This enables the dealer and OEMs to share real-time information on sales, inventory, parts, service, and warranties.
- 25. There are no reasonably interchangeable substitutes for franchise DMS, and franchise dealerships could not realistically switch to other products in the face of a SSNIP for DMS for franchise dealers.
- 26. DMS for franchise dealers has distinct qualities that other DMS products, including independent (used car) DMS does not have. A DMS for franchise dealers must have OEM certifications for the dealer to communicate with OEMs to share new car sales and parts information, and perform warranty services. Independent DMS providers and general business software do not have OEM certifications.
- 27. In addition to OEM certification, franchise dealers generally require software features tailored to franchise car dealership business operations, which are lacking in other DMS. In particular, franchise dealers demand complex automobile repair and parts software modules that independent DMS providers do not offer. In addition, independent DMS providers often lack

other software modules important to the franchise dealer, including accounting and payroll modules.

- 28. Franchise dealers do not use independent DMS providers as a competitive restraint in negotiations with franchise DMS providers. General business software programs are also not a constraint on franchise DMS providers, and franchise dealers do not use general business software as a competitive restraint in negotiations with franchise DMS providers.
- 29. Thus, DMS for franchise dealers is the relevant product market in which to analyze the Acquisition's likely effects.

B. Relevant Geographic Market

30. The relevant geographic market is the United States. Auto/Mate does not compete outside of the United States. OEM certifications are frequently limited to specific countries and many OEMs require a United States-specific certification. Because franchise DMS customers demand OEM certifications that work within their country, and those certifications are frequently nation-specific, the relevant geographic market is the United States.

VII. MARKET STRUCTURE AND THE MERGER'S PRESUMPTIVE ILLEGALITY

- 31. The U.S. Franchise DMS Market is highly concentrated, with CDK and Reynolds controlling roughly 70% of the market. CDK has approximately market share and Auto/Mate has approximately market share. Post-Acquisition, the Relevant Market would be even more highly concentrated; CDK would control nearly half the market.
- 32. The Merger Guidelines and courts often measure concentration using HHIs. HHIs are calculated by totaling the squares of the market shares of every firm in the relevant market. Under the Merger Guidelines, a merger is presumed likely to create or enhance market power and is presumptively illegal when the post-merger HHI exceeds 2,500 and the merger increases the HHI by more than 200 points.

- 33. Post-Acquisition, the Relevant Market would be substantially more highly concentrated than it is today. Post-Acquisition, CDK would control approximately 47% of this Relevant Market. Reynolds, the next largest competitor, would possess approximately of the Relevant Market. The Acquisition would result in a post-Acquisition HHI of over 2,500, and would increase concentration by well over 200 points. Therefore, the Acquisition establishes a presumption of competitive harm.
- 34. In this matter, the HHIs based on current market shares materially understate Auto/Mate's competitive significance in the Relevant Market because they do not take into consideration Auto/Mate's likely growth trajectory. Prior to the merger announcement, Auto/Mate posted significant growth year-over-year, adding new functionalities to its DMS and gaining large dealership customers. Moreover, Auto/Mate's reputation was growing in the industry and it was poised for continuing and significant growth.
- 35. The Acquisition is, therefore, presumptively unlawful under relevant case law and the Merger Guidelines.


VIII. ANTICOMPETITIVE EFFECTS: THE ACQUISITION WOULD ELIMINATE VITAL COMPETITION BETWEEN AUTO/MATE AND OTHER DMS PROVIDERS

36. The Acquisition is likely to substantially lessen competition in the Relevant Market. Auto/Mate competes aggressively against CDK today and would compete even more aggressively against CDK in the future but for the Acquisition. The merger would extinguish this competition, as well as competition between Auto/Mate and other DMS providers. The result would be higher prices, inferior service, and reduced quality and innovation.


A. Auto/Mate Competes Aggressively Against CDK Today

- 37. To successfully challenge the large incumbent DMS providers, Auto/Mate deploys aggressive sales and marketing efforts. In attempts to win CDK customers, Auto/Mate has repeatedly emphasized CDK's price increases for both its core DMS and third-party integration, CDK's restrictive contracts, and CDK's business practices in marketing blasts it sent directly to CDK customers:
 - "Pressure to increase margins has already caused prices to increase on third-party integration fees. This pressure will also cause increased prices on products for dealers directly if they have not seen it already."
 - "CDK is letting go of a substantial amount of account managers in addition to other employees" and "[t]his will surely result in decreased communications between CDK and its dealers."
 - "We believe that CDK dealers using an older web platform are being forced to migrate to a newer version and are required to pay for the cost of implementation."
 - "[I]f you are currently using an in-house server, you may be alarmed to find out that you will be forced to migrate to a cloud-based solution by January 1st, 2018."
 - "We are aware that these changes could drastically impact your bottom line. If you're tired of being locked down in an unsatisfactory contract and forced to pay for unnecessary updates, please feel free to contact me personally."
- 38. Auto/Mate also focuses on the overall price difference between Auto/Mate and CDK and Reynolds, using its website to assure prospective customers that "dealers often find their Auto/Mate monthly support bills to be 65-75 percent less than

what they're paying with Reynolds and Reynolds or CDK." Auto/Mate is successful in its attempts to target CDK and Reynolds customers. Auto/Mate touted that "[o]ver 82% of our customers are converted from CDK Global and Reynolds & Reynolds DMS systems."



- 43. Competition between CDK and Auto/Mate has substantially lowered prices for customers. The following are examples of this direct price competition:
 - In a competition between CDK, Auto/Mate and Dealertrack, a franchise dealer's consultant produced a cost comparison showing that Auto/Mate's total price over 60 months was less than Dealertrack and less than CDK's DMS. In explaining his decision to leave CDK, the franchise dealer cited the price difference as "significant" and added that the decision to leave "wasn't a very hard call."
 - A franchise dealer told CDK it was switching to Auto/Mate because "The price difference between R&R / CDK and a smaller DMS like Auto/Mate is a savings of over 60 months. That is substantial and the main reason our owners wish to go this route."
 - In competition with Auto/Mate, CDK was forced to provide a roughly discount on monthly charges (an equivalent of approximately over 60 months).




B. Auto/Mate Is Positioned to Compete Even More Aggressively in the Future Against CDK, Especially for Larger Dealership Customers

45. This Acquisition would lead to a real and significant loss of current competition. However, Auto/Mate's effect on the market is more significant than its current market share suggests, in part because of its compelling value proposition and history of continuous software innovations. These issues strongly indicate that, prior to the Acquisition, Auto/Mate was poised to become an even more aggressive and effective competitor in the Relevant Market.


46. For the past five years, Auto/Mate has been experiencing significant year-over-year rooftop growth. To drive this growth, Auto/Mate recently introduced several important functionality upgrades, including centralized accounting, which is a feature that dealerships with multiple rooftops value, and often strongly prefer. By adding centralized accounting to an already solid feature set at aggressive prices, Auto/Mate has attracted the attention of multi-rooftop dealers with very sophisticated DMS needs. Auto/Mate's introduction of centralized accounting was a and amplified its competitive threat to CDK.

47. Prior to the Acquisition's announcement, Auto/Mate was on a clear growth path and believed it was well positioned to win larger DMS franchise customers. In 2016, Auto/Mate's Chairman made its growth plans clear: "We expect that as we continue to take larger groups from CDK/R&R, that we will eventually wake the sleeping giants. Right now, we're an annoyance, and they truly think that we are not a serious competitor at dealerships of a certain size. However, they are not really aware of some of the recent changes we have made to the software, and in the coming months we will begin installing a pilot store at a very large dealer group[] that, assuming we are successful, ought to shake up the industry, at least those who are paying attention."

48. As predicted, Auto/Mate had its best year yet in 2016, the last full year prior to the Acquisition's announcement, when it won several larger dealerships and successfully started



- 49. In 2016, Auto/Mate won customers with rooftops from CDK in competitive situations. Auto/Mate also had significant success against Reynolds in 2016, winning customers with rooftops in competitive situations. Auto/Mate also won customers with rooftops from other DMS providers in competitive situations.
- 50. Auto/Mate knew its aggressive competition and strong reputation were working: "It seems that our reputation as tops in customer service, our successes at multi-store group installations, our more recent larger customer wins and some help from our competitors jacking up 3rd party integration fees has combined to create one of those 'perfect storm' moments, and we're perfectly positioned to take advantage of it."
- 51. At the end of 2016, Mike Esposito, the President and CEO of Auto/Mate highlighted to his team "We have worked very hard to get to the 'top of the hill'...we are almost on the other side. Our efforts are paying off! People don't ask anymore 'Who are you guys?' They now know who Auto/Mate is!" Mr. Esposito expected 2017 to "be the best year we have ever had."



C. The Acquisition Will Eliminate the Consumer Benefits of Head-to-Head Competition Between Auto/Mate and other DMS providers

- 53. The Acquisition would eliminate the intense head-to-head price and quality competition between CDK and Auto/Mate occurring today. Consequently, CDK would not need to compete as aggressively on price to win franchise dealer customers, and would have the incentive and ability to raise prices and lower service quality. The Acquisition would also eliminate the competition between Auto/Mate and other DMS providers, reducing the need for those providers to compete as aggressively on price, service, and innovation.
- 54. After the Acquisition, CDK and other DMS providers would face less competition to retain and gain new customers and would have less incentive to offer shorter contracts, faster software enhancements, more third-party and less expensive app integration, additional training, and better customer service. CDK was aware that it would face less competition after acquiring Auto/Mate, internally touting: "We are so serious about acquiring new customers that we bought the DMS [Auto/Mate] that has been kicking our butts."


55. Indeed, CDK was willing to pay top dollar to keep Auto/Mate out of the hands of an acquirer that would increase

Auto/Mate's already impressive growth trajectory. CDK predicted that, in the hands of a motivated and well-capitalized buyer, Auto/Mate would

To prevent this, CDK over the next highest bidder to acquire Auto/Mate, and CDK's original valuation of Auto/Mate. The gap between CDK's winning bid and its initial valuation substantially represents the defensive value to CDK of removing Auto/Mate as a competitor and preventing a well-financed alternative buyer

56. Post-Acquisition, CDK plans to severely handicap the DMS platform and remove it as a competitive alternative to CDK's other DMS products for large swaths of

from accelerating Auto/Mate's growth further.



IX. LACK OF COUNTERVAILING FACTORS

A. Barriers to Entry and Expansion

- 57. Respondents cannot demonstrate that new entry or expansion by existing firms would be timely, likely, or sufficient to offset the anticompetitive effects of the Acquisition.
- 58. New entry or repositioning by existing producers would not be timely, likely, or sufficient to counteract the anticompetitive effects of the Acquisition. *De novo* entrants into this market would face considerable barriers in replicating the competition that will be eliminated by the Acquisition. Effective entry into this market would require substantial, costly up-front investments in product development and OEM certification, and the risk of failure would be high given the substantial product development and reputational barriers to commercial success in this market. Collectively, these challenges would take many years to overcome. Auto/Mate's current success has taken many years of slow, careful growth to achieve, and new entrants would face a similarly protracted, high-risk path to success.

59. Similarly, existing DMS providers are unlikely to replace the competition that will be lost as a result of the Acquisition, because all of them lack important offerings Auto/Mate provides and that they are unlikely to develop in a timely manner if Auto/Mate is absorbed by CDK. While each firm's shortcomings are distinct, each faces real and significant challenges in becoming the next Auto/Mate. These challenges include, but are not limited to, a poor or non-existent reputation among customers, software with limited functionality, limited or non-existent OEM certifications, poor service levels, and constrained capacity. Moreover, other DMS providers are significantly higher priced than Auto/Mate and would not sufficiently replace Auto/Mate's aggressive pricing. The remaining firms in this market are not likely to replace the unique, substantial, and growing competitive significance of Auto/Mate in a timely way, either collectively or individually.

B. Efficiencies

60. Respondents have not identified and cannot demonstrate cognizable efficiencies that would be sufficient to rebut the strong presumption and evidence that Acquisition likely would substantially lessen completion in the relevant market.

X. VIOLATION

Count I – Illegal Agreement

- 61. The allegations of Paragraphs 1 through 60 above are incorporated by reference as though fully set forth herein.
- 62. The Acquisition Agreement constitutes an unfair method of competition in violation of Section 5 of the FTC Act, as amended, 15 U.S.C. § 45.

Count II—Illegal Acquisition

63. The allegations of Paragraphs 1 through 60 above are incorporated by reference as though fully set forth herein.

64. The Acquisition, if consummated, may substantially lessen competition in the relevant market in violation of Section 7 of the Clayton Act, as amended, 15 U.S.C. § 18, and is an unfair method of competition in violation of Section 5 of the FTC Act, as amended, 15 U.S.C. § 45.

NOTICE

Notice is hereby given to the Respondents that the twenty-first day of August, 2018, at 10 a.m., is hereby fixed as the time, and the Federal Trade Commission offices at 600 Pennsylvania Avenue, N.W., Room 532, Washington, D.C. 20580, as the place, when and where an evidentiary hearing will be had before an Administrative Law Judge of the Federal Trade Commission, on the charges set forth in this complaint, at which time and place you will have the right under the Federal Trade Commission Act and the Clayton Act to appear and show cause why an order should not be entered requiring you to cease and desist from the violations of law charged in the complaint.

You are notified that the opportunity is afforded you to file with the Commission an answer to this complaint on or before the fourteenth (14th) day after service of it upon you. An answer in which the allegations of the complaint are contested shall contain a concise statement of the facts constituting each ground of defense; and specific admission, denial, or explanation of each fact alleged in the complaint or, if you are without knowledge thereof, a statement to that effect. Allegations of the complaint not thus answered shall be deemed to have been admitted. If you elect not to contest the allegations of fact set forth in the complaint, the answer shall consist of a statement that you admit all of the material facts to be true. Such an answer shall constitute a waiver of hearings as to the facts alleged in the complaint and, together with the complaint, will provide a record basis on which the Commission shall issue a final decision containing appropriate findings and conclusions and a final order disposing of the proceeding. In such answer, you may, however, reserve the right to submit proposed findings and conclusions under Rule 3.46 of the Commission's Rules of Practice for Adjudicative Proceedings.

Failure to file an answer within the time above provided shall be deemed to constitute a waiver of your right to appear and to contest the allegations of the complaint and shall authorize the Commission, without further notice to you, to find the facts to be as alleged in the complaint and to enter a final decision containing appropriate findings and conclusions, and a final order disposing of the proceeding.

The Administrative Law Judge shall hold a prehearing scheduling conference not later than ten (10) days after the Respondents file their answers. Unless otherwise directed by the Administrative Law Judge, the scheduling conference and further proceedings will take place at the Federal Trade Commission, 600 Pennsylvania Avenue, N.W., Room 532, Washington, D.C. 20580. Rule 3.21(a) requires a meeting of the parties' counsel as early as practicable before the pre-hearing scheduling conference (but in any event no later than five (5) days after the Respondents file their answers). Rule 3.31(b) obligates counsel for each party, within five (5) days of receiving the Respondents' answers, to make certain initial disclosures without awaiting a discovery request.

NOTICE OF CONTEMPLATED RELIEF

Should the Commission conclude from the record developed in any adjudicative proceedings in this matter that the Merger challenged in this proceeding violates Section 5 of the Federal Trade Commission Act, as amended, and/or Section 7 of the Clayton Act, as amended, the Commission may order such relief against Respondents as is supported by the record and is necessary and appropriate, including, but not limited to:

 If the Acquisition is consummated, divestiture or reconstitution of all associated and necessary assets, in a manner that restores two or more distinct and separate, viable and independent businesses in the relevant market, with the ability to offer such products and services as CDK and Auto/Mate were offering and planning to offer prior to the Acquisition.

Final Order

- 2. A prohibition against any transaction between CDK and Auto/Mate that combines their businesses in the relevant market, except as may be approved by the Commission.
- 3. A requirement that, for a period of time, CDK and Auto/Mate provide prior notice to the Commission of acquisitions, mergers, consolidations, or any other combinations of their businesses in the relevant market with any other company operating in the relevant markets.
- 4. A requirement to file periodic compliance reports with the Commission.
- 5. Any other relief appropriate to correct or remedy the anticompetitive effects of the transaction or to restore Auto/Mate as a viable, independent competitor in the relevant market.

IN WITNESS WHEREOF, the Federal Trade Commission has caused this complaint to be signed by its Secretary and its official seal to be hereto affixed, at Washington, D.C., this nineteenth day of March, 2018.

By the Commission.

ORDER DISMISSING COMPLAINT

On March 19, 2018, the Commission issued an Administrative Complaint alleging that Respondents CDK Global, Inc. and CDK Global, LLC (collectively "CDK"), and Respondents Auto/Mate, Inc. ("Auto/Mate"), Robert Eustace, Elsa Eustace, G. Larry Colson, Jr., Michael Esposito, and Glen Eustace had executed a Stock Purchase Agreement ("Agreement") – pursuant to which CDK proposed to acquire 100% of the shares of Auto/Mate – in violation of Section 5 of the FTC Act, as amended, 15 U.S.C. § 45, and that if the acquisition covered by the Agreement were

Final Order

consummated, it would violate Section 7 of the Clayton Act, as amended, 15 U.S.C. § 18, and Section 5 of the FTC Act. Complaint Counsel and Respondents have now filed a Joint Motion to dismiss the Complaint, on the grounds that the Respondents have terminated their Stock Purchase Agreement and have withdrawn the Hart-Scott-Rodino Notification and Report Forms which they filed for the proposed acquisition.¹

The Commission has determined to dismiss the Complaint without prejudice, in light of Respondents' decision to abandon the proposed acquisition and their withdrawal of their respective Hart-Scott-Rodino Notification and Report Forms. Respondents would not be able to effectuate the proposed acquisition without filing new Hart-Scott-Rodino Notification and Report Forms, and the most important elements of the relief set out in the Notice of Contemplated Relief in the Administrative Complaint therefore have been accomplished without the need for further administrative litigation.²

For the foregoing reasons, the Commission has determined that the public interest warrants dismissal of the Administrative Complaint in this matter. The Commission has determined to do so without prejudice, however, because it is not reaching a decision on the merits. Accordingly,

IT IS ORDERED THAT the Complaint in this matter be, and it hereby is, dismissed without prejudice.

¹ See Joint Motion To Dismiss Complaint (filed March 20, 2018).

² See, e.g., In the Matter of The J.M. Smucker Company and Conagra Brands, Inc., Docket No. 9381, Order Dismissing Complaint (March 8, 2018); In the Matter of DraftKings, Inc. and FanDuel Limited, Docket No. 9375, Order Dismissing Complaint (July 14, 2017); In the Matter of Advocate Health Care Network, Advocate Health and Hospitals Corporation, and NorthShore University HealthSystem, Docket No. 9369, Order Dismissing Complaint (Mar. 20, 2017); In the Matter of The Penn State Hershey Medical Center and PinnacleHealth System, Docket No. 9368, Order Dismissing Complaint (Oct. 23, 2016); In the Matter of Superior Plus Corp. and Canexus Corporation, Docket No. 9371, Order Dismissing Complaint (Aug. 2, 2016); In the Matter of Staples Inc. and Office Depot, Inc., Docket No. 9367, Order Dismissing Complaint (May 18, 2016).

Final Order

By the Commission.

IN THE MATTER OF

BOLLMAN HAT COMPANY AND SAVEANAMERICANJOB, LLC JOINTLY D/B/A AMERICAN MADE MATTERS

CONSENT ORDER, ETC. IN REGARD TO ALLEGED VIOLATIONS OF SECTION 5 OF THE FEDERAL TRADE COMMISSION ACT

Docket No. C-4643; File No. 172 3197 Complaint, April 12, 2018 – Decision, April 12, 2018

This consent order addresses Bollman Hat Company's marketing, sale, and distribution of hats with claims that the products are of U.S.-origin, and memberships in their "American Made Matters" ("AMM") program to companies wishing to make U.S.-origin claims for their products. The complaint alleges that respondents represented that their products are "Made in USA" when, in fact, many of the respondents' hats are wholly imported, and others contain significant imported content. The complaint further alleges that the AMM seal represents by implication that respondents' products have been endorsed or certified by an independent third party, but AMM is a fictitious name for respondents, who created the AMM seal and use it in connection with the sale of their own products. The consent order prohibits respondents from making U.S.-origin claims for their products unless either: (1) the final assembly or processing of the product occurs in the United States, all significant processing that goes into the product occurs in the United States, and all or virtually all ingredients or components of the product are made and sourced in the United States; or (2) a clear and conspicuous qualification appears immediately adjacent to the representation that accurately conveys the extent to which the product contains foreign parts, ingredients or components, and/or processing.

Participants

For the Commission: Julia Solomon Ensor.

For the Respondents: Ken Vorrasi, Drinker Biddle & Reath, LLP.

COMPLAINT

The Federal Trade Commission, having reason to believe that Bollman Hat Company, a company, and SaveAnAmericanJob,

- LLC, a limited liability company, jointly d/b/a American Made Matters (collectively, "Respondents"), have violated the provisions of the Federal Trade Commission Act, and it appearing to the Commission that this proceeding is in the public interest, alleges:
- 1. Respondent Bollman Hat Company is a Pennsylvania company with its principal office or place of business at 110 East Main Street, Adamstown, Pennsylvania 19501.
- 2. Respondent SaveAnAmericanJob, LLC is a Pennsylvania limited liability company with its principal office or place of business at 110 East Main Street, Adamstown, Pennsylvania 19501. SaveAnAmericanJob, LLC is a wholly owned subsidiary of Bollman Hat Company, and Bollman Hat Company is SaveAnAmericanJob, LLC's sole member.
- 3. Bollman Hat Company and SaveAnAmericanJob, LLC jointly do business as American Made Matters, a Pennsylvania fictitious name. Respondents have operated as a common enterprise while engaging in the unlawful acts and practices alleged below. Because Respondents have operated as a common enterprise, each of them is jointly and severally liable for the acts and practices alleged below.
- 4. Respondents have advertised, labeled, offered for sale, sold, and distributed products to consumers, including, but not limited to, hats sold under the Bollman, Bailey Western, Betmar, Country Gentleman, Eddy Bros., Helen Kaminski, Jacaru, Kaminski XY, Kangol, Karen Kane, Pantropic, and private label brand names. Respondents advertise these products online, including, but not limited to, on their website, hats.com, and in stores. Respondents offer for sale, sell, and distribute their products throughout the United States.
- 5. Respondents have advertised, offered for sale, sold, and distributed memberships in their "American Made Matters" program to companies wishing to make U.S.-origin claims for their products. Respondents primarily advertise their "American Made Matters" program to businesses online including, but not limited to, on their website americanmadematters.com, and

through their social media accounts. Respondents primarily advertise their "American Made Matters" program members' products to consumers online, including, but not limited to, through their website and social media accounts.

6. The acts and practices of Respondents alleged in this complaint have been in or affecting commerce, as "commerce" is defined in Section 4 of the Federal Trade Commission Act.

"Made in USA" Claims for Bollman Hats

- 7. Respondents have disseminated or have caused to be disseminated advertisements and promotional materials for their products, including, but not necessarily limited to, the attached Exhibits A-E. These materials contain the following statements, among others:
 - a. "American Made Matters"; "Choose American" (Exhibit A, product tag);
 - b. "Buy American! American Made Matters Choose American" (Exhibit B, Bollman website);
 - c. "American Made Matters"; "Choose American" (Exhibit C, Bollman website);
 - d. "Made-in-USA since 1868"; "Made in the USA for 100 Years or More"; "Made in USA' hats for 147 years and counting" (Exhibit D, Bollman Twitter page);
 - e. "#americanmadematters #madeintheusa #buyamerican" (Exhibit E, Bollman Facebook page).
- 8. In numerous instances, including, but not limited to, the promotional materials shown in Exhibits A-E, Respondents have represented, expressly or by implication, that all of their products, including, but not limited to, hats, are all or virtually all made in the United States.

- 9. In fact, more than 70% of the hat styles Respondents sell are wholly imported as finished products. Of the remaining styles, many contain significant imported content.
- 10. Therefore, Respondents' express or implied representations that all of their products are made in the United States are false.

American Made Matters Program

11. In 2010, Respondents introduced a U.S.-origin seal for marketers to use to boost the credibility of "Made in USA" claims. The seal, depicted below, is associated with "American Made Matters," which is a fictitious name registered to Respondents ("AMM"):



- 12. In numerous instances, including, but not limited to, the promotional materials shown in Exhibits A-E, Respondents have prominently displayed the American Made Matters seal in their promotional materials. This seal represents by implication that Respondents' hats have been endorsed or certified by an independent third party.
- 13. In fact, AMM is a fictitious name owned by Respondents, and Respondents' hats have not been endorsed or certified by an independent third party.
- 14. In addition to featuring the seal in their own marketing materials, Respondents license use of the seal to other companies wishing to make "Made in USA" claims for their products.
- 15. Companies that wish to use the AMM seal must apply for program membership through Respondents' website at www.americanmadematters.com. Respondents grant AMM membership to any company, product, or entity that self-certifies

it meets Respondents' membership standard, pays the \$99 annual licensing fee, and self-identifies either a United States-based manufacturing factory, or at least one product with a U.S.-origin label.

- 16. AMM membership includes a license to use Respondents' seal on products and in marketing materials, a member page on Respondents' website, and Respondents' commitment to advertise the member's products as "Made in USA" through their websites and social media channels.
- 17. To meet Respondents' standard, AMM members must certify that at least 50% of the cost of at least one of their products was incurred in the United States, with final assembly or transformation in the United States. Respondents do not rely on an independent or objective evaluation to confirm that members meet their standard.
- 18. Respondents have disseminated, or have caused to be disseminated, advertisements and promotional materials for AMM, as well as materials for members to use to promote their products as made in the United States including, but not necessarily limited to, the attached Exhibits F-L. These materials contain the following statements, among others:
 - a. With an American Made Matters Membership/Sponsorship, "You will increase sales to consumers and businesses who are actively looking to buy American Made Products" (Exhibit F, American Made Matters Website);
 - b. "Does your business produce or sell #MadeinUSA products? Increase your reach with us." (Exhibit G, American Made Matters Twitter page);
 - c. "American Made Matters® is an organization made of over 375 member and sponsor companies. Our members are manufacturers who represent various industries from apparel and toys to steel fabrication and cleaning supplies. Sponsors include American made retailers, patriotic organizations and local

businesses who understand that American made truly matters." (Exhibit H, American Made Matters website);

- d. "Shop as a consumer . . . for consumers looking to shop for American made products directly from our members and sponsors." (Exhibit I, American Made Matters website);
- e. "American Made Directories" (Exhibit J, American Made Matters website);
- f. "#MadeinUSA"; "Buy American"; "Made in USA"; "Start your American Made product search with American Made Matters"; "Choose #AmericanMade whenever possible. Start your search for #madeinUSA products with us." (Exhibit K, American Made Matters Facebook page);
- g. "Support the #AmericanDream. How? By buying #AmericanMade products! AmericanMadeMatters .com" (Exhibit L, American Made Matters Twitter page).
- 19. In numerous instances, including, but not limited to, the promotional materials shown in Exhibits F-L, Respondents have represented by implication that entities and products using AMM marketing materials or featured on the AMM website have been independently and objectively evaluated for compliance with Respondents' membership standard.
- 20. In fact, entities and products using Respondents' AMM logo or marketing materials have not been independently and objectively evaluated for compliance with any standard.
- 21. In numerous instances, including, but not limited to, the promotional materials shown in Exhibits F-L, Respondents have represented that products sold by American Made Matters members are all or virtually all made in the United States. For example, Respondents promote a directory of members on their AMM website as a list of manufacturers selling U.S.-origin

products, and regularly highlight members on their social media channels as selling U.S.-origin products.

- 22. In fact, Respondents do not possess a reasonable basis substantiating claims that products sold by American Made Matters members are all or virtually all made in the United States.
- 23. In numerous instances, including, but not limited, to the promotional materials shown in Exhibits G-L, Respondents have distributed promotional materials to third-party marketers for use in the marketing and sale of those third parties' products.
- 24. In so doing, Respondents have provided third-party marketers with the means and instrumentalities to deceive consumers. For example, several of Respondents' members have used Respondents' AMM logo or other materials to promote products that contain significant imported content.

COUNT I

(False or Unsubstantiated Representation – Respondents' Products)

- 25. In connection with the manufacturing, labeling, advertising, promotion, offering for sale, sale, or distribution of their products, Respondents have represented, directly or indirectly, expressly or by implication, that all of their products, including, but not limited to, all hats, are all or virtually all made in the United States.
- 26. In fact, in many instances, Respondents' products are wholly imported. In other instances, Respondents source significant inputs to their products from overseas. Therefore, the representation set forth in Paragraph 25 is false or misleading, or was not substantiated at the time the representation was made.

COUNT II

(False or Misleading Representation – Independence of AMM)

27. In connection with the labeling, advertising, promotion, offering for sale, or sale of their hats, such as through the use of

their American Made Matters seal, Respondents have represented, directly or indirectly, expressly or by implication, through the use of the American Made Matters seal that an independent organization has reviewed and endorsed their products as Made in the United States.

28. In truth and in fact, American Made Matters is not an independent organization reviewing and endorsing Respondents' products as Made in the United States. Respondents created the "American Made Matters" seal, and use it in connection with the labeling, advertising, promotion, offering for sale, and sale of their own products. Therefore, the representation set forth in Paragraph 27 is false or misleading.

COUNT III (False or Misleading Representation – AMM)

- 29. In connection with the advertising, promotion, offering for sale, or sale of membership to the American Made Matters program, Respondents have represented by implication, directly or indirectly, that each entity or product licensed to use their logos or marketing materials has been independently and objectively evaluated for compliance with Respondents' membership standard.
- 30. In fact, products and entities using Respondents' membership logo have not been independently and objectively evaluated for compliance with Respondents' membership standard. Therefore, the representation set forth in Paragraph 29 is false or misleading.

COUNT IV (False or Unsubstantiated Representation – Third Party Products)

31. Respondents have represented on their websites and social media, directly or indirectly, expressly or by implication, that all AMM members sell products that are all or virtually all made in the United States.

32. In truth and in fact, in numerous instances, the representation in Paragraph 31 was false or misleading, or was not substantiated at the time the representation was made.

COUNT V (Means and Instrumentalities)

33. Respondents have distributed the promotional materials described in Paragraph 18 to third-party marketers for use in the marketing and sale of those third parties' products. In so doing, Respondents have provided the means and instrumentalities to these third-party marketers for the commission of deceptive acts or practices.

VIOLATION OF SECTION 5

34. The acts and practices of Respondents, as alleged in this complaint, constitute unfair or deceptive acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act.

THEREFORE, the Federal Trade Commission this twelfth day of April, 2018, has issued this Complaint against Respondents.

By the Commission.

Exhibit A



Exhibit A

Exhibit B

Bollman Hat Company - America's Oldest Hat Maker



FEDERAL TRADE COMMISSION DECISIONS VOLUME 165

Complaint

Exhibit C

Bollman Hat Company - America's Oldest Hat Maker






Exhibit D





FEDERAL TRADE COMMISSION DECISIONS VOLUME 165




Exhibit E




Exhibit F



p. 1 of 2



Exhibit G




Exhibit H

SHOP OUR MEMBERS AND SPONSORS

ABOUT AMERICAN MADE MATTERS®

American Made Matters® is an organization made of over 375 member and sponsor companies. Our members are manufacturers who represent various industries from apparel and toys to steel fabrication and cleaning supplies. Sponsors include American made retailers, patriotic organizations and local businesses who understand that American made truly matters. Please join our growing community today.

JOIN TODAY

Exhibit H

Exhibit I



p. 1 of 5



Exhibit I p. 2 of 5

FEDERAL TRADE COMMISSION DECISIONS VOLUME 165



p. 3 of 5



Exhibit I p. 4 of 5

FEDERAL TRADE COMMISSION DECISIONS VOLUME 165




Exhibit J



Exhibit J

Exhibit K

American Made Matters - Home | Facebook



https://www.facebook.com/AmericanMadeMatters/

8/29/2017 Exhibit K p. 1 of 6

American Made Matters - Home | Facebook



American Made Matters - Home | Facebook



https://www.facebook.com/AmericanMadeMatters/

8/29/2017 Exhibit K p. 3 of 6

American Made Matters - Home | Facebook



https://www.facebook.com/AmericanMadeMatters/

8/29/2017 Exhibit K p. 4 of 6

American Made Matters - Home | Facebook




https://www.facebook.com/AmericanMadeMatters/

8/29/2017 Exhibit K p. 5 of 6

American Made Matters - Home | Facebook



Exhibit L



DECISION

The Federal Trade Commission ("Commission") initiated an investigation of certain acts and practices of the Respondents named in the caption. The Commission's Bureau of Consumer Protection ("BCP") prepared and furnished to Respondents a draft Complaint. BCP proposed to present the draft Complaint to the Commission for its consideration. If issued by the Commission, the draft Complaint would charge the Respondents with violation of the Federal Trade Commission Act.

Respondents and BCP thereafter executed an Agreement Containing Consent Order ("Consent Agreement"). The Consent Agreement includes: 1) a statement by Respondents that they neither admit nor deny any of the allegations in the Complaint,

except as specifically stated in this Decision and Order, and that only for purposes of this action, they admit the facts necessary to establish jurisdiction; and 2) waivers and other provisions as required by the Commission's Rules.

The Commission considered the matter and determined that it had reason to believe that Respondents have violated the Federal Trade Commission Act, and that a Complaint should issue stating its charges in that respect. The Commission accepted the executed Consent Agreement and placed it on the public record for a period of 30 days for the receipt and consideration of public comments. The Commission duly considered any comments received from interested persons pursuant to Section 2.34 of its Rules, 16 C.F.R. § 2.34. Now, in further conformity with the procedure prescribed in Rule 2.34, the Commission issues its Complaint, makes the following Findings, and issues the following Order:

Findings

- 1. The Respondents are:
 - a. Respondent Bollman Hat Company is a Pennsylvania company with its principal office or place of business at 110 East Main Street, Adamstown, Pennsylvania 19501.
 - b. Respondent SaveAnAmericanJob, LLC is a Pennsylvania limited liability company with its principal office or place of business at 110 East Main Street, Adamstown, Pennsylvania 19501. SaveAnAmericanJob, LLC is a wholly owned subsidiary of Bollman Hat Company.
 - c. Bollman Hat Company and SaveAnAmericanJob, LLC jointly do business as American Made Matters, a Pennsylvania fictitious name.
- 2. The Commission has jurisdiction over the subject matter of this proceeding and over the Respondents, and the proceeding is in the public interest.

ORDER

Definitions

For purposes of this Order, the following definitions apply:

- A. "Certification Standard" means any independently-developed and objectively-applied criteria Respondents set for products or services to meet in order to use Respondents' Certification or other marketing or promotional material, including Respondents' "American Made Matters" materials, which substantiate the claim being made.
- B. "Certification" means any seal, logo, emblem, shield, or other insignia that expresses or implies approval or endorsement of any product, package, service, practice, or program, or any attribute thereof.
- C. "Clear(ly) and conspicuous(ly)" means that a required disclosure is difficult to miss (i.e., easily noticeable) and easily understandable by ordinary consumers, including in all of the following ways:
 - 1. In any communication that is solely visual or solely audible, the disclosure must be made through the same means through which the communication is presented. In any communication made through both visual and audible means, such as a television advertisement, the disclosure must be presented simultaneously in both the visual and audible portions of the communication even if the representation requiring the disclosure ("triggering representation") is made through only one means.
 - 2. A visual disclosure, by its size, contrast, location, the length of time it appears, and other characteristics, must stand out from any accompanying text or other visual elements so that it is easily noticed, read, and understood.

- 3. An audible disclosure, including by telephone or streaming video, must be delivered in a volume, speed, and cadence sufficient for ordinary consumers to easily hear and understand it.
- 4. In any communication using an interactive electronic medium, such as the Internet or software, the disclosure must be unavoidable.
- 5. On a product label, the disclosure must be presented on the principal display panel.
- 6. The disclosure must use diction and syntax understandable to ordinary consumers and must appear in each language in which the triggering representation appears.
- 7. The disclosure must comply with these requirements in each medium through which it is received, including all electronic devices and face-to-face communications.
- 8. The disclosure must not be contradicted or mitigated by, or inconsistent with, anything else in the communication.
- 9. When the representation or sales practice targets a specific audience, such as children, the elderly, or the terminally ill, "ordinary consumers" includes reasonable members of that group.
- D. "Made in the United States" means any representation, express or implied, that a product or service, or a component thereof, is of U.S.-origin, including, but not limited to, a representation that such product or service is "made," "manufactured," "built," or "produced" in the United States, or any other U.S.-origin claim.
- E. "Material Connection" shall mean any relationship that materially affects the weight or credibility of Respondents' Certification, and that would not be

reasonably expected by consumers, provided that a reasonable certification fee shall not constitute a Material Connection.

F. "Respondents" means Bollman Hat Company, also d/b/a American Made Matters, SaveAnAmericanJob, LLC, also d/b/a American Made Matters, and their successors and assigns, individually, collectively, or in any combination.

Provisions

I. PROHIBITED MISREPRESENTATIONS REGARDING U.S. ORIGIN CLAIMS

IT IS ORDERED that Respondents, and Respondents' officers, agents, employees, and attorneys, and all other persons in active concert or participation with any of them, who receive actual notice of this Order, whether acting directly or indirectly, in connection with the manufacturing, labeling, advertising, promotion, offering for sale, sale, or distribution of any hat, or any other product or service, must not make any representation, expressly or by implication, that a product or service is Made in the United States unless:

- A. The final assembly or processing of the product occurs in the United States, all significant processing that goes into the product occurs in the United States, and all or virtually all ingredients or components of the product are made and sourced in the United States; or
- B. A Clear and Conspicuous qualification appears immediately adjacent to the representation that accurately conveys the extent to which the product contains foreign parts, ingredients or components, and/or processing.

II. DISCLOSURE OF MATERIAL CONNECTION

IT IS FURTHER ORDERED that Respondents and Respondents' officers, agents, employees and attorneys, and all other persons in active concert or participation with any of them, who receive actual notice of this Order, whether acting directly or indirectly, in connection with the labeling, advertising, promotion, offering for sale, or sale of any product, package, certification, service, practice, or program, must not make any representation, in any manner, expressly or by implication, about any user or endorser of such product, package, Certification, service, practice, or program unless Respondents disclose, Clearly and Conspicuously, and in close proximity to the representation, any Material Connection, when one exists, between such user or endorser and (1) Respondents or (2) any other individual or entity affiliated with the product or service.

III. PROHIBITED MISREPRESENTATIONS REGARDING CERTIFICATIONS

- IT IS FURTHER ORDERED that Respondents, Respondents' officers, agents, servants, employees, and attorneys, and all other persons in active concert or participation with any of them, who receive actual notice of this Order, whether acting directly or indirectly, in connection with marketing, promoting, offering for sale, or selling any product, good, or service, are permanently restrained and enjoined from representing, expressly or by implication, that a product or service meets Respondents' Certification Standard, unless:
 - A. An entity with no Material Connection to Respondents or any company, group, or other association that Respondents authorize to use any "American Made Matters" Certification or other marketing or promotional material has conducted an independent and objective evaluation, audit, or verification check to confirm that the product or service meets the Certification Standard; or

B. Respondents' Certification or any other promotional materials clearly and prominently disclose(s) that products or services may meet Respondents' Certification Standard through self-certification.

IV. SUBSTANTIATION

- **IT IS FURTHER ORDERED** that Respondents, Respondents' officers, agents, servants, employees, and attorneys, and all other persons in active concert or participation with any of them, who receive actual notice of this Order, whether acting directly or indirectly, in connection with promoting or offering for sale any product or service, shall not make any representation, in any manner, expressly or by implication, regarding the country of origin of any product or service unless:
 - A. The representation is true, not misleading, and at the time it is made, Respondents possess and rely upon a reasonable basis for the representation; or
 - B. For representations made through use of Respondents' Certification or other "American Made Matters" materials, the Certification and related promotional materials clearly and prominently disclose that products or services may meet Respondents' Certification Standard through self-certification, and Respondents neither know nor should know that the self-certification is misleading.

V. MEANS AND INSTRUMENTALITIES

IT IS FURTHER ORDERED that Respondents, Respondents' officers, agents, servants, employees, and attorneys, and all other persons in active concert or participation with any of them, who receive actual notice of this Order, whether acting directly or indirectly, in connection with promoting or offering for sale any product, good, or service, shall not provide to others the means and instrumentalities with which to make any representation prohibited by Parts I, III, or IV above. For the

purposes of this Part, "means and instrumentalities" means any information, including, but not necessarily limited to, any Certification, advertising, labeling, promotional, sales training, or purported substantiation materials, for use by trade customers in their marketing of any product or service.

VI. ACKNOWLEDGMENTS OF THE ORDER

IT IS FURTHER ORDERED that Respondents obtain acknowledgments of receipt of this Order:

- A. Each Respondent, within 10 days after the effective date of this Order, must submit to the Commission an acknowledgment of receipt of this Order sworn under penalty of perjury.
- B. For 20 years after the issuance date of this Order, each Respondent must deliver a copy of this Order to: (1) all principals, officers, directors, and LLC managers and members; (2) all employees, agents, and representatives who participate in conduct related to the subject matter of the Order; and (3) any business entity resulting from any change in structure as set forth in the Provision titled Compliance Reports and Notices. Delivery must occur within 10 days after the effective date of this Order for current personnel. For all others, delivery must occur before they assume their responsibilities.
- C. From each individual or entity to which a Respondent delivered a copy of this Order, that Respondent must obtain, within 30 days, a signed and dated acknowledgment of receipt of this Order.

VII. COMPLIANCE REPORT AND NOTICES

IT IS FURTHER ORDERED that Respondents make timely submissions to the Commission:

- Α. One year after the issuance date of this Order, each Respondent must submit a compliance report, sworn under penalty of perjury, in which each Respondent must: (a) identify the primary physical, postal, and email address and telephone number, as designated points of contact, which representatives of the Commission, may use to communicate with Respondent; (b) identify all of that Respondent's businesses by all of their names, telephone numbers, and physical, postal, email, and Internet addresses; (c) describe the activities of each business, including the goods and services offered, the means of advertising, marketing, and sales and the involvement of any other Respondent; (d) describe in detail whether and how that Respondent is in compliance with each Provision of this Order, including a discussion of all of the changes the Respondent made to comply with the Order: and (e) provide a copy of Acknowledgment of the Order obtained pursuant to this Order, unless previously submitted to the Commission.
- B. Each Respondent must submit a compliance notice, sworn under penalty of perjury, within 14 days of any change in the following: (a) any designated point of contact; or (b) the structure of any Respondent or any entity that Respondent has any ownership interest in or controls directly or indirectly that may affect compliance obligations arising under this Order, including: creation, merger, sale, or dissolution of the entity or any subsidiary, parent, or affiliate that engages in any acts or practices subject to this Order.
- C. Each Respondent must submit notice of the filing of any bankruptcy petition, insolvency proceeding, or similar proceeding by or against such Respondent within 14 days of its filing.
- D. Any submission to the Commission required by this Order to be sworn under penalty of perjury must be true and accurate and comply with 28 U.S.C. § 1746,

such as by concluding: "I declare under penalty of perjury under the laws of the United States of America that the foregoing is true and correct. Executed on:

______ " and supplying the date, signatory's full name, title (if applicable), and signature.

E. Unless otherwise directed by a Commission representative in writing, all submissions to the Commission pursuant to this Order must be emailed to DEbrief@ftc.gov or sent by overnight courier (not the U.S. Postal Service) to: Associate Director for Enforcement, Bureau of Consumer Protection, Federal Trade Commission, 600 Pennsylvania Avenue NW, Washington, DC 20580. The subject line must begin: In re Bollman Hat Company, Docket No. C-4643.

VIII. RECORDKEEPING

IT IS FURTHER ORDERED that Respondents must create certain records for 20 years after the issuance date of the Order, and retain each such record for 5 years, unless otherwise specified below. Specifically, each Respondent must create and retain the following records:

- A. Accounting records showing the revenues from all goods or services sold;
- B. Personnel records showing, for each person providing services in relation to any aspect of the Order, whether as an employee or otherwise, that person's: name; addresses; telephone numbers; job title or position; dates of service; and (if applicable) the reason for termination;
- C. Copies or records of all consumer complaints and refund requests concerning the subject matter of the Order, whether received directly or indirectly, such as through a third party, and any response;

- D. All records necessary to demonstrate full compliance with each provision of this Order, including all submissions to the Commission;
- E. A copy of each unique advertisement or other marketing material making a representation subject to this Order; and
- F. For 5 years from the date of the last dissemination of any representation covered by this Order:
 - 1. All materials that were relied upon in making the representation; and
 - All evidence in Respondent's possession, custody, or control that contradicts, qualifies, or otherwise calls into question the representation, or the basis relied upon for the representation, including complaints and other communications with consumers or with governmental or consumer protection organizations.

IX. COMPLIANCE MONITORING

IT IS FURTHER ORDERED that, for the purpose of monitoring Respondents' compliance with this Order:

- A. Within 10 days of receipt of a written request from a representative of the Commission, each Respondent must: submit additional compliance reports or other requested information, which must be sworn under penalty of perjury, and produce records for inspection and copying.
- B. For matters concerning this Order, representatives of the Commission are authorized to communicate directly with each Respondent. Respondents must permit representatives of the Commission to interview anyone affiliated with any Respondent who has agreed

to such an interview. The interviewee may have counsel present.

C. The Commission may use all other lawful means, including posing through its representatives as consumers, suppliers, or other individuals or entities, to Respondents or any individual or entity affiliated with Respondents, without the necessity of identification or prior notice. Nothing in this Order limits the Commission's lawful use of compulsory process, pursuant to Sections 9 and 20 of the FTC Act, 15 U.S.C. §§ 49, 57b-1.

X. ORDER EFFECTIVE DATES

IT IS FURTHER ORDERED that this Order is final and effective upon the date of its publication on the Commission's website (ftc.gov) as a final order. This Order will terminate on April 12, 2038, or 20 years from the most recent date that the United States or the Commission files a complaint (with or without an accompanying settlement) in federal court alleging any violation of this Order, whichever comes later; *provided*, *however*, that the filing of such a complaint will not affect the duration of:

- A. Any Provision in this Order that terminates in less than 20 years;
- B. This Order's application to any Respondent that is not named as a defendant in such complaint; and
- C. This Order if such complaint is filed after the Order has terminated pursuant to this Provision.

Provided, further, that if such complaint is dismissed or a federal court rules that the Respondent did not violate any provision of the Order, and the dismissal or ruling is either not appealed or upheld on appeal, then the Order will terminate according to this Provision as though the complaint had never been filed, except that the Order will not terminate between the date such complaint

is filed and the later of the deadline for appealing such dismissal or ruling and the date such dismissal or ruling is upheld on appeal.

By the Commission.

ANALYSIS OF CONSENT ORDER TO AID PUBLIC COMMENT

The Federal Trade Commission ("FTC" or "Commission") has accepted, subject to final approval, an agreement containing a consent order from Bollman Hat Company and SaveAnAmericanJob, LLC, jointly d/b/a American Made Matters ("respondents").

The proposed consent order has been placed on the public record for thirty (30) days for receipt of comments by interested persons. Comments received during this period will become part of the public record. After thirty (30) days, the Commission will again review the agreement and the comments received, and will decide whether it should withdraw from the agreement or make final the agreement's proposed order.

This matter involves respondents' marketing, sale, and distribution of hats with claims that the products are of U.S.-origin, and respondents' marketing, sale, and distribution of memberships in their "American Made Matters" ("AMM") program to companies wishing to make U.S.-origin claims for their products.

According to the FTC's complaint, respondents represented that their products are "Made in USA." In fact, many of the respondents' hats are wholly imported, and others contain significant imported content. Therefore, this representation was false or misleading.

The complaint further alleges that the AMM seal represents by implication that respondents' products have been endorsed or certified by an independent third party. AMM, however, is a fictitious name for respondents, who created the AMM seal and use it in connection with the sale of their own products. Therefore, these representations were false or misleading.

The complaint next alleges that respondents made implied claims that products and entities using their AMM seal were independently and objectively evaluated for compliance with respondents' certification standard. These claims were false or misleading.

Finally, the complaint alleges that respondents claimed that all AMM members sell products that are all or virtually all made in the United States. Because respondents awarded the AMM certification to any company that self-certified that at least 50% of the cost of one of their products was incurred in the United States, with final assembly or transformation in the United States, this claim was false or misleading, or unsubstantiated at the time it was made.

Based on the foregoing, the complaint alleges that respondents engaged in deceptive acts or practices in violation of Section 5(a) of the FTC Act.

The proposed consent order contains provisions designed to prevent respondents from engaging in similar acts and practices in the future. Consistent with the FTC's Enforcement Policy Statement on U.S. Origin Claims, Part I prohibits respondents from making U.S.-origin claims for their products unless either: (1) the final assembly or processing of the product occurs in the United States, all significant processing that goes into the product occurs in the United States, and all or virtually all ingredients or components of the product are made and sourced in the United States; or (2) a clear and conspicuous qualification appears immediately adjacent to the representation that accurately conveys the extent to which the product contains foreign parts, ingredients or components, and/or processing.

Part II prohibits respondents from making any representation about any user or endorser of any product, package, certification, service, practice, or program, unless respondents disclose clearly and conspicuously any material connection between a user or endorser and (1) respondents or (2) any other individual or entity affiliated with the product or service.

Part III prohibits respondents from representing, expressly or by implication, that a product or service meets respondents' certification standard, unless: (1) an entity with no material connection to that covered entity conducted an independent and objective evaluation to confirm that the certification standard was met; or (2) respondents' certification and marketing materials disclose clearly and conspicuously that the certification standard may be met through self-certification.

Part IV prohibits respondents from making any country-oforigin claim about a product or service unless the claim is true, not misleading, and respondents have a reasonable basis substantiating the representation. In the alternative, for countryof-origin representations made through AMM marketing materials, respondents may make such claims if (1) they neither know or have reason to know that the self-certification is misleading, and (2) disclose clearly and prominently that products or services meet the certification standard through selfcertification.

Part V prohibits respondents from providing third parties with the means and instrumentalities to make the claims prohibited in Parts I, III, or IV.

Parts VI through IX are reporting and compliance provisions. Part VI requires respondents to acknowledge receipt of the order, to provide a copy of the order to certain current and future principals, officers, directors, and employees, and to obtain an acknowledgement from each such person that they have received a copy of the order. Part VII requires the filing of compliance reports within one year after the order becomes final and within 14 days of any change that would affect compliance with the order. Part VIII requires respondents to maintain certain records, including records necessary to demonstrate compliance with the

order. Part IX requires respondents to submit additional compliance reports when requested by the Commission and to permit the Commission or its representatives to interview respondents' personnel.

Finally, Part X is a "sunset" provision, terminating the order after twenty (20) years, with certain exceptions.

The purpose of this analysis is to aid public comment on the proposed order. It is not intended to constitute an official interpretation of the proposed order or to modify its terms in any way.

IN THE MATTER OF

TELOMERASE ACTIVATION SCIENCES, INC. AND NOEL THOMAS PATTON

CONSENT ORDER, ETC. IN REGARD TO ALLEGED VIOLATIONS OF SECTIONS 5 AND 12 OF THE FEDERAL TRADE COMMISSION ACT

Docket No. C-4644; File No. 142 3101 Complaint, April 18, 2018 – Decision, April 18, 2018

This consent order addresses Telomerase Activation Sciences, Inc.'s advertising for TA-65MD, a product that comes in capsule and powder forms, and TA-65 for Skin, a topical cream product. The complaint alleges that respondents violated Sections 5(a) and 12 of the FTC Act by making false or unsubstantiated health or performance claims regarding TA-65MD and TA-65 for Skin. The complaint further alleges that respondents represented that a 2012 paid-for segment on The Suzanne Show featuring TA-65MD was independent, educational programming and not paid commercial advertising and that consumers appearing in advertisements were independent users of TA-65MD, expressing their impartial views of satisfaction. The consent order prohibits any representation that a covered product reverses human aging; prevents or repairs DNA damage; restores aging immune systems; increases bone density; reverses the effects of aging, including improving skin elasticity, increasing energy and endurance, and improving vision; decreases recovery time of the skin after medical procedures; prevents or reduces the risk of cancer; or cures, mitigates, or treats any disease unless the representation is non-misleading and respondents possess and rely upon competent and reliable scientific evidence that substantiates that the representation is true.

Participants

For the *Commission: Devin W. Domond, David P. Frankel, Mary Johnson,* and *Andrew Wone.*

For the Respondents: Leonard L. Gordon, Michelle C. Jackson, Kristen Klesh, Claudia A. Lewis, and Brian M. Likins, Venable, LLP.

COMPLAINT

The Federal Trade Commission, having reason to believe that Telomerase Activation Sciences, Inc. ("TAS"), a corporation, and Noel Thomas Patton, individually and as an officer of TAS

(collectively, "Respondents"), have violated the provisions of the Federal Trade Commission Act, and it appearing to the Commission that this proceeding is in the public interest, alleges:

- 1. Respondent Telomerase Activation Sciences, Inc. is a Delaware corporation with its principal place of business at 420 Lexington Avenue, Suite 2900, New York, NY 10170.
- 2. Respondent Noel Thomas Patton ("Patton") is the founder, Chairman, CEO, and majority owner of TAS. Individually or in concert with others, he has formulated, directed, controlled, had the authority to control, or participated in the acts and practices alleged in this complaint. His principal office or place of business is the same as that of TAS.
- 3. Respondents have manufactured, advertised, labeled, offered for sale, sold, and distributed products to consumers, including TA-65MD and TA-65 for Skin ("TA-65 Skin") (collectively "the TA-65 products"). TA-65MD is either a food and/or drug within the meaning of Sections 12 and 15 of the Federal Trade Commission Act. TA-65 Skin is either a drug and/or cosmetic within the meaning of Sections 12 and 15 of the Federal Trade Commission Act.
- 4. The acts and practices of Respondents alleged in this complaint have been in or affecting commerce, as "commerce" is defined in Section 4 of the Federal Trade Commission Act.

Respondents' Business Activities

- 5. TA-65MD is a product that comes in both capsule and powder form. Respondents have manufactured, advertised, labeled, offered for sale, distributed, and sold TA-65MD since 2007.
- 6. TA-65 Skin is a topical cream product. Respondents have manufactured, advertised, labeled, offered for sale, distributed, and sold TA-65 Skin since 2013.
- 7. The active ingredient in the TA-65 products is a proprietary extract derived from the roots of the *Astragalus*

membranacious plant. The extract is chemically known as cycloastragenol.

- 8. Respondents claim that the active ingredient in the TA-65 products activates an enzyme known as telomerase, which is dormant in most human cells. According to Respondents, activating telomerase lengthens telomeres. Telomeres form the ends of human chromosomes in cells. Sometimes likened to the hard plastic tips at the end of shoelaces that prevent them from fraying, telomeres protect human cells during cell division. Each time a cell divides, its telomeres shorten. When telomeres reach a critically short level, a cell ceases to divide known as cell senescence. Respondents claim that the TA-65 products activate telomerase, lengthen short telomeres, and, thereby, extend the cellular lifespan of normal cells.
- 9. Respondents have advertised and marketed TA-65MD through a television infomercial, a paid appearance on *The Suzanne Show*, magazine advertisements, health professional conferences and seminars, trade conferences and shows, TAS-hosted meetings and workshops, online advertisements and websites, email blasts, product packaging, and other promotional materials to consumers, including trade customers for use in other finished products marketed to consumers.
- 10. Respondents have represented that TA-65MD, among other things, is clinically proven to reverse aging, repair DNA damage, restore aging immune systems, and increase bone density.
- 11. Respondents have sold TA-65MD through licensees, infomercial call centers, and online retailers (including, but not limited to, Amazon.com, Vita-Stream.com, RevGenetics.com, ChosenMeds.com, and ebay.com).
- 12. Respondents also have sold TA-65MD powder to their trade customers directly.
- 13. According to the TAS website (www.tasciences.com), the retail price of one TA-65MD 90-capsule (250-unit dosage per capsule) bottle is \$600 and of one 30-capsule (100-unit dosage per

capsule) bottle is \$100. According to earlier versions of the website, TA-65MD capsules retailed for the following approximate amounts: \$600 for a three-month supply at a low dose level (one 250-unit capsule daily); \$1,200 for a three-month supply at a mid-dose level (two 250-unit capsules daily); and \$2,200 for a three-month supply at a high-dose level (four 250-unit capsules daily).

- 14. Respondents have advertised and marketed TA-65 Skin through health professional conferences and seminars, trade conferences and shows, TAS-hosted meetings and workshops, online advertisements and websites, product packaging, and other promotional materials.
- 15. Respondents have represented that TA-65 Skin, among other things, reverses aging, including through improving skin elasticity, and decreases recovery time of the skin after medical procedures.
- 16. Respondents have sold TA-65 Skin through licensees and online retailers (including, but not limited to, Amazon.com, myHealthMarket.com, and ebay.com).
- 17. The retail cost for TA-65 Skin is approximately \$500 for a one fluid ounce bottle and \$1,000 for a four fluid ounce tube.
- 18. Respondent TAS grossed at least \$56 million in sales for the TA-65 products from 2010 to filing of this Complaint, and sales have been ongoing. TA-65MD accounts for most of these sales.

A. Respondents' Promotion and Sale of the TA-65 Products Through Licensed Persons

- 19. Respondents have distributed the TA-65 products through persons that TAS licenses to sell and distribute the products ("TAS Licensee" or "TAS Licensees"). The majority of sales for TA-65MD capsules and TA-65 Skin are through TAS Licensees.
- 20. Most TAS Licensees are health professionals, including licensed medical doctors.

- 21. Respondents sell and distribute the TA-65 products to TAS Licensees at a discount, to then be resold and redistributed to consumers. According to Respondents' advertisements for their licensee program, product discounts for TAS Licensees range from 25 to 45 percent off the retail price.
- 22. TAS Licensees market, promote, offer for sale, and sell the TA-65 products to consumers through their own online websites and other online websites, including Amazon.com storefronts and ebay.com, and physical storefronts or offices.
- 23. For example, TAS Licensee Age Reverse, LLC (a New York limited liability company described by Respondents as one of their "biggest USA distributors"), markets and sells TA-65MD capsules and TA-65 Skin to consumers through its websites www.ta65doctor.com and www.ta-65direct.com; through its Amazon storefronts ta65doctor, ta-65direct, and TA65DIRECT; and through www.ebay.com.
- 24. Respondents promote the TA-65 products to prospective and actual TAS Licensees at health professional conferences and trade shows, through practitioner-oriented publications, and through other promotional materials. Respondents also have hosted meetings and workshops for health professionals, whose practices often involve aging or general health, to promote the TA-65 products and the TAS Licensee program as a source of ancillary revenue.
- 25. Respondents also have furnished prospective and actual TAS Licensees copies of their advertising and marketing materials for the TA-65 products and materials purporting to substantiate the products' efficacy.

B. Respondents' Marketing and Promotion of the TA-65 Products to the General Public

26. In 2012, Respondents paid \$89,900, in addition to in-kind compensation of approximately twelve TA-65MD 90-capsule bottles, for celebrity Suzanne Somers to promote TA-65MD on *The Suzanne Show*, which aired on Lifetime Television. Ms. Somers was the show's host and one of the show's producers.

- 27. Ms. Somers introduced the paid-for segment on *The Suzanne Show* featuring TA-65MD as an "ask the experts" segment, which was styled as an educational interview of Respondent Patton and Dr. Edward Park, a purported medical expert, who was also a TAS Licensee. During the interview, Respondent Patton and Dr. Park discussed purported health benefits of TA-65MD and directed consumers to the TAS website (www.tasciences.com). There was no indication to viewers that this segment was a paid advertisement.
- 28. Respondents also provided free TA-65MD 90-capsule bottles, on a quarterly basis, to another producer of *The Suzanne Show* from 2012 until, at least, the end of 2013. The total value of monetary and in-kind compensation that Respondents paid the show's producers until January 2014 was approximately \$113,900. Respondents also provided discounted TA-65 products to producers of *The Suzanne Show*.
- 29. In addition to the paid-for segment on *The Suzanne Show* promoting TA-65MD, TA-65MD was featured in website advertisements and other promotional materials promoting *The Suzanne Show* segment.
- 30. Respondents also marketed the TA-65 products in an infomercial, released in 2014, for TA-65MD ("TAS infomercial").
- 31. The TAS infomercial included consumer endorsers discussing health benefits they purportedly experienced due to their use of TA-65MD. Video clips of and quoted language from these consumer endorsements have appeared on Respondents' website. Respondents provided thousands of dollars of free TA-65MD products to the consumer endorsers appearing in the TAS infomercial and other promotional materials. For example, Respondents provided eight TA-65MD 90-capsule bottles, valued at approximately \$4,000 total, to each consumer endorser featured in the TAS infomercial.
- 32. Respondents did not disclose, or did not disclose adequately, in advertisements or other promotional materials featuring consumer endorsers, including the 2014 TAS

infomercial, that they provided thousands of dollars of TA-65MD to consumer endorsers at no cost.

33. The TAS infomercial featured endorsements by medical professionals or "experts" discussing health benefits purportedly experienced by TA-65MD users, such as the medical professionals' patients and themselves. Video clips of and quoted language from the TAS infomercial also appeared on Respondents' website.

C. Respondents' Promotion and Sale of TA-65MD Powder to Trade Customers for Use in Other Finished Products

- 34. Respondents market, promote, and offer for sale TA-65MD powder to trade customers for use in the trade customers' finished products.
- 35. Respondents have furnished prospective trade customers copies of their advertising and marketing materials for TA-65MD and materials purporting to substantiate TA-65MD's efficacy, including materials targeting prospective TAS Licensees. One or more of Respondents' trade customers have used these materials to market TA-65MD powder to consumers nationwide and abroad.
- 36. For example, Respondents' trade customer Jeunesse, LLC (a Florida limited liability, multi-level marketing company) has used Respondents' materials to produce promotional materials for its product FinitiTM, a product sold in capsule form that contains TA-65MD powder as a purported active ingredient. Online advertising and product packaging for Finiti contains the mathematical symbol for infinity (∞) and the tag line "Aging Ends Here."
- 37. Respondents also have provided other services to their trade customers to assist in marketing TA-65MD powder to consumers nationwide and abroad. For example, Respondents have provided technical, clinical, and marketing support to their trade customers, including making Respondent Patton or other TAS representatives available to speak at trade customers' events.

In addition, Respondents have reviewed the formulation of and advertisements for their trade customers' products prior to dissemination to consumers.

D. Individual Respondent

- 38. Among other things, Respondent Patton has created, reviewed, edited, and approved advertisements, packaging, and promotional materials for the TA-65 products. He has been involved actively in developing and reviewing advertising claims for the TA-65 products, including the advertising claims set forth in this Complaint. In addition, Respondent Patton has marketed the TA-65 products at conferences and seminars, making presentations about the products' purported benefits. As part of a paid-for segment on *The Suzanne Show* promoting TA-65MD, Ms. Somers interviewed Respondent Patton. Respondent Patton also appeared in the TAS infomercial.
- 39. Respondent Patton has reviewed and approved advertisements, packaging, and promotional materials for products manufactured by Respondents' trade customers containing TA-65MD powder. Respondent Patton has promoted TA-65MD powder when marketing products manufactured by Respondents' trade customers at trade customers' events. Moreover, Respondent Patton has been responsible for reviewing the scientific materials that purportedly substantiate claims for the TA-65 products.

E. Examples of Advertisements, Packaging, and Other Promotional Materials

40. To induce prospective and actual TAS Licensees to purchase the TA-65 products for distribution, Respondents have disseminated or have caused to be disseminated advertisements and promotional materials for the TA-65 products and Respondents' Licensee program, including, but not necessarily limited to, those attached as Exhibits A through D. These advertisements contain the following statements and depictions:

a. TA-65MD Health Professional's Brochure FTC-TAS0053507-18 (Exhibit A)

To Meet the Challenges of Aging

OUR MISSION IS YOUR MISSION:

Our **mission** is to minimize the decline associated with aging and maximize the potential for health and longevity through Telomerase Activation **TA**^{65®}

- Safe and efficacious with over 5 years of testing
- Only available through physicians trained and licensed by T.A. Sciences.

Short Telomeres are associated with unhealthy aging and a shorter lifespan

...

Short Telomeres have been associated with maladies in these tissues:

- Immune cells memory and naïve
- Heart cardiomyocytes
- Hematopoietic stem cells
- Lung alveolar cells
- Skin dermis, epidermis, vasculature
- Vascular intima (endothelium)
- Osteoblasts, MSCs
- Liver hepatocytes
- Retinal pigmented tissue of eye
- Chondrocytes
- Skeletal muscle
- Kidney cortex
- Neurons

• • •

People currently taking TA-65 have seen the following results:*

...

- Improved Immune system: In particular, the % and absolute number of senescent CD8+/28- cells has significantly decreased. This is a reversal of what normally happens with age.
- Improved bone density
- Improved cardiovascular and hormonal biomarkers that normally show decline with age.
- There are also anecdotal results, such as improved energy and athletic performance, but these effects are not universal and vary among individuals.

*Human trial results substantiating these claims to be published soon in a peer-reviewed scientific journal

...

How to become a T.A. Sciences licensee?

- 1. The physician must sign the Licensee Agreement.
- 2. There is a one time \$1,000 Administrative Fee that covers licensee set up, marketing support and operations support.
- The physician must study the Doctor's Manual and pass the Telomere, Telomerase and TA⁶⁵ basic knowledge exam.
 - Your practice will then have the ability to purchase the products – TA⁶⁵ and Support Packs, along with Telomere Length and Specialized Immunology tests at licensee discount rates.
 - TA⁶⁵ profit for the doctor is \$2000 per client per year.
 - Cash Flow positive for the licensee: No investment in TA⁶⁵ inventory is required.
 Patients pay for TA⁶⁵ before you have to pay TA Sciences.

- Set your practice apart by offering the only scientifically proven Telomerase Activator in the world to your patients, TA⁶⁵
- b. Health Practitioner Magazine Advertisement FTC-TAS0043860 (Exhibit B)



Add Nobel Prize Technology

to your Practice **TA**^{65®}MD
Cell Rejuvenation **Through Telomerase Activation**

. .

- Repairs DNA Damage
- Rejuvenates Aging Immune Systems
- Increases Bone Density
- Improves Biomarkers that Decline With Age
- c. TAS Licensee Program Advertisement FTC-TAS0065578 (Exhibit C)

T.A. SCIENCES

CELL REJUVENATION THROUGH TELOMERASE ACTIVATION

Right now is the best time to start providing the world's most unique anti-aging supplement.

It is now <u>FREE</u> and <u>EASY</u> to sign up and become a TA-65[®]MD Licensee.

TA-65®MD is the world's only proven telomerase activator with in vivo studies to show efficacy and safety.

Telomerase activation is the most effective way to lengthen short telomeres and to combat age related dysfunctions.

In addition, TA-65[®]MD has proven to rejuvenate the immune system and increase bone density.

As a Licensee, you will receive discounts for each bottle. The savings range between 25% to almost 45%. Our Licensees value TA-65®MD not only for the health benefits to their patients, but for the significant increase of revenue for their practice.

Customers have reported several amazing anecdotal benefits which include:

- increased energy and endurance
- better joint movements
- improved sleep
- more youthful skin (age spots going away, dry patches disappearing, wrinkles smoothening)
- improved strength and flexibility
- sharper memory
- sexual enhancement

When you sign up to **become a Licensee**, you will receive the TA-65[®]MD Manual and Test to learn more about the product. To help with sales, you receive free marketing material to share with your staff and patients, a dedicated website for online orders and of course a discount on every bottle you order!

Call us today to learn how you can become a TA-65®MD Licensee and start generating more revenue for your practice!

Request a TA-65[®]MD Licensee Agreement by phone or email:

212-588-8805 or sales@tasciences.com.

d. TA-65MD and TA-65 Skin physician conference flier FTC-TAS0059953 (Exhibit D)

Cellular Aging Stops Here

Inside every cell of your body, there is a powerful clock ticking away. It's telling your body to age, wrinkle, gray, and slow down.

That clock is your telomeres, the caps at the end of each strand of DNA that protect it, like the plastic tips at the end of shoelaces.

Telomeres shorten over time, leaving your DNA vulnerable to damage and causing your cells to age. But now, there is a groundbreaking new way to help slow down, or possibly even reverse, age and lifestyle related telomere shortening.

Based on Nobel Prize winning science, TA-65[®] – a proprietary, all natural plant-based compound – can help maintain or rebuild telomeres.

TA-65[®] is available from T.A. Sciences[®] as TA-65MD[®] nutritional supplements, or in a new skin cream formulation.

41. To induce consumers to purchase the TA-65 products, including trade customers and TAS Licensees who distribute the TA-65 products to consumers, Respondents have disseminated or have caused to be disseminated advertisements, packaging, and promotional materials for the TA-65 products, including, but not necessarily limited to, those attached as Exhibits E through O. These advertisements contain the following statements and depictions:

a. Paid-for TA-65 segment on *The Suzanne Show*, DVD and transcript (Exhibits E and F, respectively)

ON SCREEN: ask the experts

SUZANNE SOMERS: All right, I'm going to ask you a sensitive question. How old are you? Well, the fact is most of us don't really know because there are two answers. There's your calendar age - that's the birthday you celebrate every year – and then there's the age of your body's individual cells. And your cells may be much younger or older than your actual years. The exciting new science of telomere biology is showing us how to not only determine our cellular age, but how to actually reverse – I say it again – reverse the aging process. My guests today are Noel Thomas Patton, founder of T.A. Sciences, and Dr. Ed Park, an expert in telomeres. Welcome, both of you.

NOEL PATTON: Glad to be here.

SUZANNE SOMERS: Well, you know, I know both of you very well because I interviewed you, Noel Patton, for my book, *Bombshell*, because I was so fascinated about telomeres. Is your product – it's a supplement called TA65 – is this the fountain of youth?

(4:4-24)

. . .

ON SCREEN: Dr. Ed Park, MD, MPH

Telomere and Telomerase

Expert

(6:10-11)

. . .

SUZANNE SOMERS: Inside the cell, these Nobel Prize winners discovered that there's an enzyme called?

DR. ED PARK: Right, telomerase.

SUZANNE SOMERS: Telomerase.

DR. ED PARK: So, it literally is the oldest trick in the book. . . . All plants and animals on earth require it to keep their stem cells young. So, this is always on and the thing that TA65 does is it just gives it better gasoline so it operates at higher efficiency. Now, the good news is you can do telomerase activation naturally by meditating, by going to the gym, by eating well, sleeping, but if you don't have time or the disposition, now we have a supplement that can safely turn up that healing.

(7:15 - 8:5)

. . .

SUZANNE SOMERS: But, well, does TA65 strengthen the immune system?

NOEL PATTON: It absolutely does. That's one of the key things that we do. As we get older, our immune system is deteriorating and everybody knows it intuitively.

SUZANNE SOMERS: Right.

NOEL PATTON: But you can measure that. There's a test – a blood test done at UCLA's immunology laboratory that shows how your immune system is aging. . . . And we measure that with people that have – they do a blood test. The same thing, as you're getting older, you have more and more cancer cells. . . . See, we all have cancer

cells, even when we're young. . . . But our immune system kills them. . . . So, if those two lines cross . . . we get cancer and we die, one third of us die. So, what we're doing is we rejuvenate the immune system, turn that curve -- that line $down - \ldots - put$ it back up hoping to keep it above the cancer line. And if it is kept above the cancer line, you won't – you wouldn't get cancer, your immune system would kill the cancer cells before they kill you.

. . .

NOEL PATTON: Our website is tasciences.com.

ON SCREEN: www.tasciences.com

SUZANNE SOMERS: Very interesting stuff. Thank you, Dr. Park. Thank you, Noel, for coming....

(9:6-11:13)

b. TA-65 infomercial, DVD and transcript (Exhibits G and H, respectively)

ON SCREEN: ACTUAL TA65 CUSTOMERS

BEFORE AND AFTER PHOTOS

MALE ANNOUNCER: Some studies have shown how this amazing discovery could help support immune health and even reverse measurable, obvious effects of cellular aging. Too good to be true? Watch and decide for yourself. . ..

(7:22 - 8:3; see also 35:14-18; 43:22 – 44:1)

. . .

MALE ANNOUNCER: . . . Join investigative journalist and former CNN anchor . . . Kathleen Kennedy as she sits with the premier experts in anti-aging science and debunks the myths, discovers the truth and reveals the secrets you need to know. . . .

KATHLEEN KENNEDY: A growing new body of evidence is shattering long-held beliefs about aging and it's creating quite a controversy. Today we are going to talk to some of the world's leading edge scientists that work in the private sector developing the science that they say promises to change your life. . . .

ON SCREEN: Calvin B. Harley, Ph.D.

PRESIDENT & CSO, TELOME HEALTH, INC.

KATHLEEN KENNEDY: My guests are Dr. Cal Harley, Ph.D. and expert on cellular regeneration and telomeres.

ON SCREEN: Dr. Joseph Raphaelle [sic],

M.D.

CO-FOUNDER, PHYSIO-AGE

MEDICAL GROUP

KATHLEEN KENNEDY: Dr. Joseph Raphaelle [*sic*], a Princeton graduate and internal medicine expert with a leading anti-age practice, Physio-Age, right here in Manhattan.

ON SCREEN: Noel Patton

CEO AND FOUNDER OF T.A.

SCIENCES®

KATHLEEN KENNEDY: Noel Patton, CEO of T.A. Sciences and producer of TA65, a natural telomerase activating supplement.

ON SCREEN: Dr. Ed Park, MD, MPH

AUTHOR: "TELOMERE

TIMEBOMBS"

KATHLEEN KENNEDY: And longevity expert and private practicing anti-aging physician, Edward Park, from Orange County, California.

(8:3-10:3)

. . .

ON SCREEN: Bill Wismann, Age 58

Taking TA65 for 4 months

These results are atypical and other consumers may not

achieve such results.

BILL WISMANN: I've noticed that not only am I healthier, but I'm not catching the cough that, you know, my wife or my son or others around me are getting. My condition is just a healthier one and I have more energy.

ON SCREEN: Carol Wayne, Age 74

Taking TA65 for 1 year

These results are atypical and other consumers may not

achieve such results.

CAROL WAYNE: TA65 is such a great product. It makes your whole body healthier and stronger and more energetic.

(14:17 - 15:6)

. . .

MALE ANNOUNCER: But only TA65 has been shown to activate telomerase which starts life's most important cellular anti-aging chain reaction.

.. Some studies have shown how this amazing discovery could help support immune health and even reverse measurable obvious effects of cellular aging. Why wait one more minute when the clock is ticking?

(23:9-19)

. . .

ON SCREEN: Carol Wayne, Age 74 Taking TA65 for 1 year

CAROL WAYNE: At my age, at 74, I want to enjoy the time I have left, whatever that is. I want to have as much vitality and energy as I can possibly get. . . . And I find that with the TA65, I have the energy that I want and I need to do all the things I like to do. I like to travel. It helps with my quality of life.

(29:14-24)

. . .

NOEL PATTON: Well, I was looking for a solution to aging for myself and discovered TA65. We've been working on it for ten years. And it works for me, it's worked for my family, my friends, loved ones, and now for tens of thousands of people, and we've made it affordable and accessible to everyone, and I'm really proud to be at the beginning of this revolution in science.

(42:8-15)

c. TA-65MD Product Packaging (30 capsules) FTC-TAS0007347 (Exhibit I)

Front Panel:

Telomerase Activation works on

targeted cells in your body and can improve your quality of life!

TA65®MD

CELL

REJUVENATION

THROUGH

TELOMERASE

ACTIVATIONTM

. . .

- Helps Prevent DNA Damage
- Rejuvenates Aging Immune Systems



Nobel Prize Technology

Side Panel:

ROOT CAUSE OF AGING

- As we age our telomeres shorten
- Scientific studies have shown that short telomeres are associated with age related decline and dysfunction
- Evidence also clearly shows that people with long telomeres age healthier and live longer
- The only way to lengthen telomeres is through the activation of an enzyme called telomerase
- Currently the only way to activate telomerase is to take **TA-65**®_{MD}
- d. TA-65 Patient Brochure FTC-TAS0043861-62 (Exhibit J)

. .

TA-65®_{MD} is proven to:

. . .

- ✓ Restore an aging immune system
- **✓** Increase bone density
- ✓ Improve various biomarkers that usually decline with age

Our clients report anecdotal benefits such as:

- ✓ Increased energy
- ✓ Improved endurance
- **✓** Vision improvements
- ✓ Enhanced libido
- **✓** Better skin elasticity
- ✓ and more . . .
- e. TA-65 Patient Poster FTC-TAS0005116 (Exhibit K)

Can we age healthier and live longer?

What's the key to aging healthy and living longer?

Telomeres!

. . .

TA-65MD is proven to:

. . .

Restore an aging immune system Increase bone density Improve various biomarkers that usually decline with age.

Our clients report anecdotal benefits, such as:

Increased energy Improved endurance Vision improvements Enhanced libido Better skin elasticity and more

. .

Ask your physician if you can benefit from antiaging therapy with TA-65.

f. TA-65MD Coupon Advertisement FTC-TAS0053232 (Exhibit L)

TA-65® Is the first product to emerge from Nobel Prize winning science, focused on improving your health and quality of life.

TA⁶⁵ is the world's only telomerase activator proven in published studies to safely lengthen critically short telomeres, prevent DNA damage, and restore an aging immune system. TA-65 has been shown to increase bone density and improve various biomarkers which usually decline with age.

. . .

Visit <u>www.tasciences.com</u> or call us at 212-588-8805

g. TAS website excerpts, January 24, 2014 (Exhibit M)

TA-65 Dosing Guideline

The statistics showing TA-65's efficacy in the ground breaking scientific paper published Sept. 8, 2010 in the peer-reviewed scientific journal *Rejuvenation Research* allows [sic] us to offer different dosing options. . .

1. <u>250 units (1 capsule daily)</u> is efficacious for healthy adults in their 40's or 50's. . . . Clients who took this dose were shown to have increased short telomere length and significantly improved

immune system function. There are also anecdotal reports of increased endurance and other benefits.

. . .

2. **500 units (2 capsules daily)** has been proven to lengthen short telomeres, restore the immune system, and improve other important bio markers [*sic*]. Anecdotal reports included increased energy, endurance, vision improvements, sexual enhancement, and more. . . .

3. 1000 units (4 capsules daily)

. . .

It is expected that this dose will give an increased benefit over the lower doses (although not a proportional benefit). Study subjects experienced lengthened telomeres, restoration of weak immune systems, bone density improvements and other important bio marker [sic] improvements which usually decline with age. Anecdotal reports include energy increase, endurance, cognitive improvements, improved vision, sexual enhancement, and an overall feeling of well being [sic].

h. TAS website excerpts, December 1, 2014 (Exhibit N)

New Products

T.A. Sciences[®] is dedicated exclusively to creating research-based, clinically tested wellness products that help address cellular aging through the science of Telomerase Activation. Built upon a foundation strongly grounded in scientific evidence, T.A. Sciences[®] is widely recognized as the leader in the field of Telomere Biology.

. . .

TA-65® for Skin

. .

TA-65MD[®] nutritional supplements have been shown to improve skin elasticity and decrease the amount of time it takes skin to recover after a procedure. Due to the large number of requests from physicians and customers for a TA-65[®] product that can be applied directly to particular areas of the skin, the company added topical formulation development to its research plan. After conducting three-dimensional modeling, invitro, and in-vivo studies on a variety of formulations, T.A. Sciences[®] developed its first topical product, TA-65[®] for Skin.

TA-65[®] for Skin is available now. . . .

i. TAS Facebook page excerpts, December 3, 2014 (Exhibit O)

T.A. Sciences September 22[, 2014]

Did you know that human skin is the largest organ in the body? There are about 19 million skin cells in every inch of the body! TA-65® for Skin may improve skin elasticity and recovery time post-procedure!

For more info, call 888-360-8886 or email info@tasciences.com today!

. . .

T.A. Sciences March 4, 2013

Another happy customer placed an order for TA-65 today. She said both her husband's and her hands have less wrinkles than they did when they started taking TA-65--only a month and a half ago!

. . .

T.A. Sciences February 25, 2013

It doesn't really matter what time of day you take your TA-65. Here are a few things our customers have reported to us:

Taking TA-65 in the morning: Customers have reported having more energy throughout the day, being more productive, and having more endurance....

. . .

T.A. Sciences November 1, 2012

Your cells are on a timer - one that's running out. Learn how you can modify cells to literally reverse the aging process.

Count I False or Unsubstantiated Efficacy Claims

- 42. Through the means described in Paragraphs 40 and 41, Respondents have represented, directly or indirectly, expressly or by implication, that:
 - a. TA-65 products reverse aging;
 - b. TA-65MD prevents and repairs DNA damage;
 - c. TA-65MD restores aging immune systems;

- d. TA-65MD increases bone density;
- e. TA-65MD reverses the effects of aging, including improving skin elasticity, increasing energy and endurance, and improving vision;
- f. TA-65MD prevents or reduces the risk of cancer;
- g. TA-65 Skin reverses the effects of aging, including improving skin elasticity; and
- h. TA-65 Skin decreases recovery time of the skin after medical procedures.
- 43. The representations set forth in Paragraph 42 are false or misleading, or were not substantiated at the time the representations were made.

Count II False Establishment Claims

- 44. Through the means described in Paragraphs 40 and 41, Respondents have represented, directly or indirectly, expressly or by implication, that TA-65MD is clinically or scientifically proven to:
 - a. Reverse aging;
 - b. Prevent and repair DNA damage;
 - c. Restore aging immune systems; and
 - d. Increase bone density.
- 45. In fact, TA-65MD is not clinically or scientifically proven to reverse aging; prevent and repair DNA damage; restore aging immune systems; and increase bone density. Therefore, the representations set forth in Paragraph 44 are false or misleading.

Count III Deceptive Format

- 46. Through the means described in Paragraphs 26-29 and 41(a), Respondents have represented, directly or indirectly, expressly or by implication, that the 2012 paid-for segment on *The Suzanne Show* featuring TA-65MD was independent, educational programming and not paid commercial advertising.
- 47. In fact, the 2012 paid-for segment on *The Suzanne Show* featuring TA-65MD was not independent, educational programming and was paid commercial advertising. Therefore, the representation set forth in Paragraph 46 is false or misleading.

Count IV Deceptive Failure to Disclose Material Connections with Consumer Endorsers

- 48. Through the means described in Paragraphs 30-32 and 41, Respondents have represented, directly or indirectly, expressly or by implication, that consumers appearing in advertisements and promotional materials for TA-65MD, including the TAS infomercial, are satisfied users of TA-65MD expressing their views about the product.
- 49. In instances in which Respondents have made the representation set forth in Paragraph 48, Respondents have failed to disclose, or failed to disclose adequately, that certain of those individuals had material connections with Respondents. provided Respondents the consumer endorsers in-kind compensation, specifically, thousands of dollars of free TA-65MD. These facts would be material to consumers in their evaluation of the user reviews in connection with their purchase or use decisions regarding TA-65MD.
- 50. Respondents' failure to disclose, or disclose adequately, the material information described in Paragraph 49, in light of the representation described in Paragraph 48, is a deceptive act or practice.

Count V False Independent Users Claims

- 51. Through the means described in Paragraphs 30-32 and 41, Respondents have represented, directly or indirectly, expressly or by implication, that consumers appearing in advertisements and promotional materials for TA-65MD, including the TAS infomercial, are independent users of TA-65MD expressing their impartial views about the product.
- 52. In fact, customers appearing in advertisements and promotional materials for TA-65MD, including the TAS infomercial, are not independent users of TA-65MD expressing their impartial views about the product. Respondents provided the consumer endorsers in-kind compensation, specifically, thousands of dollars of free TA-65MD. Therefore, the representation set forth in Paragraph 51 is false or misleading.

Count VI Means and Instrumentalities to Trade Customers

- 53. Respondents have provided to their trade customers advertising, promotional, and purported substantiation materials and support referred to in Paragraphs 35-37, 40, and 41, containing, among other things, false and unsubstantiated representations, as described in Paragraphs 42 through 45 above.
- 54. By providing to their trade customers the advertising, promotional, and substantiation materials referred to in Paragraphs 35-37, 40, and 41, Respondents have provided their trade customers the means and instrumentalities for the commission of deceptive acts and practices.
- 55. Therefore, Respondents' practice as described in Paragraph 53 is a deceptive act or practice.

Violations of Sections 5 and 12


56. The acts and practices of Respondents as alleged in this complaint constitute unfair or deceptive acts or practices, and the making of false advertisements, in or affecting commerce in

violation of Sections 5(a) and 12 of the Federal Trade Commission Act.

THEREFORE, the Federal Trade Commission this eighteenth day of April, 2018, has issued this Complaint against Respondents.

By the Commission.

Exhibit A



To Meet the Challenges of Aging



OUR MISSION IS YOUR MISSION:

Our **mission** is to minimize the decline associated with aging and maximize the potential for health and longevity through Telomerase Activation



- The only scientifically-proven Telomerase Activator in the world available to the public
- A highly purified and naturally occurring single molecule from the astragalus plant
- It activates (transiently) the telomerase enzyme which can lengthen telomeres
- Safe and efficacious with over 5 years of testing
- Only available through physicians trained and licensed by T.A. Sciences


Exhibit A - Page 2

We are committed to the science and the promise of Telomere Biology

"... telomere shortening could be the reason for ageing, not only in the individual cells but also in the organism as a whole... These discoveries have added a new dimension to our understanding of the cell, shed light on disease mechanisms, and stimulated the development of potential new therapies."

(Nobel Prize Committee Press Release)

The first product to emerge from this new science is TA-65, a single small molecule that is derived from the root of the Astragalus plant. TA-65® is the only proven telomerase activator to rejuvenate telomeras in humans.



Highly respected telomere biologist, Bill Andrews says:

"Control of telomere length may be the most important step in eliminating the 125-year limit on our lifespan and taking the first crucial steps toward allowing us to live young, healthy lives."




The Nobel Prize in Physiology or Medicine 2009 was awarded jointly to Elizabeth H. Blackburn. Carol W. Greider and Jack W. Szostak, for the discovery of "how chromosomes are protected by telomeres and the enzyme telomerase". These three scientists have solved a major problem in biology: how the chromosomes can be copied in a complete way during cell divisions and how they are protected against degradation.

(Nobel Prize PRESS RELEASE 2009-10-05)

TA-65 has been shown to activate telemerase and increase telemere length in humans. This has led to improvements in immune cell function, bone density, and a number of other important age related bio-marker improvements.





The only way to lengthen telomeres is to: **Activate Telomerase** Telomerase Impacts Aging/Disease in Mice Telomerase Null /short telomeres **Shortening telomeres** Gray and Thinning Hair Weakened Immune System Intestinal Atrophy Decreased Wound Healing Decreased Lifespan Infertility Healthy and Thriving **Activated Telomerase/Long telomeres** These mice are the same age! LONG TELOMERES ARE ASSOCIATED WITH HEALTHY AGING AND LONGEVITY "As we suspected, humans of exceptional longovity are better able to maintain the length of their telomeres," said Yousin Suh. Ph.D., associate professor of medicine and of genetics at Einstein and senior author of the paper. "And we found that they owe their longevity, at least in part, to advantageous variants of genes involved in telomere maintenance." Violent Suin, Ph.D. Genetictic Varietian in Human Telamenses is Associated with Telamene Leagth in Ashkerag Cestessarans. More specifically, the researchers found that participants who have lived to a very old age have inherited mutant genes that make their telomerase-making system extra active and able to maintain telomere length more effectively. For the most part, these people were spared age-related diseases such as cardiovascular disease and diabetes, which cause most deaths among elderly people. Abort Einstein College of Medicine of Yeshiva University






Exhibit A - Page 6



is a single small molecule derived from the Chinese herb astragalus. In laboratory studies using human cell lines including fibroblast cells which normally do not express any telomerase, TA-65 was shown to unequivocally lengthen telomeres. TA-65 is the first and only commercially available telomerase activator that is safe for human consumption.

Each batch of TA-65 starts with 3 tons of astragalus root grown in a specific region of Inner Mongolia: Through a closely guarded proprietary process, a single molecule (TA-65) is extracted from the astragalus root and purified to a very high degree. There are no other similar preparations available on the market.

The illustrations below show the above ground astragalus and the root. TA-65 is an ultrapurification of one of the 2000 bioactive compounds found in the astragalus root.

T.A. Sciences Educational Manual



Astragalus plant




Astragalus root

"Our findings suggest that telomere length and variants of telomerase genes combine to help people live very long lives, perhaps by protecting them from the diseases of old age," says Dr. Suh. "We're now trying to understand the mechanism by which these genetic variants of telomerase maintain telomere length in centenarians. Ultimately, it may be possible to develop drugs that mimic the telomerase that our centenarians have been blessed with."

Genetic Variation in Aument Telomerase is Associated with Telomere Leopth in Antiversor Cardenarism.

Quoted from a study at the Albert Einstein College of Medicine of Yeshiva University





FEDERAL TRADE COMMISSION DECISIONS VOLUME 165

Complaint



Exhibit A - Page 9

The Patton Protocol

The Patton Protocol was named after Noel Thomas Patton in honor of his contributing to the science of staying young. Mr. Patton is the founder of T.A. Sciences and the first person on the planet to take purified TA-65[®] long term.

The Patton Protocol has gone through several iterations as a result of Mr. Patton's experience and the information garnered from testing and data from clients since T.A. Sciences[®] obtained the exclusive license from Geron in 2002.

Recommended daily dose for TA-65[®]: Generally people take half their daily dose in the moming and the other half in the evening. Out of personal preference, some clients take the entire dose in the morning and others take it all in the evening. We do not have evidence as to which routine is best, but we do recommend that people taking resveratrol, curcumin, or the other possible inhibitors, take the full dose in the morning/evening and the potential "inhibitors" 12 hours later.

What clients are saying

Meev 9 months of taking TA-65, I am very pleased. Not one had day and incredible feeling of well-being, darker and thinker hair, smoother and younger hinding skin. I just fool younger and more energetic.

4r69 Lam passing for 55 or below.

Bub W. 69, Seattle, WA

I'm mure active physically than am time I can remember, At age 80 I feel like the "poster bey" for IA Sciences.

Ralph A. 80, Lus Angeles, CA

As a praesticing MD, I can suspensed at the improvement in one immune govern after only 6 months.

Dr. Fred Vagnini, 70, New York, NY

My eye dozior saya he'il never soen the accumulative reserve increase in someone my age. It only goes down with time. Bill Turon, 64, Berkley Hts, NJ.

I was already a competitive athlete when I began the Pattan Prestocol. My regular 30-mile bike ride with a 4000 fisch climb-anik me 2 hours and 20 minutes. After 3 manths on TA-65 it went stron to 2 hours.

Shelby Blackburn, 45, Redwood City, CA

For the first time in more than almost five wars I can smell again. I can smell dinner cooking and I can tell whether it's chicken or fish.... It probably doesn't mean much, but it sure pleases me!

Ralph A. 82, Calabasus, CA

"Going in TA-65 is the best 50th birthday gift I could have given myzell. I just spent the weekend shing and I that ware than 20 runs in one day. A year ago that would have been unleard of. My knees doin't hather me and I had plenty of energy. I can't wait for my parents to get on the program..."

Steve P., 50, New York, NY



Reasons why you should offer TA65 to your patients

- There is a growing body of evidence associating most age-related maladies with short tolomeres.
- This same body of evidence also clearly establishes that people with long telements age healthier and look younger.
- 3 As we age our telomeres shorten.
- Exercising and healthy habits over an extended period of time can slow the attrition of telemeres, but telemere length continually declines as we age.
- 5 People who have not led a healthy lifestyle have accelerated the decime of their feloment. lengths, and most likely will suffer premature aging and associated maladies.
- 6 The only way to lengthen telomeres is through the activation of an enzyme called telomerase.
- 7 Currently the only commercially available way to activate telomerase is by taking TA⁶⁶

How to become a T.A. Sciences licensee?

- 1. The physician must sign the Licensee Agreement.
- There is a one time \$1,000 Administrative Fee that covers licensed set-up, marketing support and operations support.
- The physician must study the Doctor's Manual and pass the Telomere-Telomerase and The pasic knowledge exam.
 - Your practice will then have the ability to purchase the products \(\overline{\chi_0}^{65} \) and Support Packs, along with Telomere Length and Specialized Immunology tests at licensee discount rates.
 - o TAS profit for the doctor is \$2000 per client per year.
 - Cash Flow positive for the licensee: No investment in TA^{ist} inventory is required. Patients pay for TA^{ist} before you have to pay TA Sciences.
 - Set your practice apart by offering the only scientifically proven Telomerase Activator in the world to your patients.

Want More Information?

Call Dean Miller at (631) 697-3241 or (212) 588-8805 Email- dean@tasciences.com



Exhibit A - Page 12

Exhibit B

SUMMER 2011

Histic Primary Care 7

Telomerase Activation, Inhibition of Cellular Aging Becomes a Clinical Reality

state. Are professed to the rate of the browners.

It is a little loss, I reas interiorated in first a little loss, I reas interiorated in first as a little loss, I reason to convinced that it are all disc to environmental factors, as if a person were that an eld frush evadineing and rushing away it is in first. I could follow the disc and will be people in the fortice were the greater why people in the fortice enemy to people at the figurator despite the service reservant differences. Dischards to the following th

tolometrate on arrough you regist not deep year.

In the spirit generation, even charge for section in the legislation and one of the short section of the spirit generation in the spirit generation of the spirit generatio



available through Healthcare Practitioners who are licensed by TA Sciences. Help your patients live a longer, healthier life. Contact Marissa today at 212-588-8805 or visit

www.tasciences.com.

Exhibit C



Right now is the best time to start providing the world's most unique anti-aging supplement.

It is now FREE and EASY to sign up and become a TA-658 MD Licensee.

TA-65 mo is the world's only proven telemerase activator with in vivo studies to show efficacy and safety.

Telomerase activation is the most effective way to lengthen short telomeres and to combat age related dysfunctions.

In addition, TA-65 to has proven to rejuvenate the immune system and increase bone density.

As a Licensee, you will receive discounts for each bottle. The savings range between 25% to almost 45%. Our Licensees value TA-65[®]MO not only for the health benefits to their patients, but for the significant increase of revenue for their practice.



Customers have reported several amazing anecdotal benefits which include:

- increased energy and endurance
- better joint movements
- improved sleep

- improved strength and flexibility
- sharper memory
- sexual enhancement
- more youthful skin (age spots going away, dry patches disappearing, wrinkles smoothening)

When you sign up to **become a Licensee**, you will receive the TA-65[®] Mo Manual and Test to learn more about the product. To help with sales, you receive free marketing material to share with your staff and patients, a dedicated website for online orders and of course a discount on every bottle you order!

Call us today to learn how you can become a TA-65 time Licensee and start generating more revenue for your practice!

Request a TA-65 mp Licensee Agreement by phone or email: 212-588-8805 or sales@tasclences.com.

Visit us online at www.tasciences.com

Exhibit D



Exhibit E

Video

Ask the Experts on The Suzanne Show

Segment about TA-65

Exhibit F

OFFICIAL TRANSCRIPT PROCEEDING FEDERAL TRADE COMMISSION MATTER NO. 1423103 TITLE TELOMERASE ACTIVATION SCIENCES, INC. DATE RECORDED: DATE UNKNOWN TRANSCRIBED: JANUARY 22, 2015 REVISED: JANUARY 28, 2015 PAGES 1 THROUGH 12 ASK THE EXPERTS SEGMENT WITH SUZANNE SOMERS NOEL PATTON TA SCIENCES LIFETIME

Complaint

FEDERAL TRADE COMMISSION In the Matter of: 4 Telomerase Activation) Matter No. 1423103 Sciences, Inc. -----) Date Unknown The following transcript was produced from a digital file provided to For The Record, Inc. on January 15, 2015.

1	PROCEEDINGS
2	
3	ASK THE EXPERTS SEGMENT
4	ON SCREEN: ask the experts
5	SUZANNE SOMERS: All right, I'm going to ask
6	you a sensitive question. How old are you? Well, the
7	fact is most of us don't really know because there are
8	two answers. There's your calendar age that's the
9	birthday you celebrate every year and then there's the
10	age of your body's individual cells. And your cells may
11	be much younger or older than your actual years.
12	The exciting new science of telomere biology is
13	showing us how to not only determine our cellular age,
14	but how to actually reverse I say it again reverse
15	the aging process.
16	My guests today are Noel Thomas Patton, founder
17	of T.A. Sciences, and Dr. Ed Park, an expert in
18	telomeres. Welcome, both of you.
19	NOEL PATTON: Glad to be here.
20	SUZANNE SOMERS: Well, you know, I know both of
21	you very well because I interviewed you, Noel Patton, for
22	my book, Bombshell, because I was so fascinated about
23	telomeres. Is your product it's a supplement called
24	TA65 is this the fountain of youth?
25	NOEL PATTON: Well, I wish I could say yes, but

caps.

Complaint

5

1	we're not quite there, yet.
2	ON SCREEN: Noel Thomas Patton
3	Founder and C.E.O., TA Sciences
4	SUZANNE SOMERS: Uh-huh.
5	NOEL PATTON: But this activating of
6	telomerase, this ensyme that our pill activates
7	SUZANNE SOMERS: Mm-hmm.
8	NOEL PATTON: is a very important key
9	medical breakthrough. The Nobel Prize was awarded three
10	years ago for the discovery of this ensyme telomerase
11	SUZANNE SOMERS: Mm-hmm.
12	NOEL PATTON: that our product, TA65, bring:
13	forward. And the reason it got the Nobel Prize is
14	because the shortening of the telomeres, which is what's
15	affected by telomerase, is the root cause of aging.
16	SUZANNE SOMERS: Mm-hmm.
17	NOEL PATTON: And Dr. Park will explain this a
18	little bit better, but this is breakthrough, really
19	important science. It's not the usual snake oil stuff
20	that everybody seems to talk about.
21	SUZANNE SOMERS: Well, it is pretty exciting.
22	How does this all work, Dr. Park?
23	DR. ED PARK: Basically, in every cell if I
24	can use these props you have ends that are protective

Complaint

SUZANNE SOMERS: Right.
DR. ED PARK: So, every time a cell divides,
they get shorter.
SUZANNE SOMERS: Mm-hmm.
DR. ED PARK: If they get too short, then the
actual DNA is damaged and you have a problem. So,
telomerase is something that is involved with stem cells.
You've heard of stem cells?
SUZANNE SOMERS: Right.
ON SCREEN: Dr. Ed Park, MD, MPH
Telomere and Telomerase Expert
DR. ED PARK: Well, stem cells are not like
regular cells, they have telomerase. All the other cells
don't.
SUZANNE SOMERS: Mm-hmm.
DR. ED PARK: So, that's why they can go ahead
and create more length and that's why they can run copies
of themselves millions of times over.
SUZANNE SOMERS: Okay. So, my understanding is
human beings, approximately 50 trillion or so cells. I
don't know who counted.
DR. ED PARK: Yeah.
SUZANNE SOMERS: And on the end of each cell is
a little tail.

Exhibit F - Page 6

DR. ED PARK: Yeah.

25

Complaint

1	SUZANNE SOMERS: And that tail is what we call
2	the telomere, right? And every time that cell
3	replicates, which each cell replicates about 50 times, i
4	that right?
5	DR. ED PARK: That's right.
6	SUZANNE SOMERS: Approximately.
7	DR. ED PARK: Uh-huh, exactly.
8	SUZANNE SOMERS: It gets shorter. That's what
9	you were just describing, the tail gets shorter.
10	DR. ED PARK: Mm-hmm.
11	SUZANNE SOMERS: It replicates, the tail gets
12	shorter.
13	ON SCREEN: The "Balancing Act@" will return
14	tomorrow.
15	SUZANNE SOMERS: Inside the cell, these Nobel
16	Prize winners discovered that there's an enzyme called?
17	DR. ED PARK: Right, telomerase.
18	SUZANNE SOMERS: Telomerase.
19	DR. ED PARK: So, it literally is the oldest
20	trick in the book.
21	SUZANNE SOMERS: Right.
22	DR. ED PARK: All plants and animals on earth
	20 00000 20 000 00 00 00 00 00 00 00 00
23	require it to keep their stem cells young. So, this is
24	always on and the thing that TA65 does is it just gives

Exhibit F - Page 7

it better gasoline so it operates at higher efficiency.

Complaint

1 Now, the good news is you can do telomerase activation 2 naturally by meditating, by going to the gym, by eating 3 well, sleeping, but if you don't have time or the 4 disposition, now we have a supplement that can safely 5 turn up that healing. SUZANNE SOMERS: So, if I take your supplement, 7 TA65, this promotes the growth of the telomere at the end of each cell, right? 8 NOEL PATTON: Yeah, the TA65 is a single 9 10 molecule. It's a natural molecule that comes from a 11 plant. SUZANNE SOMERS: What's the name of that plant? 12 13 NOEL PATTON: The plant is the astragalus 14 plant. SUZANNE SOMERS: Right. 15 NOEL PATTON: It comes from China. It's been 16 used for 2,000 years in traditional Chinese medicine. SUZANNE SOMERS: Mm-hmm. 18 NOEL PATTON: But it's not a normal extract, 19 it's a single molecule. There's thousands of molecules 21 in the plant and we take out only one. It's quite a 22 burdensome technology to do so. And that single 23 molecule, when it gets inside of one of these 50 trillion

Exhibit F - Page 8

cells, it turns on a gene that's normally turned off.

SUZANNE SOMERS: Okay.

25

Complaint

9

1	NOEL PATTON: And that gene activates the
2	ensyme telomerase and it's the telomerase that makes the
3	telomeres and the ends of the chromosomes grow back long.
4	SUZANNE SOMERS: So
5	NOEL PATTON: So, that's what our pill does.
6	SUZANNE SOMERS: But, well, does TA65
7	strengthen the immune system?
8	NOEL PATTON: It absolutely does. That's one
9	of the key things that we do. As we get older, our
10	immune system is deteriorating and everybody knows it
11	intuitively.
12	SUZANNE SOMERS: Right.
13	NOEL PATTON: But you can measure that.
14	There's a test a blood test done at UCLA's immunology
15	laboratory that shows how your immune system is aging.
16	SUZANNE SOMERS: Uh-huh.
17	NOEL PATTON: And we measure that with people
18	that have they do a blood test. The same thing, as
19	you're getting older, you have more and more cancer
20	cells.
21	SUZANNE SOMERS: Uh-huh.
22	NOEL PATTON: See, we all have cancer cells,
23	even when we're young.
24	SUZANNE SOMERS: Right.

Exhibit F - Page 9

NOEL PATTON: But our immune system kills them.

Complaint

1	SUZANNE SOMERS: Right.
2	NOEL PATTON: So, if those two lines cross
3	SUZANNE SOMERS: Right.
4	NOEL PATTON: we get cancer and we die, one-
5	third of us die. So, what we're doing is we rejuvenate
6	the immune system, turn that curve that line down
7	SUZANNE SOMERS: Right.
8	NOEL PATTON: put it back up hoping to keep
9	it above the cancer line. And if it is kept above the
10	cancer line, you won't you wouldn't get cancer, your
11	immune system would kill the cancer cells before they
12	kill you.
13	SUZANNE SOMERS: Can you measure your
14	telomeres? Is there a blood test?
15	NOEL PATTON: Yes.
16	SUZANNE SOMERS: Yeah?
17	NOEL PATTON: There are three companies
18	SUZANNE SOMERS: Uh-huh.
19	NOEL PATTON: right now in the United States
20	that do telomere measurements.
21	SUZANNE SOMERS: Mm-hmm.
22	NOEL PATTON: And if you go to one of our
23	doctors, we have over 600 doctors that are licensed from
24	us who have to pass a test so that they know what

Exhibit F - Page 10

25

about telomeres, telomerase --

1	SUZANNE SOMERS: (Inaudible) test.
2	NOEL PATTON: and so on. Dr. Park is one of
3	our best doctors, but we have another 599.
4	SUZANNE SOMERS: Uh-huh.
5	NOEL PATTON: And you go on our website and you
6	can find a doctor near you. Go and have a blood test and
7	you can have it sent to one of these three companies to
8	measure your telomere level.
9	SUZANNE SOMERS: The website is TA
10	NOEL PATTON: Our website is tasciences.com.
11	ON SCREEN: www.tasciences.com
12	SUZANNE SOMERS: Very interesting stuff. Thank
13	you, Dr. Park. Thank you, Noel, for coming. When we
14	come back, we'll tell you some more interesting things.
15	(The recording was concluded.)
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	

Complaint

CERTIFICATION OF TYPIST 2 MATTER NUMBER: 1423103 3 CASE TITLE: TELOMERASE ACTIVATION SCIENCES, INC. TAPING DATE: DATE UNKNOWN TRANSCRIPTION DATE: JANUARY 22, 2015 REVISION DATE: JANUARY 28, 2015 I HEREBY CERTIFY that the transcript contained 8 9 herein is a full and accurate transcript of the tapes transcribed by me on the above cause before the FEDERAL 10 TRADE COMMISSION to the best of my knowledge and belief. 11 12 DATED: JANUARY 28, 2015 13 14 ELIZABETH M. FARRELL 16 17 CERTIFICATION OF PROOFREADER 19 20 I HEREBY CERTIFY that I proofread the transcript for 21 accuracy in spelling, hyphenation, punctuation and 22 format. 23 24 25 SARA J. VANCE

Exhibit F - Page 12

Exhibit G

TA-65 Infomercial Video

Exhibit H

OFFICIAL TRANSCRIPT PROCEEDING FEDERAL TRADE COMMISSION MATTER NO. 1423103 TITLE TELOMERASE ACTIVATION SCIENCES, INC. DATE RECORDED: JANUARY 7, 2014 TRANSCRIBED: JUNE 9, 2014 REVISED: JANUARY 19, 2015 PAGES 1 THROUGH 46 TELOMERASE INFOMERCIAL

Complaint

FEDERAL TRADE COMMISSION 3 In the Matter of: Telomerase Activation) Matter No. 1423103 Sciences, Inc. -----) January 7, 2014 The following transcript was produced from a digital file provided to For The Record, Inc. on May 21, 2014.

		4
1	PROCEEDINGS	
2		
3	TELOMERASE INFOMERCIAL	
4	ON SCREEN: CESARI DIRECT	
5	ISCI CODE: TA02	
6	TA65 Show #2	
7	TRT: 28:30 min	
8	Date: 01.07.2014	
9	ON SCREEN: The following is a paid program for	
10	TA65 MD	
11	Sponsored by T.A. Sciences	
12	CELL REJUVENATION THROUGH TELOMERASE ACTIVATION	
13	ON SCREEN: These statements have not been	
14	evaluated by the Food and Drug Administration. This	
15	product is not intended to diagnose, treat, cure or	
16	prevent any disease.	
17	MALE ANNOUNCER: The following is a paid	
18	program for TA65, sponsored by T.A. Sciences.	
19	These statements have not been evaluated by the	
20	Food and Drug Administration. This product is not	
21	intended to diagnose, treat, cure or prevent any disease.	
22	Right now, inside every cell of your body,	
23	there's a powerful clock ticking away. It's telling your	
24	body to age, to wrinkle, to gray, to slow down. But can	
25	this cellular aging be slowed, stopped or even reversed.	

Complaint

5

1	Sound like science fiction? Maybe not. Stay tuned.
2	ON SCREEN: BIOLOGICAL BREAKTHROUGHS
3	Breaking the Age Code
4	MALE ANNOUNCER: Today, on Biological
5	Breakthroughs, we're breaking the age code. You're going
6	to hear about an earth-shaking discovery your doctor may
7	not even know yet.
8	ON SCREEN: 2009 Nobel Prize Laureates
9	Nobel Prize in Physiology or Medicine
10	"For the discovery of the ensyme telemorase"
11	MALE ANNOUNCER: You'll hear in detail about
12	the science around this discovery that was awarded the
13	Nobel Prize for medicine in 2009. You'll understand how
14	and why your very own DNA tells your cells it's time to
15	die. You'll learn about telomeres deep inside your
16	cells.
17	At the tips of all 23 pairs of your
18	chromosomes, there is a section of replicated DNA
19	sequencing that acts to protect your chromosome every
20	time it duplicates and allows your cells to replicate
21	perfectly. These are called telomeres. As long as they
22	maintain their length, they allow perfect cellular
23	replication. Unfortunately, nature uses telomere length
24	like a fuse. Every time your cells divide, the telomere

Exhibit H - Page 5

section shortens. When your telomeres get critically

short,	the	cell	processes	shut	down	replication	and

- 3 in what you see as cellular aging.
- 4 The good news is that a 2009 Nobel winning
- 5 discovery in medicine unveiled an ensyme called
- 6 telomerase. Naturally produced on the DNA chain itself,

cellular death occurs. Old, dead and worn cells manifest

- 7 it can extend and rebuild telomeres. It's a fact.
- 8 Longer telomeres mean healthier cells that can live
- 9 longer.

1

2

- 10 Listen for the next few minutes and you'll
- 11 learn about a natural way you can activate the production
- 12 of telomerase in your cells. 10,000 people, including
- 13 doctors, scientists and clients at elite anti-aging
- 14 clinics, are safely doing this right now and they are
- 15 getting results.
- 16 ON SCREEN: Letter written by Roger Daltrey on
- 17 the screen:
- 18 I have been interested in alternative medicine
- 19 since the early days of my career.
- 20 Maintaining good health through the stresses
- 21 and strains of touring and singing with The Who requires
- 22 enormous stamina. I was recommended TA65 by a good
- 23 friend and decided to try it.
- 24 After taking TA65 for one year I noticed
- 25 considerable improvement in energy levels. Colds and

Complaint

1	winter infections have been a rarity.
2	Recently I took a 6 week break from taking the
3	product, and noticed significant energy drop off.
4	Although to my knowledge the evidence of
5	benefit to everyone is not proven, I have no doubt that
6	this product works for me. I hope it does the same for
7	you.
8	Roger Daltrey
9	I was recommended T65and decided to try it.
10	I noticed considerable improvement in energy
11	levels.
12	Coldshave been a rarity.
13	Roger Daltrey
14	Lead singer of "The Who"
15	ROGER DALTREY: I was recommended TA65 by a
16	good friend and decided to try it. After taking TA65 for
17	one year, I noticed considerable improvement in energy
18	levels. Colds and winter infections have been a rarity.
19	Although, to my knowledge, the evidence of benefit to
20	everyone is not proven, I have no doubt that this product
21	works for me. I hope it does the same for you.
22	ON SCREEN: ACTUAL TA65 CUSTOMERS
23	BEFORE AND AFTER PHOTOS
24	MALE ANNOUNCER: Some studies have shown how

Exhibit H - Page 7

this amazing discovery could help support immune health

Complaint

1 and even reverse measurable, obvious effects of cellular aging. Too good to be true? Watch and decide for 3 yourself. Join investigative journalist and former CNN 4 anchor --ON SCREEN: Kathleen Kennedy 5 6 INVESTIGATIVE JOURNALIST MALE ANNOUNCER: -- Kathleen Kennedy as she sits with the premier experts in anti-aging science and 8 9 debunks the myths, discovers the truth and reveals the secrets you need to know. 10 This is Biological Breakthroughs: Breaking the 11 Age Code. 12 ON SCREEN: BIOLOGICAL BREAKTHROUGHS 13 14 Breaking the Age Code 15 KATHLEEN KENNEDY: Hi and welcome, I'm Kathleen 16 Kennedy. Today we're discussing probably the most important topic in your life, telomeres. And in 2009, a group of scientists were awarded the Nobel Prise in 18 19 medicine for the research that led to the discovery of 20 telomerase. ON SCREEN: Kathleen Kennedy 22 INVESTIGATIVE JOURNALIST 23 KATHLEEN KENNEDY: A growing new body of 24 evidence is shattering long-held beliefs about aging and

25

Exhibit H - Page 8

it's creating quite a controversy.

Complaint

9

Today we are going to talk to some of the
world's leading edge scientists that work in the private
sector developing the science that they say promises to
change your life. Listen for the next few minutes as we
delve into the new science of anti-aging at the cellular
level and make up your own mind about what the
implications are for you.
ON SCREEN: Calvin B. Harley, Ph.D.
PRESIDENT & CSO, TELOME HEALTH, INC.
KATHLEEN KENNEDY: My guests are Dr. Cal
Harley, Ph.D. and expert on cellular regeneration and
telomeres.
ON SCREEN: Dr. Joseph Raphaelle, M.D.
CO-FOUNDER, PHYSIO-AGE MEDICAL GROUP
KATHLEEN KENNEDY: Dr. Joseph Raphaelle, a
Princeton graduate and internal medicine expert with a
leading anti-age practice, Physio-Age, right here in
Manhattan.
ON SCREEN: Noel Patton
CEO AND FOUNDER OF T.A. SCIENCES®
KATHLEEN KENNEDY: Noel Patton, CEO of T.A.
Sciences and producer of TA65, a natural telomerase
activating supplement.
ON SCREEN: Dr. Ed Park, MD, MPH

Exhibit H - Page 9

AUTHOR: "TELOMERE TIMEBOMBS"

Complaint

1	KATHLEEN KENNEDY: And longevity expert and
2	private practicing anti-aging physician, Edward Park,
3	from Orange County, California.
4	The topic is telomeres, and in 2009, a group of
5	scientists were awarded the Nobel Prize in medicine for
6	the research that led to the discovery of telomerase. I
7	want to start with you Dr. Cal Harley. You can tell us
8	the significance of this discovery.
9	ON SCREEN: Calvin B. Harley, Ph.D.
10	PRESIDENT & CSO, TELOME HEALTH, INC.
11	"THE DISCOVERY OF TELOMERASE WAS A BREAKTHROUGH
12	IN MEDICINE"
13	DR. CALVIN HARLEY: Right. The discovery of
14	telomerase and the role that telomeres play at the end of
15	chromosomes was a major breakthrough in medicine. It
16	allowed us to understand the mechanism of cellular aging
17	and what you can do about it. Aging, of course, is very
18	complex, but it's clear now that the tips of the
19	chromosomes provide a counting mechanism for cellular
20	aging. It was only about 40 or 50 years ago that people
21	thought our normal body cells were immortal. That's not
22	the case.
23	ON SCREEN: Calvin B. Harley, Ph.D.
24	PRESIDENT ε CSO, TELOME HEALTH, INC.
25	"OUR BODY CELLS HAVE A TICKING CLOCK"

1 "SHORT TELOMERES CAN LEAD TO CELL DEATH" DR. CALVIN HARLEY: They have a clock that 2 3 ticks down. When the telomeres become short enough, that 4 triggers cellular senescence, loss of normal cell and tissue function. 5 KATHLEEN KENNEDY: Ah, so short telomeres are 6 7 the culprit. DR. CALVIN HARLEY: Right. This is a double 8 9 helix, it's a single chromosome. ON SCREEN: Calvin B. Harley, Ph.D. 10 PRESIDENT & CSO, TELOME HEALTH, INC. 11 12 DR. CALVIN HARLEY: But these tips at the ends of the chromosomes protect the chromosomen from 13 undergoing what's called genomic instability or the 14 15 inappropriate division of chromosomes between the two daughter cells. 16 17 So, every time a cell divides because of 18 something called the end replication problem, we lose a little bit of our telomeric DNA. And that's basically 19 20 the counting mechanism. 21 ON SCREEN: Calvin B. Harley, Ph.D. 22 PRESIDENT & CSO, TELOME HEALTH, INC.

Exhibit H - Page 11

"CRITICALLY SHORT TELOMERES CAN LEAD TO

DR. CALVIN HARLEY: When the telomere gets

23

24

25

CELLULAR AGING"

11

Complaint

critically short, that will trigger cellular aging --KATHLEEN KENNEDY: So, if we could stop that or 2 slow the process, we can --3 DR. CALVIN HARLEY: This is still very early 4 years in understanding this biology and what the clinical 5 6 outcomes might be. 7 ON SCREEN: Dr. Joseph Raphaelle, M.D. CO-FOUNDER, PHYSIO-AGE MEDICAL GROUP 8 "BAD DIET AND EXERCISE CAN LEAD TO SHORT 9 TELOMERES" 10 DR. JOSEPH RAPHAELLE: The thing that's really 11 12 fascinating to me is all that we've learned about over 13 the years and decades about diet, exercise, good 14 nutrition, supplements, all those things that we know are 15 good for us, telomere biology ties that all together, 16 because if you have bad diet and exercise habits, you 17 have shorter telomeres, all things being equal. 18 ON SCREEN: Dr. Joseph Raphaelle, M.D. 19 CO-FOUNDER, PHYSIO-AGE MEDICAL GROUP 20 "WE MUST DO EVERYTHING WE CAN TO KEEP OUR TELOMERES HEALTHY" 21 DR. JOSEPH RAPHAELLE: You want to do 22 23 everything you can to keep your telomeres healthy. That includes having a healthy diet, exercising regularly. 24

25

Exhibit H - Page 12

And then, if that's not enough, after we've measured your

13

1	telomeres, then it's time to intervene with something
2	more.
3	KATHLEEN KENNEDY: All right. I'd like to turn
4	to you now, Noel Patton, CEO of T.A. Sciences. Tell us
5	about the science that led to this. This is Nobel Prise
6	winning science.
7	ON SCREEN: Noel Patton
8	CEO AND FOUNDER OF T.A. SCIENCES
9	"THE DISCOVERY OF TELOMERASE WON THE NOBEL
10	PRIZE"
11	NOEL PATTON: Well, yes, the discovery of the
12	enzyme, telomerase, won the Nobel Prize three years ago.
13	But we understand now that telomeres are the ends of the
14	chromosomes, like the plastic tips at the end of a
15	shoelace, and they get shorter with age, and that's the
16	ticking clock in every cell.
17	ON SCREEN: Noel Patton
18	CEO AND FOUNDER OF T.A. SCIENCES
19	"TELOMERES ARE THE TICKING CLOCK IN EVERY CELL"
20	NOEL PATTON: Now, what is telomerase, because
21	our pill, TA65, is a telomerase activator. Telomerase is
22	a natural ensyme that's produced inside the cells and it
23	has the ability to add back
24	ON SCREEN: Noel Patton
25	CEO AND FOUNDER OF T.A. SCIENCES

Complaint

1 "TELOMERASE CAN LENGTHEN SHORT TELOMERES" 2 NOEL PATTON: -- DNA at the ends of the 3 chromosomes, to add back length to the telomeres. ON SCREEN: TA65 MD 4 5 ON SCREEN: Dr. Fredric Stern The Stern Center for Aesthetic Surgery 6 7 DR. FREDRIC STERN: What TA65 does, which is 8 completely unique, is that it has a very purified substance in it which helps to reactivate the ensyme 9 10 called telomerase, which helps to repair the telomeres 11 and lengthen the short telomeres in the body. There is 12 excellent clinical evidence in clinical studies that have been done that are very well supported that demonstrate 14 that the active substance in TA65 does, in fact, simulate the telomerase ensyme which then lengthens the shorter 15 16 telomeres in the cells. ON SCREEN: Bill Wismann, Age 58 17 Taking TA65 for 4 months 18 19 These results are atypical and other consumers 20 may not achieve such results. 21 BILL WISMANN: I've noticed that not only am I 22 healthier, but I'm not catching the cough that, you know, 23 my wife or my son or others around me are getting. My 24 condition is just a healthier one and I have more energy. ON SCREEN: Carol Wayne, Age 74 25

15

1	Taking TA65 for 1 year
2	These results are atypical and other consumers
3	may not achieve such results.
4	CAROL WAYNE: TA65 is such a great product. It
5	makes your whole body healthier and stronger and more
6	energetic.
7	ON SCREEN: Keith Clearwater, Age 53
8	Taking TA65 for 2.5 years
9	KEITH CLEARWATER: I'm a golfer, I play on the
10	PGA Tour, now the Champions Tour. You know, I take TA65
11	every day only because it's working. It makes me feel
12	better.
13	ON SCREEN: These results are atypical and
14	other consumers may not achieve such results.
15	KEITH CLEARWATER: This thing's really doing
16	something and it's doing it at the cellular level. So,
17	you're changing your body. I mean, and it affects
18	everything.
19	KATHLEEN KENNEDY: Now, let's turn to you, Dr.
20	Ed Park. You have a very successful anti-aging business
21	in Orange County, California. This is a community that's
22	very attuned to the latest and greatest in anti-aging.
23	How did you first get involved with TA65?
24	ON SCREEN: Dr. Ed Park, MD, MPH
25	AUTHOR: "TELOMERE TIMEBOMBS"

Complaint

1 DR. ED PARK: When Noel's company came out in 2007 with a product that they claimed would lengthen the 2 3 telomeres, it's not hard to figure out that that would be a good thing. So, I looked at all the safety data that was published and got in contact with Dr. Raphaelle and 5 Noel and it seemed legit. I looked at all the safety efficacy and, so, I started trying it. 7 KATHLEEN KENNEDY: Now, this is remarkable. 8 9 DR. ED PARK: Yeah. KATHLEEN KENNEDY: This is you how long ago? 10 DR. ED PARK: Well, this is me actually when I 11 12 was 32 and I'm 45 now. ON SCREEN: These results are atypical and 13 14 other consumers may not achieve such results. 15 Dr. Ed Park, MD, MPH AUTHOR: "TELOMERE TIMEBOMBS" 16 17 "THIS IS ME AT 32, I'M 45 NOW" KATHLEEN KENNEDY: That really truly is 18 19 remarkable. 20 DR. ED PARK: I was practicing OB/GYN, so my patients would come back for their annual exams and 21 they'd say, you literally look like a different person. 23 ON SCREEN: Dr. Ed Park, MD, MPH 24 AUTHOR: "TELOMERE TIMEBOMBS" "I LOOK LIKE A DIFFERENT PERSON"

17

1	DR. ED PARK: What happened, what are you
2	taking?
3	KATHLEEN KENNEDY: So, at what point did you
4	start prescribing it for your patients?
5	ON SCREEN: Dr. Ed Park, MD, MPH
6	AUTHOR: "TELOMERE TIMEBOMBS"
7	"THIS STUFF WORKS, MY PATIENTS WANT IT"
8	DR. ED PARK: About a year into it, I called
9	Noel. I was patient number 19, I think, somewhere around
10	there. I called Noel and I said, this stuff works, my
11	patients want it, what can we do. So, that was 2008.
12	KATHLEEN KENNEDY: What is it that you tell
13	your patients when recommending TA65?
14	ON SCREEN: Dr. Ed Park, MD, MPH
15	AUTHOR: "TELOMERE TIMEBOMBS"
16	"IT'S VERY SAFE AND I TAKE IT EVERY NIGHT"
17	DR. ED PARK: I explain to them that it really
18	is about maintaining your health and that this is
19	literally the oldest trick in your book. All of your
20	stem cells, as Dr. Raphaelle said, have this mechanism to
21	stay healthy. So, I tell them it's nothing unnatural,
22	it's very safe, and something that I take every night.
23	I've even given it to my family, so
24	ON SCREEN: Kathleen Kennedy
25	INVESTIGATIVE JOURNALIST

Complaint

1	KATHLEEN KENNEDY: Through today's program, you
2	can find out how to learn more about TA65. You can call
3	or go online right now for more information.
4	ON SCREEN: This is a paid program for TA65
5	BuyTA65Direct.com
6	KATHLEEN KENNEDY: You can also find out if you
7	qualify to order TA65 directly. Plus, if you're a
8	physician interested in TA65 for yourself or maybe for
9	your patients, they can help you as well.
10	ON SCREEN: Consult your physician before
11	beginning any dietary supplement program, particularly if
12	you have special medical needs.
13	BuyTA65Direct.com
14	(Scrolling) CALL NOW FOR MORE INFORMATION -
15	CALL IF YOU ARE A PHYSICIAN INTERESTED IN DISTRIBUTING
16	TA65 - CALL TO SEE IF YOU ARE QUALIFIED TO PURCHASE TA65
17	DIRECTLY
18	KATHLEEN KENNEDY: Coming up next, you'll hear
19	from more doctors around the world that are utilizing
20	telomerase activation for their clients and we'll ask
21	some tougher questions. We'll ask our doctors about
22	which ones here take TA65 and why and how they know it
23	works. Stay tuned.
24	ON SCREEN: Letter written by Roger Daltrey on

25

the screen:

19

1	I have been interested in alternative medicine
2	since the early days of my career.
3	Maintaining good health through the stresses
4	and strains of touring and singing with The Who requires
5	enormous stamina. I was recommended TA65 by a good
6	friend and decided to try it.
7	After taking TA65 for one year I noticed
8	considerable improvement in energy levels. Colds and
9	winter infections have been a rarity.
10	Recently I took a 6 week break from taking the
11	product, and noticed significant energy drop off.
12	Although to my knowledge the evidence of
13	benefit to everyone is not proven, I have no doubt that
14	this product works for me. I hope it does the same for
15	you.
16	Roger Daltrey
17	Maintaining good healthwhile touring and
18	singing with The \mbox{Who} requires enormous stamina.
19	I was recommended TA65and decided to try it.
20	I noticed considerable improvement in energy
21	levels.
22	Coldshave been a rarity.
23	Recently, I took a 6-week break from the
24	product, and noticed a significant energy drop-off.
25	Roger Daltrey

Complaint

Lead singer of "The Who" 1 ROGER DALTREY: Well, I've been interested in 2 3 alternative medicine since the early days of my career. Maintaining good health through the stresses and strains 4 of touring and singing with The Who required enormous 5 6 stamina. I was recommended TA65 by a good friend and decided to try it. After taking TA65 for one year, I 7 noticed considerable improvement in energy levels. Colds 8 and winter infections have been a rarity. 9 10 Recently, I took a six-week break from the 11 product and noticed significant energy drop-off. Although, to my knowledge, the evidence of benefit to 12 everyone is not proven, I have no doubt that this product 13 works for me. I hope it does the same for you. 14 ON SCREEN: TA65 MD 15 16 MALE ANNOUNCER: It's no secret that your body 17 is silently aging daily. 18 ON SCREEN: Photos at age 19, age 37, age 56 19 MALE ANNOUNCER: Look at photos of yourself 20 five years, 10 years, 20 years apart. Can you see it? Of course you can. Time takes its toll. You want to hit 21 the stop button, don't you? But can your cellular aging 23 be slowed, stopped or even reversed? Listen closely. 24 ON SCREEN: 2009 Nobel Prise Laureates

Exhibit H - Page 20

Nobel Prize in Physiology or Medicine

25

21

1	"for the discovery of the enzyme telemorase"
2	MALE ANNOUNCER: A profound discovery related
3	to this led to the Nobel Prize for medicine in 2009. It
4	unlocked potentially the most powerful anti-aging secret
5	science has ever discovered.
6	Sound like science fiction? It's not. It's
7	science fact and has become a reality for you in TA65.
8	ON SCREEN: CALL NOW
9	BuyTA65Direct.com
10	MALE ANNOUNCER: Deep inside of you, there is a
11	biological clock ticking away in every one of your three
12	trillion cells. In young people, cells divide easily,
13	replicating themselves. As we age, this process slows.
14	Deep inside the nucleus, the secret of aging is revealed.
15	In every cell, you have 23 pairs of chromosomes. At the
16	tips are a sequence of repeating DNA code called
17	telomeres. This section protects the DNA during
18	duplication, much the same way the plastic tip of a
19	shoelace protects it from fraying.
20	Unfortunately, every time division occurs, the
21	telomeres shorten. Eventually, they shorten so much,
22	they can no longer protect the replication process. The
23	cell can no longer divide. Its healthy replication over,
24	it becomes senescent or dies.
25	Some scientists today accept this as a root

Complaint

cause of cellular aging. This was the research behind 1 2 the awarding of the Nobel Prise. ON SCREEN: EXTRACTED FROM NATURAL PLANT 3 4 MOLECULES CALL NOW 5 6 BuyTA65Direct.com MALE ANNOUNCER: T.A. Sciences has developed a process for extracting a naturally-occurring plant 8 9 molecule and refining it in a capsule you can take to signal your body that it's time to lengthen your 10 11 telomeres. 12 Here's how it works. TA65 enters the 13 bloodstream and travels throughout the body where it passes through individual cells and activates the 14 15 production of an ensyme called telomerase. This ensyme travels to the tips of the chromosome and attaches and 16 17 add lengths to the telomeres and restores them. This effect allows healthy cells to live longer and 18 19 potentially replicate many more times. More healthy 20 identical cellular replication is what you want. ON SCREEN: KEYS TO HEALTH: 21 22 - Quality Sleep 23 - Good Nutrition - Regular Exercise CALL NOW 25

Complaint

23

1	BuyTA65Direct.com
2	MALE ANNOUNCER: Call now and discover TA65 for
3	yourself. Yes, you need great quality sleep, healthy
4	eating and nutrition. Even exercise helps retain
5	cellular health.
6	ON SCREEN: PROVEN TELOMERASE ACTIVATION
7	CALL NOW
8	BuyTA65Direct.com
9	MALE ANNOUNCER: But only TA65 has been shown
10	to activate telomerase which starts life's most important
11	cellular anti-aging chain reaction.
12	ON SCREEN: SUPPORTS IMMUNITY
13	CALL NOW
14	BuyTA65Direct.com
15	MALE ANNOUNCER: Some studies have shown how
16	this amazing discovery could help support immune health
17	and even reverse measurable obvious effects of cellular
18	aging. Why wait one more minute when the clock is
19	ticking?
20	ON SCREEN: CALL NOW FOR MORE INFORMATION
21	CALL NOW
22	BuyTA65Direct.com
23	(Scrolling) TA65 IS A PATENTED PRODUCT ONLY
24	AVAILABLE FROM TA SCIENCES

Exhibit H - Page 23

MALE ANNOUNCER: Call now and find out more

Complaint

1 about TA65. ON SCREEN: CALL NOW IF YOU ARE A PHYSICIAN YOU MAY QUALITY TO ORDER DIRECT 3 4 CALL NOW BuyTA65Direct.com 5 MALE ANNOUNCER: If you're a doctor and want to 6 learn more, consultants are standing by. You can even see if you qualify to purchase TA65 directly through a 8 9 special direct program, only available to viewers of this 10 program. 11 ON SCREEN: AFFORDABLE & EFFECTIVE AVAILABLE AS A NUTRITIONAL SUPPLEMENT 12 CALL NOW 13 BuyTA65Direct.com MALE ANNOUNCER: TA65 is affordable, it works, 15 and it's available direct to you as a nutritional 17 supplement. ON SCREEN: CALL NOW FOR MORE INFORMATION 18 19 30 day money-back guarantee less s/h 20 CALL NOW 21 BuyTA65Direct.com MALE ANNOUNCER: It's only available from one 22 company in the world, T.A. Sciences. Don't hesitate. 23 24 Call now. 25 ON SCREEN: BIOLOGICAL BREAKTHROUGHS

Complaint

1	Breaking the Age Code
2	KATHLEEN KENNEDY: Welcome back to Biological
3	Breakthroughs. Today we're talking to a team of
4	scientists and doctors around the world about an
5	explosive growth topic for baby boomers and younger.
6	ON SCREEN: Kathleen Kennedy
7	INVESTIGATIVE JOURNALIST
8	KATHLEEN KENNEDY: The topic is telomeres, and
9	in 2009, a group of scientists were awarded the Nobel
10	Prise in medicine for the research that led to the
11	discovery of telomerase.
12	ON SCREEN: Calvin B. Harley, Ph.D.
13	PRESIDENT & CSO, TELOME HEALTH, INC.
14	KATHLEEN KENNEDY: For those of you just
15	joining us, Dr. Cal Harley, since the beginning of time
16	we have thought that the wrinkles we get, the skin
17	becoming thinner, our bones becoming more brittle is all
18	part of just being old. But what we're learning now is
19	that this is simply a manifestation of something else, is
20	that correct?
21	ON SCREEN: Calvin B. Harley, Ph.D.
22	PRESIDENT & CSO, TELOME HEALTH, INC.
23	"THERE IS A CLOCKING MECHANISM FOR OUR DNA"
24	DR. CALVIN HARLEY: Yeah, that's correct,

Exhibit H - Page 25

Kathleen. Basically, what we see on the surface are a

25

Complaint

1	manifestation of what's going on inside the body in cells
2	and surrounding cells. So, it's quite clear now that
3	there is a clocking mechanism for aging within our DNA,
4	and it's very clear that telomerase can elongate
5	telomeres.
6	KATHLEEN KENNEDY: I think most people want to
7	know, where does it derive from?
8	ON SCREEN: Calvin B. Harley, Ph.D.
9	PRESIDENT & CSO, TELOME HEALTH, INC.
10	"TA65 IS DERIVED FROM A NATURAL PRODUCT"
11	DR. CALVIN HARLEY: So, TA65 is supplement.
12	It's not a drug, at least not at this point in time. But
13	what's important is that it's derived from a natural
14	product. So, aspirin, Digitoxin, the heart medicine,
15	penicillin, Taxol, these are all natural product derived
16	entities.
17	ON SCREEN: Calvin B. Harley, Ph.D.
18	PRESIDENT & CSO, TELOME HEALTH, INC.
19	"5000 DIFFERENT EXTRACTS WERE SCREENED TO
20	IDENTIFY THE COMPOUND IN TA65"
21	DR. CALVIN HARLEY: It turns out that this
22	particular molecule is derived from a plant that was
23	known to have health maintenance or longevity type
24	properties. We actually screened 5,000 different
25	extracts of natural products. We screened them for the

27

1	ability to activate telomerase in normal human cells that
2	have telomerase capability or are able to activate
3	telomerase. And one compound stood out amongst all of
4	them and that's the product that went into TA65.
5	KATHLEEN KENNEDY: And Noel Patton, your
6	company, T.A. Sciences, has the exclusive global
7	distribution of TA65. I think most people want to know,
8	is this going to cost me a fortune?
9	ON SCREEN: Noel Patton
10	CEO AND FOUNDER OF T.A. SCIENCES
11	"TONS OF PLANT MATERIAL ARE REQUIRED TO PRODUCE
12	A SMALL AMOUNT OF TA65"
13	NOEL PATTON: As Dr. Harley said, this is a
14	very rare molecule in the plant. We literally start with
15	tons of plant material to end up with a small amount of
16	TA65. So, it started out very expensive. Most of our
17	clients were either really rich people or professional
18	athletes, movie stars, these kinds of people. But, now,
19	we have tens of thousands of people that are taking the
20	product and the costs have been able to come down.
21	KATHLEEN KENNEDY: So, it's not going to cost
22	me an arm and a leg?
23	ON SCREEN: Noel Patton
24	CEO AND FOUNDER OF T.A. SCIENCES
25	"IT'S AFFORDABLE FOR EVERYONE"

Complaint

1 NOEL PATTON: Not going to cost you an arm and 2 a leg. Now it's affordable for everyone. ON SCREEN: Kathleen Kennedy 3 4 INVESTIGATIVE JOURNALIST KATHLEEN KENNEDY: Good news, all right. Well, 5 Dr. Raphaelle, your practice offers independent testing 6 of telomeres. Tell me a little bit about the process. ON SCREEN: Dr. Joseph Raphaelle, M.D. 8 9 CO-FOUNDER, PHYSIO-AGE MEDICAL GROUP 10 "IT'S MORE IMPORTANT TO KNOW YOUR TELOMERE LENGTH THAN YOUR CHOLESTEROL" 11 12 DR. JOSEPH RAPHAELLE: Well, the process is 13 pretty simple. The patient comes in and we can get a sample of blood or saliva and send it off to a lab and 14 15 we'll have the results in a couple of weeks. I like all 16 my patients to get their telomeres tested in my practice 17 now because I really think that it's probably more 18 important to know what your telomere length is than to 19 know what your cholesterol is. It gives you more 20 information about the health of your body, not just your 21 vascular system, about all the other organ systems that 22 we've been talking about. ON SCREEN: TA65 23 DR. FREDRIC STERN: People coming to see me are 24

25

Exhibit H - Page 28

coming for various reasons, but what it comes down to is

29

1	they're wanting to feel better, they're wanting to look
2	better, they're wanting to appear more refreshed and
3	youthful.
4	ON SCREEN: Dr. Fredric Stern
5	The Stern Center for Aesthetic Surgery
6	DR. FREDRIC STERN: And I can offer them
7	procedures, I can offer them laser procedures, I can
8	offer them cosmetic surgeries to improve these things.
9	But, now, I have something that I can offer them that
10	they can take that I can feel confident can also promote
11	their health and make them feel better internally and get
12	down to the very basic genetic nature of what causes
13	aging.
14	ON SCREEN: Carol Wayne, Age 74
15	Taking TA65 for 1 year
16	CAROL WAYNE: At my age, at 74, I want to enjoy
17	the time I have left, whatever that is. I want to have
18	as much vitality and energy as I can possibly get.
19	ON SCREEN: These results are atypical and
20	other consumers may not achieve such results.
21	CAROL WAYNE: And I find that with the TA65, I
22	have the energy that I want and I need to do all the
23	things I like to do. I like to travel. It helps with my
24	quality of life.
25	KARL GITTELMAN: I still play baseball. And

Complaint

1 one of the things I noticed was that when I went to throw 2 a ball -- normally, when you throw a ball, you reach back like this and throw. 3 ON SCREEN: Karl Gittelman, Age 75 5 Taking TA65 for 2 years KARL GITTELMAN: When I tried to do that, I felt pain in this shoulder. And, so, I adapted to that and I was able to throw from my ear, you know, and I was able to throw pretty well. 9 10 ON SCREEN: These results are atypical and other consumers may not achieve such results. 11 KARL GITTELMAN: Well, I started taking TA65, 12 as I said, in April, I'm out there throwing my short arm 12 14 one day, and all of a sudden, I reach back and throw, no 15 pain. Two years later, I am -- that's the way I throw 16 now. I have never had an inch of pain or any kind of indication of pain. You can see where my arm's out here, 17 18 which I could never have done, you know, three years ago. I mean, for 23 years, I couldn't do it and, all of a 19 20 sudden, bam, I started taking TA65, and six months later, 21 I could do it. 22 ON SCREEN: Keith Clearwater, Age 53 23 Taking TA65 for 2.5 years 24 KEITH CLEARWATER: I'm 53 years old. I don't

feel any different than when I was 20, and that's

25

31

1	genuine. I do the same things. I'm very active with
2	kids, grandkids.
3	ON SCREEN: These results are atypical and
4	other consumers may not achieve such results.
5	KEITH CLEARWATER: And for me, I believe that
6	I'll be able to do these things late into my eighties and
7	nineties. My goal is to fight this thing forever and be
8	able to maintain, I don't know, the kind of lifestyle and
9	activity level that I've had my whole life.
10	KATHLEEN KENNEDY: What would you say, Dr.
11	Park, is the most surprising benefit you've seen for your
12	patients?
13	ON SCREEN: Dr. Ed Park, MD, MPH
14	AUTHOR: "TELOMERE TIMEBOMBS"
15	DR. ED PARK: Thanks to Dr. Raphaelle and T.A.
16	Sciences, we have a whole way of measuring and that model
17	allows us to tell you, hey, this stuff is worth it, it's
18	working.
19	KATHLEEN KENNEDY: And let me just see a show
20	of hands right now. Who here is taking TA65?
21	ON SCREEN: Consult your physician before
22	beginning any dietary supplement program, particularly if
23	you have special medical needs.
24	KATHLEEN KENNEDY: Well, that speaks volumes to
25	me.

Complaint

1	All right. Well, the secret of aging silently
2	ticks away inside your cells.
3	ON SCREEN: Consult your physician before
4	beginning any dietary supplement program, particularly if
5	you have special medical needs.
6	BuyTA65Direct.com
7	KATHLEEN KENNEDY: That secret is revealed in
8	your telomeres. Your body seems to have the secret
9	itself to lengthening your telomeres with an ensyme
10	created in the DNA chain itself, telomerase.
11	ON SCREEN: This is a paid program for TA65
12	BuyTA65Direct.com
13	(Scrolling) CALL NOW FOR MORE INFORMATION
14	CALL IF YOU ARE A PHYSICIAN INTERESTED IN DISTRIBUTING
15	TA65 - CALL TO SEE IF YOU ARE QUALIFIED TO PURCHASE TA65
16	DIRECTLY - CALL TO FIND OUT ABOUT TELOMERE TESTING
17	KATHLEEN KENNEDY: If you'd like to learn more
18	on how you can educate yourself further or try TA65, go
19	to the web address on your screen or call the number
20	below. There is no obligation. The call is absolutely
21	free. There are informed people just waiting to answer
22	your questions.
23	We'll be back after this short break.
24	ON SCREEN: TA65 MD
25	HOW WILL YOU LOOK?

Complaint

33

1	(PHOTOS)
2	AGE 70
3	AGE 80
4	AGE 90
5	MALE ANNOUNCER: Longevity experts have
6	identified key factors that define what your personal
7	cellular aging will look like, quality sleep, active
В	exercise, good nutrition, plus genetics are all
9	important.
10	ON SCREEN: LIVE HEALTHY LONGER
11	CALL NOW
12	BuyTA65Direct.com
13	MALE ANNOUNCER: If you're the kind of person
14	that wants a long healthy life, you probably make good
15	choices daily. But what can be done about your cellular
16	health?
17	Deep inside of you, there is a biological clock
18	ticking away in every one of your three trillion cells.
19	In young people, cells divide easily, replicating
20	themselves. As we age, this process slows. Deep inside
21	the nucleus, the secret of aging is revealed. In every
22	cell, you have 23 pairs of chromosomes. At the tips are
23	a sequence of repeating DNA code called telomeres. This
24	section protects the DNA during duplication, much the

Exhibit H - Page 33

same way the plastic tip of a shoelace protects it from

Complaint

1	fraying.
2	Unfortunately, every time division occurs, the
3	telomeres shorten. Eventually, they shorten so much,
4	they can no longer protect the replication process. The
5	cell can no longer divide. Its healthy replication over
6	it becomes senescent or dies.
7	Some scientists today accept this as a root
8	cause of cellular aging. This was the research behind
9	the awarding of the Nobel Prise.
10	ON SCREEN: EXTRACTED FROM NATURAL PLANT
11	MOLECULES
12	CALL NOW
13	BuyTA65Direct.com
14	MALE ANNOUNCER: T.A. Sciences has developed a
15	process for extracting a naturally-occurring plant
16	molecule and refining it in a capsule you can take to
17	signal your body that it's time to lengthen your
18	telomeres.
19	Here's how it works. TA65 enters the
20	bloodstream and travels throughout the body where it
21	passes through individual cells and activates the
22	production of an ensyme called telomerase. This ensyme
23	travels to the tips of the chromosome and attaches and
24	add lengths to the telomeres and restores them. This

effect allows healthy cells to live longer and

25

35

1	potentially replicate many more times. More healthy
2	identical cellular replication is what you want.
3	There's only one company in the world that
4	distributes patented TA65, T.A. Sciences.
5	ON SCREEN: PROVEN TELOMERASE ACTIVATION
6	CALL NOW
7	BuyTA65Direct.com
8	MALE ANNOUNCER: Call now. Discover TA65 for
9	yourself. TA65 could be a component to your cellular
10	health.
11	ON SCREEN: SUPPORTS IMMUNITY
12	CALL NOW
13	BuyTA65Direct.com
14	MALE ANNOUNCER: Some studies have shown how
15	this amazing discovery could help support immune health
16	and even reverse measurable obvious effects of cellular
17	aging. Why wait one more minute when the clock is
18	ticking?
19	ON SCREEN: CALL NOW FOR MORE INFORMATION
20	CALL NOW
21	BuyTA65Direct.com
22	(Scrolling) TA65 IS A PATENTED PRODUCT ONLY
23	AVAILABLE FROM TA SCIENCES
24	MALE ANNOUNCER: Call now to find out more
25	about TA65.

Complaint

1 ON SCREEN: CALL NOW IF YOU ARE A PHYSICIAN 2 YOU MAY QUALITY TO ORDER DIRECT CALL NOW 3 4 BuyTA65Direct.com MALE ANNOUNCER: If you're a doctor and want to 5 learn more, we can help you as well. You may even 6 inquire to purchase TA65 directly through a special direct program. 9 ON SCREEN: AFFORDABLE & EFFECTIVE AVAILABLE AS A NUTRITIONAL SUPPLEMENT CALL NOW 11 12 BuyTA65Direct.com MALE ANNOUNCER: TA65 is affordable, it works, and it's available direct to you as a nutritional 14 15 supplement. ON SCREEN: CALL NOW FOR MORE INFORMATION 16 CALL NOW 17 BuyTA65Direct.com 18 MALE ANNOUNCER: There's even an available 19 20 testing protocol to demonstrate that you, in fact, are 21 lengthening your telomeres over time with TA65. Over 22 10,000 people are currently experiencing TA65. ON SCREEN: CALL NOW FOR MORE INFORMATION 23 24 30 day money back guarantee less s/h

CALL NOW

25

Complaint

37

1	BuyTA65Direct.com	
2	MALE ANNOUNCER: Now, it's your turn. Don't	
3	hesitate. Call T.A. Sciences now.	
4	ON SCREEN: TA65 MD	
5	ON SCREEN: Letter written by Roger Daltrey on	
6	the screen:	
7	I have been interested in alternative medicine	
8	since the early days of my career.	
9	Maintaining good health through the stresses	
10	and strains of touring and singing with The Who requires	
11	enormous stamina. I was recommended TA65 by a good	
12	friend and decided to try it.	
13	After taking TA65 for one year I noticed	
14	considerable improvement in energy levels. Colds and	
15	winter infections have been a rarity.	
16	Recently I took a 6 week break from taking the	
17	product, and noticed significant energy drop off.	
18	Although to my knowledge the evidence of	
19	benefit to everyone is not proven, I have no doubt that	
20	this product works for me. I hope it does the same for	
21	you.	
22	Roger Daltrey	
23	Maintaining good healthwhile touring and	
24	singing with The Whorequires enormous stamina.	

Exhibit H - Page 37

I was recommended TA65...and decided to try it.

Complaint

1 I noticed considerable improvement in energy levels. 2 Colds..have been a rarity. Recently, I took a 6-week break from the 4 product, and noticed a significant energy drop-off. 5 Roger Daltrey 7 Lead singer of "The Who" ROGER DALTREY: Well, I've been interested in 8 alternative medicine since the early days of my career. 9 Maintaining good health through the stresses and strains 10 11 of touring and singing with The Who required enormous 12 stamina. I was recommended TA65 by a good friend and 13 decided to try it. After taking TA65 for one year, I 14 noticed considerable improvement in energy levels. Colds 15 and winter infections have been a rarity. 16 Recently, I took a six-week break from the 17 product and noticed significant energy drop-off. 18 Although, to my knowledge, the evidence of benefit to 19 everyone is not proven, I have no doubt that this product 20 works for me. I hope it does the same for you. ON SCREEN: TA65 MD 21 ON SCREEN: Greg Gerber, Age 61 22 23 Taking TA65 for 2 years 24 GREG GERBER: When I first started using TA, it

Exhibit H - Page 38

was to see what I could do with reentering competitive

25

Complaint

39

1	swimming. That has been the primary marker that I've
2	used is to watch my swimming times plummet.
3	ON SCREEN: These results are atypical and
4	other consumers may not achieve such results.
5	GREG GERBER: All of a sudden, you go from
6	being, yeah, he's 59 or 60 and kind of one of the guys in
7	the water. All of a sudden, you end up being one of the
8	guys in the water getting out first.
9	My recovery time for anything I do is
10	negligible.
11	ON SCREEN: Consult a physician before
12	beginning any dietary supplement program, particularly if
13	you have special medical needs.
14	GREG GERBER: If I do a four-hour race or a
15	four-hour swim or a four-mile race and two hours, $\mathrm{I}'\mathrm{m}$
16	able to go again within 90 minutes. And the other
17	fellows my age group just plain can't do that. They're
18	recovering, they're telling about their aches and pains
19	the day after, their shoulders ache, their muscles ache.
20	And I just sort of look at them and shrug and say, well,
21	see, isn't that interesting, guys, I don't have any of
22	that.
23	ON SCREEN: BIOLOGICAL BREAKTHROUGHS
24	Breaking the Age Code

Exhibit H - Page 39

KATHLEEN KENNEDY: Gentlemen, thank you all for

Complaint

being here today. 1 ON SCREEN: Kathleen Kennedy 2 3 INVESTIGATIVE JOURNALIST KATHLEEN KENNEDY: I want to hear from all of you if there was one thing that you could tell our 5 viewers today, that you could convey to them about 6 telomeres, telomerase, TA65, what would it be, Dr. Harley? 8 9 ON SCREEN: Calvin B. Harley, Ph.D. PRESIDENT & CSO, TELOME HEALTH, INC. 10 11 DR. CALVIN HARLEY: Kathleen, I think -- I've 12 been working in the area for over 30 years now and I'm 13 excited about the opportunity for anti-aging 14 interventions, using the knowledge that we have now, 15 understanding the basic mechanisms that we hope to 16 leverage in the future for mankind. KATHLEEN KENNEDY: Dr. Raphaelle? 17 ON SCREEN: Dr. Joseph Raphaelle, M.D. 18 CO-FOUNDER, PHYSIO-AGE MEDICAL GROUP 19 DR. JOSEPH RAPHAELLE: I always tell my 20 21 patients the most important thing to know is where you 22 are in the aging process, because in some organ systems, 23 you're aging faster than in others. ON SCREEN: Dr. Joseph Raphaelle, M.D. 24

Exhibit H - Page 40

CO-FOUNDER, PHYSIO-AGE MEDICAL GROUP

25

FEDERAL TRADE COMMISSION DECISIONS VOLUME 165

Complaint

41

1 "TELOMERE TESTING IS A GOOD WAY TO KNOW WHERE YOU ARE IN THE AGING PROCESS" 2 DR. JOSEPH RAPHAELLE: Telomere measurements 3 4 are a good way to get an overall idea about where your body is in the aging process so that you know when it's 5 time to intervene with something like TA65 or anything 7 else that can help you age as slowly as possible. 8 KATHLEEN KENNEDY: And, Dr. Park, what about 9 you? ON SCREEN: Dr. Ed Park, MD, MPH 10 AUTHOR: "TELOMERE TIMEBOMBS" "NOW WE HAVE A TOOL TO DO SOMETHING ABOUT 12 13 AGING" 14 DR. ED PARK: I agree. I think that there are real objective ways to measure aging and now we have a 15 16 tool that can actually do something about it. Last time I checked, there was 15,000 articles relating to 17 18 telomeres. So, I think it's just a matter of time before 19 the science catches up to what my patients are already 20 experiencing --ON SCREEN: Dr. Ed Park, MD, MPH 21 AUTHOR: "TELOMERE TIMEBOMBS" 22 23 "MY PATIENTS EXPERIENCE BETTER HEALTH, BETTER QUALITY OF LIFE" 24

Exhibit H - Page 41

DR. ED PARK: -- which is better health, just a

Complaint

1 better quality of life and something that is safe and 2 something that I have been taking for five years. 3 KATHLEEN KENNEDY: And, Noel, your message? 4 ON SCREEN: Noel Patton CEO AND FOUNDER OF T.A. SCIENCES 5 "TA65 WORKS FOR ME, MY FAMILY, MY FRIENDS, MY 6 LOVED ONES" NOEL PATTON: Well, I was looking for a 8 9 solution to aging for myself and discovered TA65. We've 10 been working on it for ten years. And it works for me, 11 it's worked for my family, my friends, loved ones, and now for tens of thousands of people, and we've made it 12 13 affordable and accessible to everyone, and I'm really 14 proud to be at the beginning of this revolution in 15 science. 16 KATHLEEN KENNEDY: This truly is compelling 17 stuff. ON SCREEN: (Scrolling) CALL NOW FOR MORE 18 INFORMATION - CALL IF YOU ARE A PHYSICIAN INTERESTED IN 19 DISTRIBUTING TA65 - CALL TO SEE IF YOU ARE QUALIFIED TO 20 PURCHASE TA65 DIRECTLY 22 This is a paid program for TA65 23 CALL NOW 24 BuyTA65Direct.com 25 KATHLEEN KENNEDY: That's all the time that we

1	have today, but if you want to learn more about TA65 or
2	telomeres or your telomere length or how you can order
3	TA65 today, go to the web address on your screen or,
4	better yet, call. There's no obligation, no cost for the
5	call, just friendly, trained information consultants who
6	will answer your specific questions. They're trained to
7	get you the answers that you're looking for.
8	Thanks for watching. Bye now.
9	ON SCREEN: TA65 MD
10	ON SCREEN: CALL NOW
11	BuyTA65Direct.com
12	MALE ANNOUNCER: There's only one company in
13	the world that distributes patented TA65, T.A. Sciences.
14	Call now.
15	ON SCREEN: PROVEN TELOMERASE ACTIVATION
16	CALL NOW
17	BuyTA65Direct.com
18	MALE ANNOUNCER: Discover TA65 for yourself.
19	ON SCREEN: SUPPORTS IMMUNITY
20	CALL NOW
21	BuyTA65Direct.com
22	MALE ANNOUNCER: Some studies have shown how
23	this amazing discovery could help support immune health
24	and even reverse measurable obvious effects of cellular
25	aging. Why wait one more minute when the clock is

Exhibit H - Page 43

43

Complaint

1 ticking? 2 ON SCREEN: CALL NOW FOR MORE INFORMATION CALL NOW 3 BuyTA65Direct.com 5 MALE ANNOUNCER: Call now to find out more about TA65. ON SCREEN: CALL NOW IF YOU ARE A PHYSICIAN 8 YOU MAY QUALIFY TO ORDER DIRECT (Scrolling) TA65 IS A PATENTED PRODUCT ONLY 9 AVAILABLE FROM TA SCIENCES 10 CALL NOW BuyTA65Direct.com 12 MALE ANNOUNCER: If you're a doctor and want to 14 learn more, we can help you as well. You may even 15 inquire to purchase TA65 directly through a special 16 direct program. ON SCREEN: AFFORDABLE & EFFECTIVE 17 18 AVAILABLE AS A NUTRITIONAL SUPPLEMENT CALL NOW 19 20 BuyTA65Direct.com 21 MALE ANNOUNCER: TA65 is affordable, it works, and it's available direct to you as a nutritional 23 supplement. 24 ON SCREEN: CALL NOW FOR MORE INFORMATION

Exhibit H - Page 44

30 day money-back guarantee less s/h

25

Complaint

45

1	CALL NOW
2	BuyTA65Direct.com
3	MALE ANNOUNCER: Now, it's your turn. Don't
4	hesitate. Call T.A. Sciences now.
5	ON SCREEN: TA65 MD
6	ON SCREEN: The preceding was a paid program
7	for TA65 MD
8	Sponsored by T.A. Sciences
9	CELL REJUVENATION THROUGH TELOMERASE ACTIVATION
10	MALE ANNOUNCER: The preceding was a paid
11	program for TA65, sponsored by T.A. Sciences.
12	(The recording was concluded.)
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	

Complaint

1 CERTIFICATION OF TYPIST 2 MATTER NUMBER: 1423103 3 CASE TITLE: TELOMERASE ACTIVATION SCIENCES, INC. 4 TAPING DATE: JANUARY 7, 2014 TRANSCRIPTION DATE: JUNE 9, 2014 REVISION DATE: JANUARY 19, 2015 8 I HEREBY CERTIFY that the transcript contained 9 herein is a full and accurate transcript of the tapes transcribed by me on the above cause before the FEDERAL 10 TRADE COMMISSION to the best of my knowledge and belief. 11 12 DATED: JANUARY 19, 2015 13 14 15 ELIZABETH M. FARRELL 16 17 18 CERTIFICATION OF PROOFREADER 19 I HEREBY CERTIFY that I proofread the transcript for 20 21 accuracy in spelling, hyphenation, punctuation and 22 format. 23 24 25 SARA J. VANCE

FEDERAL TRADE COMMISSION DECISIONS VOLUME 165

Complaint

Exhibit I




Exhibit J



Why should you consider taking TA-65 MD?

As we age, our Telomeres shorten

Regular exercise and healthy habits can slow the attrition of telomeres, but telomere length continually declines as we age

*Anyone who's immune system is compromised and can benefit from

*Everyone who is concerned about

its restoration

aging healthy and living longer

"Anyone who had a telomere length

test and has short telomeres

Who Should Take TA-65 MD?

If you have not followed a healthy lifestyle, your telomeres are shorter than they should be

Many recent scientific studies have shown short telomeres are associated with age related decline and dysfunction

Evidence also clearly shows people with long telomeres age healthier and look younger The only way to lengthen telomeres is through the activation of an enzyme called telomerase The world's only commercially available way to

activate telomerase is to take TA-65° ND



T.A. Sciences, Inc. 24E 64" Street, 5" Floor, New York, NY 10085 Phone: 212-588-8905 Fax: 212-588-0058

What people are saying:

As a practicing MD, I am surprised at the imp in my knimune system after only 6 months.

-Dr. Fred Vagnini, 70, New York, NY

I'm more active physically than any time I can remember. At age 80 I feel like the "poster boy" for TA

-Ralph A. 80, Los Angeles, CA

re about TA-85MD and how it can help you, a of our licensed healthcare practitioners or visit: www.tasciences.com To learn more consult one c



FEDERAL TRADE COMMISSION DECISIONS VOLUME 165

Complaint

What is the key to aging healthy and living longer?

Telomeres!!!

Telomeres: Strings of DNA located at the ends of chromosomes. They maintain the structure of the chromosome and protect the genes.



telomeres (some call them burning fuses) get shorter. When one becomes critically short, the cell either stops functioning properly or dies. Telomere biology won the 2009 Nobel Prize in responsible for maintaining the integrity of our DNA. Each and every time our cells divide, these contains 92 telomeres, clocks. Medicine for good reason. human cell ticking biological Every

physical, and emotional snear can be done to keep telomeres from shortening, can be done to keep telomeres from shortening is Birth marks the beginning of telomere erosion in most tissues throughout life. Telomere portening inevitably proceeds as we grow older. is further accentuated by environmental,

Exhibit J - Page 2

What can be done to keep telomeres long?

Lead a healthy lifestyle
This will only help slow down the shortening of your telomeres

Activate Telomerase

In published studies, it has been proven to be the only way to lengthen short

What is Telomerase?

Telomerase is an enzyme that maintains the is usually turned off in most cells. When resembles a molecular motor and adds chromosomes in order to prevent cell death. The gene producing the telomerase new DNA onto the ends of telomeres, thus activated, end of lengthening short telomeres. S the the telomerase gene at the telomeres



TA-65° we has the ability to activate the dormant TELOMERASE enzyme



Activated Telomerase causes telomeres at the end of the chromosome to grow longer



is there a way to activate telomerase?

According to published studies, the only proven way available is:

TA-65 MD

TA-658 ND is a purified molecule originating from the Astragalus plant. Astragalus is a well-respected Chinese medicinal plant which has been in use for over 2,000 years.

TA-65® MD is proven to:

- Activate telomerase
- Restore an aging immune system Lengthen short telomeres
 - Increase bone density
- Improve various biomarkers that usually decline with age

Our clients report anecdotal benefits such as:

- Increased energy
- Improved endurance
- Vision improvements
- Better skin elasticity

Exhibit K




Exhibit L

Maximize Your Potential for Health and Longevity

Minimize Your Age Related Decline and Dysfunction



TA-65[®] Is the first product to emerge from Nobel Prize winning science, focused on improving your health and quality of life.

TA⁶⁵ is the world's only telomerase activator proven in published studies to safely lengthen critically short telomeres, prevent DNA damage, and restore an aging immune system. TA-65 has been shown to increase bone density and improve various biomarkers which usually decline with age.

Hypoallergenic: Contains no yeast, dairy, eggs, gluten, corn, soy, wheat, sugar, starch, salt, preservatives, artificial color, flavor, or fragrances.

Visit www.tasciences.com or call us at 212-588-8805

Mention this ad and receive 5% off your purchase. Offer expires: Sept. 30" 2011

Exhibit M

Telomere Science Page 1 of 1 TOLL-FREE 888.360,8886 PHONE: 212,588,8805 ORDER TA-65 ONLINEFind a doctor Select. ₹ Go · Home · About Us · Team « Events · About TA-65® Pricing
 TA-65 Dosing Guideline Quality Standards · Video a Testimonials · Partnerships · Telomere Science Licensee · FAQ · Press Contact · Find a Doctor


Telomere Science

There are trillions of cells in our body and at any given time a great number are dividing furiously to keep us alive and well. The process is directed by genes sitting on the 23 pairs of chromosomes found in the nucleus of each and every cell. The chromosomes are long sequences of DNA that contain all our genetic material. Each pair of chromosomes consists of one from your mother and one from your father and they are twisted around each other to form a structure called the double helix.

FEDERAL TRADE COMMISSION DECISIONS VOLUME 165


Complaint

Telomere Science Page 2 of 3



Of particular interest to the scientists at T.A. Sciences are the ends of each chromosome known as telomeres. Telomeres have no genetic function; they are simply stretches of DNA (repeats of base pairs) that protect the rest of the chromosome. These little bits of DNA are critical to healthy cell function and have been likened to the plastic tips on shoelaces because they prevent the chromosome from "fraying."

However, telomeres become progressively shorter each time the cell divides. When they get too short, cells reach replicative senescence and can no longer divide. The result can be the various conditions associated with old age.



Scientists have only recently begun to understand the critical importance of shortened telomeres. Research has shown that people over 60 who have long telomeres experience greater heart and immune system health than their age-matched counterparts with shorter telomeres. Thus, it is becoming well-understood that maintaining telomere length is preventing age-related decline.

The phenomenon of cellular aging was first noted by Professor Lenhard Hayflick in 1961. He discovered that cells cannot divide beyond a specific number of times. This is called the Hayflick Limit. Cells reaching this limit become old. Although Professor Hayflick discovered this important scientific principle, he had no idea what caused it.

l'elomere Science	Page 3 of 1

It took almost 30 more years before the role telomeres play in cellular aging was finally understood. In 1990; Calvin Harley at McMaster University in Canada and Carol Greider at Cold Spring Harbor Laboratory in the USA discovered that telomere shortening goes hand-in-hand with the aging process and is the direct cause of cells reaching the Hayflick Limit.



DISCLAIMER: The information provided on this website is intended for educational purposes only. The educational material contained in this site is based on a careful analysis of the scientific literature and the experience of the T.A. Sciences team. Telomerase Activation is cutting edge science and knowledgeable scientists have differing views as to its benefits and safety. We urge each prospective client to become educated about TA and to consult their own experts prior to using any product that is a true telomerase activator.

This product is not intended to diagnose, treat, cure, or prevent any disease.

C 2010 - 2014 Telomerase Activation Sciences, Inc. All rights reserved.

Long

Complaint

TA-65 Dosing Guideline

Page I of ?



TA-65 Dosing Guideline

The statistics showing TA-65's efficacy in the ground breaking scientific paper published Sept. 8, 2010 in the peer-reviewed scientific journal Rejuvenation Research allows us to offer different dosing options. Below is the guideline for you to choose the appropriate dosage and price for your unique situation:

- 1. 250 units (1 capsule daily) is efficacious for healthy adults in their 40's or 50's. Also 250 units can serve as a maintenance dose for older people who have been taking higher doses of TA-65 for several years and want to continue on a reduced cost program. Clients who took this dose were shown to have increased short telomere length and significantly improved immune system function. There are also anecdotal reports of increased endurance and other benefits. Cost: US \$600.00 for each 3 month segment.
 - 500 units (2 capsules daily) has been proven to lengthen short telomeres, restore the immune system, and improve other important bio markers. Anecdotal reports included increased energy.

Exhibit M - Page 4

httm://www.tasciences.com/ta-65/ta-65-dosine-guideline/

1/24/2014

Complaint


TA-65 Dosing Guideline

Page 2 of 1

endurance, vision improvements, sexual enhancement, and more. This medium strength dose is recommended for people who are generally in good health and want to be proactive in longevity and healthy aging. Many people in their 50's or 60's fall into this category. Cost: US \$1,200.00 for each 3 month segment.

- 3. 1000 units (4 capsules daily) This is considered the HIGH DOSE and is recommended for clients who are:
 - 1. Over 70 years of age, or
 - 2. Are of any age and have measured their telomeres and found them to be short, or
 - Have reason to believe that strengthening their immune system would have particular benefit.

It is expected that this dose will give an increased benefit over the lower doses (although not a proportional benefit). Study subjects experienced lengthened telomeres, restoration of weak immune systems, bone density improvements and other important bio marker improvements which usually decline with age. Anecdotal reports include energy increase, endurance, cognitive improvements, improved vision, sexual enhancement, and an overall feeling of well being. Cost: US \$2,200.00 for each 3 month segment.



DISCLAIMER: The information provided on this website is intended for educational purposes only. The educational material contained in this site is based on a careful analysis of the scientific literature and the experience of the T.A. Sciences team. Telomerase Activation is cutting edge science and knowledgeable scientists have differing views as to its benefits and safety. We urge each prospective client to become educated about TA and to consult their own experts prior to using any product that is a true telomerase activator.

This product is not intended to diagnose, treat, cure, or prevent any disease.

© 2010 - 2014 Telomerase Activation Sciences, Inc. All rights reserved.

Crien

FEDERAL TRADE COMMISSION DECISIONS VOLUME 165

Complaint

FAQ Page 1 of 4



TOTAL PRISE 888.360.8886 PHONE: 212.588.8805

ORDER TA-55 ONLINE Find a doctor Select ...





- * Home:
- About Us
 - Team
 - Eyents
- About TA-65®
 - a Pricing
 - TA-65 Dosing Guideline
 - Quality Standards
 - · Video
 - * Testimonials
 - · Partnerships
- Telomere Science
- Licensee
- · FAQ
- Press
- Contact
 - · Find a Doctor

FAQ

What are telomeres?

Telomeres (ie--lo-meres) are buffers, protective pieces of DNA material at the ends of each and every chromosome in every cell in the body. Imagine a shoelace with the little plastic endpiece that keeps the strings of the lace bound together. This is what a telomere looks like and how it functions. Just as a shoelace unravels if the protective tip is missing, so the genetic material of the chromosomes degrades if not properly protected by telomeres of a certain length.

What is Telomerase Activation?

Telomerase (te-lo-m-er-use) is a naturally-occurring enzyme in the body and a vital factor in cell health. It helps maintain the protective telomeres located at the ends of all

Exhibit M - Page 6

http://www.tasciences.com/faq/

1/24/2014

Complaint

PAQ Page 2 of

chromosomes. Scientific studies have shown that controlled activation of telomerase in normal cells can increase telomere length, improve functional capacity, and promote the proliferative lifespan of cells. The Telomeraso-Activating potency of the molecule TA-65 has been independently proven in rigorous tests by 3rd party laboratories.

Have these products been tested?

T.A. SciencesTM follows stringent scientific procedures to back up the safety and efficacy of our products. For more than a decade, we have conducted a series of studies including, most importantly, a 2005 Anti-Aging Trial designed to directly measure the effect of TA-65 when taken internally. In this trial we saw a reduction in the signs of aging from the introduction of TA-65 into the bloodstream. A 125-person safety study showed no negative effects from daily use of TA-65. More exciting nows on testing will be available as soon as on-going studies are completed.

Is there real science behind these products?

The presence of telomerase and the effects of telomere shortering are so basic to human aging and the maladies of old age that an entirely new branch of biology (Telomere Biology) has sprung up in the last two decades. The science of telomeres and telomerase activation is a new frontier, attracting some of the brightest scientific minds in both the academic and pharmaceutical worlds. To maintain its leadership role in Telomerase Activation, T.A. Sciences TM maintains unique relationships with leading edge biotech firms and opinion leaders in the field of Telomere Biology. Dr. Calvin Harley, who first discovered the link between Telomeres and aging, works closely with T.A. Sciences to integrate the latest scientific discoveries into T.A. Sciences' products, T.A. Sciences has also established working relationships with several other of the world's leading Telomere Biologists.

For more information on the science behind TA Activation click here.

How does T.A. Sciences assure the quality of its products?

Quality and purity are assured through a series of analytical tests. Here is the process from the heginning to the end of the supply chain:

- T.A. Sciences harvests high-potency, naturally grown Astragatus. The raw plant material is refined into a base powder at our exclusive plant-extraction facility.
- This refined base material is then further extracted and purified through a proprietary process
 perfected over more than a decade of research and development to yield the single molecule TA
 -65 at over 98% purity. Using HPLC/ELSD/CAD, mass spectrometry, and gas chromatography
 TA-65 is tested for purity, solvent residue, microbial, heavy metals, and pesticides.
- The Purified TA-65 is then sent to an FDA-certified facility for further processing utilizing advanced delivery technology to improve the bioavailability of the TA-65 molecule.
- The bioenhanced TA-65 is blended with USP (United States Pharmacopein) grade GRAS
 (Generally Recognized As Safe) excipients and encapsulated and packaged at our
 subcontractor's state of the art GMP (Good Manufacturing Practices) certified facility. The
 final product must pass another series of tests including microbial and heavy metals before it
 can be released.
- Through these and other rigorous quality programs, T.A. Sciences can assure our clients that what we say on our label is 100% accurate.

What is the plant from which TA-65 is derived?

Exhibit M - Page 7

http://www.tasciences.com/faq/

1/24/2014

FEDERAL TRADE COMMISSION DECISIONS VOLUME 165

Complaint

FAO Page 3 of 4

TA-65 is a naturally occurring molecule found in an ancient Chinese medicinal herb. Well known to most of China's 1.3 billion people for over 1000 years, this medicinal root can be found in every traditional Chinese herbal shop. Major health benefits from this plant have long been recognized by practitioners in China, but never before has the TA-65 active ingredient been isolated and purified.

If TA-65 is a molecule coming from an ancient medicinal plant and extracts are available in any vitamin shop, why not just buy those inexpensive commercial products?

To answer this question, we purchased four commonly available extract products and had them tested to verify how much, if any, TA-65 is present. In all four cases, the testing lab could not detect any TA-65. Their assay is accurate to one part per million.

This is not surprising because not only is the TA-65 molecule rare, but extraction processes used by Chinese processing companies—normally destroy it. T.A. Sciences uses a proprietary production process that took years of research and over several million dollars to develop. Several patents have been issued to T.A. Sciences over the years related to this technology.

Are there any allergens in the product I should be aware of?

TA-65 does not contain dairy, eggs, gluten, corn, soy, wheat, sugar, starch, salt, preservatives, artificial color, flavor, or fragrances.

Is TA-65 Scientifically Supported?

T.A. Sciences is the first and only company in the world to offer Telomerase-Activating products to combat the effects of cellular aging through leading-edge science. After more than 10 years of rigorous Research and Development, T.A. Sciences is proud to market the unique and potent TA-65 molecule available in TA-65MD®.

Is TA-65 a drug?

TA-65 is a nutritional supplement, not a drug, It activates telomerase and this helps keep cells functioning in a normal and healthy way as we age. TA-65 is not a drug and we make no claims that it prevents or treats any disease.

Is there a risk of unwanted cell proliferation?

TA-65 is a single molecule found in the Astragalus plant. Astragalus extracts have been safely consumed by humans for over a thousand years and are available in any vitamin shop. TA-65's method of action is to activate the enzyme telomerase which in turn affects the telomeres, which are located at the tips of every chromosome in every cell of the body. Telomeres are the cellular clock of aging, every time a cell divides, telomeres get shorter. When telomeres get too short, cells can no longer divide and proliferate, they become old cells. Maintaning telomere health and length allows cells to continue to divide and proliferate for a longer time; they simply live and function longer. However if cells live longer, there is a theoretical concern that they might over proliferate. Therefore, theoretically, TA-65 could stimulate unwanted growth and cell overpopulation. Of course what TA-65 aims to do is to keep healthy cells alive and functioning for as long as possible. But what about the possibility of allowing unhealthy cells to live longer?

Complaint

FAQ Page 4 of 4

There is evidence that suggests that TA-65 boosts and strengthens the immune system, which we believe should address or suppress any cell overpopulation. Thus, we believe the overall effect of TA-65 regarding cell proliteration to be positive.

Furthermore, we believe that a number of physical changes associated with old age are due to the presence of short telomeres. TA-65 is specifically designed to promote overall cell health and longevity by increasing telomere length or slowing the rate of telomere shortening. When telomerase is activated, cell distress due to shortened telomeres is reduced.

In summary, considering the lack of evidence of TA-65 causing unwanted human cell proliferation, we believe the potential beneficial effects of activating telomerase and maintaining healthy tissue function outweigh any theoretical risk. And we practice what we preach; many T.A. Sciences employees are currently taking TA-65.

A doctor or professional health care provider who is familiar with Telomere Biology is in the best position to assess if TA-65 is right for you. Products that activate telomerase are on the frontiers of science and before you take TA-65, you should consult your physician or health care provider.

TA-65 sounds too good to be true. How do I know this is not just snake oil like other so-called anti-aging products?

TA-65 has been proven by outside, 3rd party laboratories to activate telomerase. Telomerase lengthens telomeres and longer telomeres allow cells to continue to divide and replicate longer.

In 2005 we did an Anti-Aging Trial that statistically shows in black and white what real people experienced from TA-65. This was a double-blind, placebo controlled study with data interpreted by Stanford University Ph.D., Dr. Jochen Kumm.

T.A. Sciences is solidly grounded in patented telemerase technology and validated by additional controlled studies.

Join our mailing list Enter your e-mail:

DISCLAIMER: The information provided on this website is intended for educational purposes only. The educational material contained in this site is based on a careful analysis of the scientific literature and the experience of the T.A. Sciences team. Telomerase Activation is cutting edge science and knowledgeable scientists have differing views as to its benefits and safety. We urge each prospective client to become educated about TA and to consult their own experts prior to using any product that is a true telomerase activator.

This product is not intended to diagnose, treat, cure, or prevent any disease

© 2010 - 2014 Telomerase Activation Sciences, Inc. All rights reserved.

Exhibit M - Page 9

http://www.tasciences.com/faq/

1/24/2014

FEDERAL TRADE COMMISSION DECISIONS VOLUME 165

Complaint

Exhibit N




Exhibit N - Page 1



FEDERAL TRADE COMMISSION DECISIONS VOLUME 165




Exhibit N - Page 3

Complaint

Exhibit O



Exhibit O - Page 1

FEDERAL TRADE COMMISSION DECISIONS VOLUME 165



Exhibit O - Page 2



Exhibit O - Page 3

FEDERAL TRADE COMMISSION DECISIONS VOLUME 165



Exhibit O - Page 4



Exhibit O - Page 5

FEDERAL TRADE COMMISSION DECISIONS VOLUME 165



Exhibit O - Page 6



Exhibit O - Page 7

DECISION

The Federal Trade Commission ("Commission") initiated an investigation of certain acts and practices of the Respondents named in the caption. The Commission's Bureau of Consumer Protection ("BCP") prepared and furnished to Respondents a draft Complaint. BCP proposed to present the draft Complaint to the Commission for its consideration. If issued by the Commission, the draft Complaint would charge the Respondents with violation of the Federal Trade Commission Act.

Respondents and BCP thereafter executed an Agreement Containing Consent Order ("Consent Agreement"). The Consent Agreement includes: 1) statements by Respondents that they neither admit nor deny any of the allegations in the Complaint, except as specifically stated in this Decision and Order, and that only for purposes of this action, they admit the facts necessary to establish jurisdiction; and 2) waivers and other provisions as required by the Commission's Rules.

The Commission considered the matter and determined that it had reason to believe that Respondents have violated the Federal Trade Commission Act, and that a Complaint should issue stating its charges in that respect. The Commission accepted the executed Consent Agreement and placed it on the public record for a period of 30 days for the receipt and consideration of public comments. The Commission duly considered the comment received from an interested person pursuant to Commission Rule 2.34, 16 C.F.R. § 2.34. Now, in further conformity with the procedure prescribed in Commission Rule 2.34, the Commission issues its Complaint, makes the following Findings, and issues the following Order:

Findings

1. The Respondents are:

a. Respondent Telomerase Activation Sciences, Inc., is a Delaware corporation with its principal office or place of business at 420 Lexington Avenue, Suite 2900, New York, NY 10170.

- b. Respondent Noel Thomas Patton is the founder, Chairman, CEO, and majority owner of the Corporate Respondent, Telomerase Activation Sciences, Inc. Individually or in concert with others, he formulates, directs, or controls the policies, acts, or practices of Telomerase Activation Sciences, Inc. His principal office or place of business is the same as that of Telomerase Activation Sciences, Inc.
- 2. The Commission has jurisdiction over the subject matter of this proceeding and over the Respondents, and the proceeding is in the public interest.

ORDER

Definitions

For purposes of this Order, the following definitions apply:

- A. "Clearly and conspicuously" means that a required disclosure is difficult to miss (i.e., easily noticeable) and easily understandable by ordinary consumers, including in all of the following ways:
 - 1. In any communication that is solely visual or solely audible, the disclosure must be made through the same means through which the communication is presented. In any communication made through both visual and audible means, such as a television advertisement, the disclosure must be presented simultaneously in both the visual and audible portions of the communication even if the representation requiring the disclosure ("triggering representation") is made through only one means.
 - 2. A visual disclosure, by its size, contrast, location, the length of time it appears, and other characteristics, must stand out from any

accompanying text or other visual elements so that it is easily noticed, read, and understood.

- 3. An audible disclosure, including by telephone or streaming video, must be delivered in a volume, speed, and cadence sufficient for ordinary consumers to easily hear and understand it.
- 4. In any communication using an interactive electronic medium, such as the Internet or software, the disclosure must be unavoidable.
- 5. On a product label, the disclosure must be presented on the same display panel as the representation that requires the disclosure appears.
- 6. The disclosure must use diction and syntax understandable to ordinary consumers and must appear in each language in which the triggering representation appears.
- 7. The disclosure must comply with these requirements in each medium through which it is received, including all electronic devices and face-to-face communications.
- 8. The disclosure must not be contradicted or mitigated by, or inconsistent with, anything else in the communication.
- 9. When the representation or sales practice targets a specific audience, such as children, the elderly, or the terminally ill, "ordinary consumers" includes reasonable members of that group.
- B. "Close proximity" means that the disclosure is very near the triggering representation. For example, a disclosure made through a hyperlink, pop-up, interstitial, or other similar technique is not in close proximity to the triggering representation.

- C. "Cosmetic" means: (a) articles to be rubbed, poured, sprinkled, or sprayed on, introduced into, or otherwise applied to the human body or any part thereof intended for cleansing, beautifying, promoting attractiveness, or altering the appearance, and (b) articles intended for use as a component of any such article; except that such term shall not include soap.
- D. "Covered product" means TA-65MD® and TA-65® for Skin or any other drug, food, dietary supplement, or cosmetic.
- E. "Dietary supplement" means:
 - 1. any product labeled as a dietary supplement or otherwise represented as a dietary supplement; or
 - 2. any pill, tablet, capsule, powder, softgel, gelcap, liquid, or other similar form containing one or more ingredients that are a vitamin, mineral, herb or other botanical, amino acid, probiotic, or other dietary substance for use by humans to supplement the diet by increasing the total dietary intake, or a concentrate, metabolite, constituent, extract, or combination of any ingredient described above, that is intended to be ingested, and is not represented to be used as a conventional food or as a sole item of a meal or the diet.
- F. "Drug" means: (a) articles recognized in the official United States Pharmacopoeia, official Homoeopathic Pharmacopoeia of the United States, or official National Formulary, or any supplement to any of them; (b) articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in humans or other animals; (c) articles (other than food) intended to affect the structure or any function of the body of humans or other animals; and (d) articles intended for use as a component of any article specified in (a), (b), or (c); but does not include devices or their components, parts, or accessories.

- G. "Essentially equivalent product" means a product that contains the identical ingredients, except for inactive ingredients (e.g., inactive binders, colors, fillers, excipients), in the same form and dosage, and with the route of administration (e.g., sublingually), as the covered product; provided that the covered product may contain additional ingredients if reliable scientific evidence generally accepted by experts in the field indicates that the amount and combination of additional ingredients are unlikely to impede or inhibit the effectiveness of the ingredients in the essentially equivalent product.
- H. "Food" means: (a) any article used for food or drink for humans or other animals; (b) chewing gum; and (c) any article used for components of any such article.
- I. "Licensee" means any person licensed, or otherwise authorized, by Respondents to advertise, market, or sell any covered product.
- J. "Licensee-Patient Relationship" means the relationship between a licensee and an individual when the licensee affirmatively has provided a medical or healthcare service to that individual by examining, diagnosing, treating, or agreeing to examine, diagnose, or treat such individual.
- K. "Person" means a natural person, an organization, or other legal entity, including a corporation, partnership, sole proprietorship, limited liability company, association, cooperative, or any other group or combination acting as an entity.
- L. "Respondents" means the Corporate Respondent and the Individual Respondent, individually, collectively, or in any combination.
 - 1. "Corporate Respondent" means Telomerase Activation Sciences, Inc., , and its successors and assigns.

2. "Individual Respondent" means Noel Thomas Patton.

Provisions

I. Prohibited Representations: Disease and Other Specific Health Claims

IT IS ORDERED that Respondents, Respondents' officers, agents, and employees, and all other persons in active concert or participation with any of them, who receive actual notice of this Order, whether acting directly or indirectly, in connection with the manufacturing, labeling, advertising, promoting, offering for sale, sale, or distribution of any covered product, must not make any representation, expressly or by implication, that such product:

- A. Reverses human aging;
- B. Prevents or repairs DNA damage;
- C. Restores aging immune systems;
- D. Increases bone density;
- E. Reverses the effects of aging, including:
 - 1. Improves skin elasticity;
 - 2. Increases energy and endurance; or
 - 3. Improves vision;
- F. Decreases recovery time of the skin after medical procedures;
- G. Prevents or reduces the risk of cancer; or
- H. Cures, mitigates, or treats any disease,

unless the representation is non-misleading, including that, at the time such representation is made, Respondents possess and rely

upon competent and reliable scientific evidence that substantiates that the representation is true. For purposes of this Provision, "competent and reliable scientific evidence" means human clinical testing of the covered product, or of an essentially equivalent product, that is sufficient in quality and quantity, based on standards generally accepted by experts in the relevant disease, condition, or function to which the representation relates, when considered in light of the entire body of relevant and reliable scientific evidence, to substantiate that the representation is true. Such testing must (1) be randomized, double-blind, and placebocontrolled; and (2) be conducted by researchers qualified by training and experience to conduct such testing. In addition, all underlying or supporting data and documents generally accepted by experts in the field as relevant to an assessment of such testing as described in the Provision entitled Preservation of Records Relating to Competent and Reliable Human Clinical Tests or Studies must be available for inspection and production to the Commission. Respondents will have the burden of proving that a product satisfies the definition of an essentially equivalent product.

II. Prohibited Representations Other Health-Related Claims or Safety

IT IS **FURTHER ORDERED** that Respondents, Respondents' officers, agents, and employees, and all other persons in active concert or participation with any of them, who receive actual notice of this Order, whether acting directly or indirectly, in connection with the manufacturing, labeling, advertising, promoting, offering for sale, sale, or distribution of any covered product, must not make any representation, other than representations covered under the Provision titled Prohibited Representations: Disease and Other Specific Health Claims, expressly or by implication, about the health benefits, performance, efficacy, safety, or side effects of such product, unless the representation is non-misleading, including that, at the time such representation is made, Respondents possess and rely upon competent and reliable scientific evidence that is sufficient in quality and quantity based on standards generally accepted by experts in the relevant disease, condition, or function to which the representation relates, when considered in light of the entire body

of relevant and reliable scientific evidence, to substantiate that the representation is true. For purposes of this Provision, "competent and reliable scientific evidence" means tests, analyses, research, or studies (1) that have been conducted and evaluated in an objective manner by experts in the relevant disease, condition, or function to which the representation relates; (2) that are generally accepted by such experts to yield accurate and reliable results; and (3) that are randomized, double-blind, and placebo-controlled human clinical testing of the covered product, or of an essentially equivalent product, when such experts would generally require such human clinical testing to substantiate that the representation is true. In addition, when such tests or studies are human clinical tests or studies, all underlying or supporting data and documents generally accepted by experts in the field as relevant to an assessment of such testing as described in the Provision of this Order entitled Preservation of Records Relating to Competent and Reliable Human Clinical Tests or Studies must be available for inspection and production to the Commission. Respondents will have the burden of proving that a product satisfies the definition of essentially equivalent product.

III. Prohibited Misrepresentations: Regarding Tests, Studies, or Other Research

- IT IS FURTHER ORDERED that Respondents, Respondents' officers, agents, and employees, and all other persons in active concert or participation with any of them, who receive actual notice of this Order, whether acting directly or indirectly, in connection with the manufacturing, labeling, advertising, promoting, offering for sale, sale, or distribution of any product must not:
 - A. Make any misrepresentation, expressly or by implication, that any covered product is:
 - 1. Clinically or scientifically proven to reverse human aging;
 - 2. Clinically or scientifically proven to prevent or repair DNA damage;

- 3. Clinically or scientifically proven to restore aging immune systems; or
- 4. Clinically or scientifically proven to increase bone density;
- B. Make any misrepresentation, expressly or by implication, that the performance or benefits of any product are scientifically or clinically proven or otherwise established; or
- C. Make any misrepresentation, expressly or by implication, about the existence, contents, validity, results, conclusions, or interpretations of any test, study, or other research.

IV. FDA Approved Claims

IT IS FURTHER ORDERED that nothing in this Order prohibits Respondents, Respondents' officers, agents, and employees, or all other persons in active concert or participation with any of them from:

- A. For any drug, making a representation that is approved in labeling for such drug under any tentative final or final monograph promulgated by the Food and Drug Administration, or under any new drug application approved by the Food and Drug Administration; and
- B. For any product, making a representation that is specifically authorized for use in labeling for such product by regulations promulgated by the Food and Drug Administration pursuant to the Nutrition Labeling and Education Act of 1990 or permitted under Sections 303-304 of the Food and Drug Administration Modernization Act of 1997.

V. Prohibited Misrepresentations: Paid Commercial Advertising

IT IS FURTHER ORDERED that Respondents, Respondents' officers, agents, and employees, and all other persons in active concert or participation with any of them, who receive actual notice of this Order, whether acting directly or indirectly, in connection with the marketing, advertising, or promoting of any product, service, or program must not make any misrepresentation, expressly or by implication, that paid commercial advertising is independent programming, including independent, educational programming.

VI. Required Disclosures: Material Connections

IT IS **FURTHER ORDERED** that Respondents, Respondents' officers, agents, and employees, and all other persons in active concert or participation with any of them, who receive actual notice of this Order, whether acting directly or indirectly, in connection with the manufacturing, labeling, advertising, promoting, offering for sale, sale, or distribution of any covered product must not make any representation, expressly or by implication, about any user, consumer, or endorser of such product without disclosing, clearly and conspicuously, and in close proximity to that representation, any unexpected material connection between such endorser and (1) any Respondent; or (2) any other individual or entity affiliated with the product. For purposes of this Provision, "unexpected material connection" means any relationship that might materially affect the weight or credibility of the testimonial or endorsement and that would not reasonably be expected by consumers.

VII. Prohibited Misrepresentations: Endorsements

IT IS FURTHER ORDERED that Respondents, Respondents' officers, agents, and employees, and all other persons in active concert or participation with any of them, who receive actual notice of this Order, whether acting directly or indirectly, in connection with the manufacturing, labeling,

advertising, promoting, offering for sale, sale, or distribution of any covered product, must not make any misrepresentation, expressly or by implication, about the status of any endorser or person providing a review of the product, including a misrepresentation that the endorser or reviewer is an independent or ordinary user of the product.

VIII. Means and Instrumentalities

IS **FURTHER ORDERED** IT that Respondents, Respondents' officers, agents, and employees, and all other persons in active concert or participation with any of them, who receive actual notice of this Order, whether acting directly or indirectly, in connection with the manufacturing, labeling, advertising, promoting, offering for sale, sale, or distribution of any covered product, must not provide the means and instrumentalities with which to make, directly or indirectly, any false or misleading statement of material fact, including the prohibited representations covered by Provisions I, II, and III of For purposes of this Provision, "means and this Order. instrumentalities" mean any information, document, or article referring or relating to any covered product, including any advertising, labeling, promotional, or purported substantiation materials, for use by a licensee to market or sell any covered product.

IX. Preservation of Records Relating to Competent and Reliable Human Clinical Tests or Studies

- IT IS FURTHER ORDERED that, with regard to any human clinical test or study ("test") upon which Respondents rely to substantiate any claim covered by this Order, Respondents must secure and preserve all underlying or supporting data and documents generally accepted by experts in the field as relevant to an assessment of the test, including:
 - A. All protocols and protocol amendments, reports, articles, write-ups, or other accounts of the results of the test, and drafts of such documents reviewed by the test sponsor or any other person not employed by the research entity;

- B. All documents referring or relating to recruitment; randomization; instructions, including oral instructions, to participants; and participant compliance;
- C. Documents sufficient to identify all test participants, including any participants who did not complete the test, and all communications with any participants relating to the test; all raw data collected from participants enrolled in the test, including any participants who did not complete the test; source documents for such data; any data dictionaries; and any case report forms;
- D. All documents referring or relating to any statistical analysis of any test data, including any pretest analysis, intent-to-treat analysis, or between-group analysis performed on any test data; and
- E. All documents referring or relating to the sponsorship of the test, including all communications and contracts between any sponsor and the test's researchers.

Provided, however, the preceding preservation requirement does not apply to a reliably reported test, unless the test was conducted, controlled, or sponsored, in whole or in part by (1) any Respondent; (2) any Respondent's officers, agents, representatives, or employees; (3) any other person or entity in active concert or participation with any Respondent; (4) any person or entity affiliated with or acting on behalf of any Respondent; (5) any supplier of any ingredient contained in the product at issue to any of the foregoing or to the product's manufacturer; or (6) the supplier or manufacturer of such product.

For purposes of this Provision, "reliably reported test" means a report of the test has been published in a peer-reviewed journal, and such published report provides sufficient information about the test for experts in the relevant field to assess the reliability of the results.

For any test conducted, controlled, or sponsored, in whole or in part, by Respondents, Respondents must establish and maintain reasonable procedures to protect the confidentiality, security, and integrity of any personal information collected from or about participants. These procedures must be documented in writing and must contain administrative, technical, and physical safeguards appropriate to Respondents' size and complexity, the nature and scope of Respondents' activities, and the sensitivity of the personal information collected from or about the participants.

X. Acknowledgments of the Order

IT IS FURTHER ORDERED that Respondents obtain acknowledgments of receipt of this Order:

- A. Each Respondent, within 7 days after the effective date of this Order, must submit to the Commission an acknowledgment of receipt of this Order sworn under penalty of perjury.
- B. For 8 years after the issuance date of this Order, each Individual Respondent for any business that such Respondent, individually or collectively with any other Respondent, is the majority owner or controls directly or indirectly, and Corporate Respondent, must deliver a copy of this Order to: (1) all principals, officers, directors, and LLC managers and members; (2) all employees, agents, and representatives who participate in conduct related to the subject matter of the Order; and (3) any business entity resulting from any change in structure as set forth in the Provision titled Compliance Report and Notices. Delivery must occur within 7 days after the effective date of this Order for current personnel. For all others, delivery must occur before they assume their responsibilities.
- C. From each individual or entity to which a Respondent delivered a copy of this Order, that Respondent must obtain, within 30 days, a signed and dated acknowledgment of receipt of this Order.

XI. Compliance Report and Notices

IT IS FURTHER ORDERED that Respondents make timely submissions to the Commission:

- A. Sixty days after the issuance date of this Order, each Respondent must submit a compliance report, sworn under penalty of perjury, in which:
 - 1. Each Respondent must: (a) identify the primary physical, postal, and email address and telephone number, as designated points of contact, which representatives of the Commission, may use to communicate with Respondent; (b) identify all of that Respondent's businesses by all of their names, telephone numbers, and physical, postal, email, and Internet addresses; (c) describe the activities of each business, including the goods and services offered, the means of advertising, marketing, and sales, and the involvement of any other Respondent (which Individual Respondent must describe if he knows or should know due to his own involvement): (d) describe in detail whether and how that Respondent is in compliance with each Provision of this Order, including a discussion of all of the changes the Respondent made to comply with the Order; and (e) provide a copy of each Acknowledgment of the Order obtained pursuant to this Order, unless previously submitted to the Commission.
 - 2. Additionally, Individual Respondent must: (a) identify all his telephone numbers and all his physical, postal, email and Internet addresses, including all residences; (b) identify all his business activities, including any business for which such Respondent performs services whether as an employee or otherwise and any entity in which such Respondent has any ownership interest; and (c) describe in detail such Respondent's involvement in each such business

activity, including title, role, responsibilities, participation, authority, control, and any ownership.

- B. For 10 years after the issuance date of this Order, each Respondent must submit a compliance notice, sworn under penalty of perjury, within 14 days of any change in the following:
 - 1. Each Respondent must submit notice of any change in: (a) any designated point of contact; or (b) the structure of Corporate Respondent or any entity that Respondent has any ownership interest in or controls directly or indirectly that may affect compliance obligations arising under this Order, including: creation, merger, sale, or dissolution of the entity or any subsidiary, parent, or affiliate that engages in any acts or practices subject to this Order.
 - 2. Additionally, Individual Respondent must submit notice of any change in: (a) name, including alias or fictitious name, or residence address; or (b) title or role in any business activity, including (i) any business for which such Respondent performs services whether as an employee or otherwise and (ii) any entity in which such Respondent has any ownership interest and over which Respondents have direct or indirect control. For each such business activity, also identify its name, physical address, and any Internet address.
- C. Each Respondent must submit notice of the filing of any bankruptcy petition, insolvency proceeding, or similar proceeding by or against such Respondent within 14 days of its filing.
- D. Any submission to the Commission required by this Order to be sworn under penalty of perjury must be true and accurate and comply with 28 U.S.C. § 1746, such as by concluding: "I declare under penalty of

E. Unless otherwise directed by a Commission representative in writing, all submissions to the Commission pursuant to this Order must be emailed to DEbrief@ftc.gov or sent by overnight courier (not the U.S. Postal Service) to: Associate Director for Enforcement, Bureau of Consumer Protection, Federal Trade Commission, 600 Pennsylvania Avenue NW, Washington, DC 20580. The subject line must begin: In re Telomerase Activation Sciences, Inc.

XII. Recordkeeping

IT IS FURTHER ORDERED that Respondents must create certain records for 10 years after the issuance date of the Order, and retain each such record for 5 years. Specifically, Corporate Respondent, in connection with the manufacturing, labeling, advertising, promoting, offering for sale, sale, or distribution of any covered product, and Individual Respondent for any business that such Respondent, individually or collectively with any other Respondent, is a majority owner or controls directly or indirectly, must create and retain the following records:

- A. Accounting records showing the revenues from all goods or services sold;
- B. Personnel records showing, for each person providing services, whether as an employee or otherwise, that person's: name; addresses; telephone numbers; job title or position; dates of service; and (if applicable) the reason for termination:
- C. Copies or records of all consumer complaints and refund requests, whether received directly or indirectly, such as through a third party, and any response;

- D. All records necessary to demonstrate full compliance with each provision of this Order, including all submissions to the Commission; and
- E. A copy of each unique advertisement or other marketing material.

XIII. Compliance Monitoring

IT IS FURTHER ORDERED that, for the purpose of monitoring Respondents' compliance with this Order:

- A. Within 30 days of receipt of a written request from a representative of the Commission, each Respondent must: submit additional compliance reports or other requested information, which must be sworn under penalty of perjury, and produce records for inspection and copying.
- B. For matters concerning this Order, representatives of the Commission are authorized to communicate directly with each Respondent. Respondents must permit representatives of the Commission to interview anyone affiliated with any Respondent who has agreed to such an interview. The interviewee may have counsel present.
- C. The Commission may use all other lawful means, including posing through its representatives as consumers, suppliers, or other individuals or entities, to Respondents or any individual or entity affiliated with Respondents, without the necessity of identification or prior notice. Nothing in this Order limits the Commission's lawful use of compulsory process, pursuant to Sections 9 and 20 of the FTC Act, 15 U.S.C. §§ 49, 57b-1.
- D. Upon written request from a representative of the Commission, any consumer reporting agency must furnish consumer reports concerning Individual

Respondent, pursuant to Section 604(2) of the Fair Credit Reporting Act, 15 U.S.C. § 1681b(a)(2).

XIV. Notice and Monitoring of Licensees

IT IS FURTHER ORDERED that Respondents must:

- A. Send, within 30 days after the issuance date of this Order, by first class mail, postage prepaid and return receipt requested, or by courier service with signature proof of delivery, in one envelope, a copy of this Order and an exact copy of the notice and acknowledgment form attached hereto as Appendix A, showing the date of mailing, to each licensee. For any future licensees, delivery by first class mail, postage prepaid and return receipt requested, or by courier service with signature proof of delivery, in one envelope of a copy of this Order and an exact copy of the notice and acknowledgement form attached hereto as Appendix B, showing the date of the mailing, must occur within 10 days of becoming a licensee. Any mailing required by this Paragraph must not include any other documents or enclosures.
- B. Obtain from each licensee, within 20 days after receipt of the notice and acknowledgement form required by Paragraph A of this Provision, a signed and dated acknowledgment form that the licensee has received the notice and expressly agrees to comply with it.
- C. Establish, implement, and thereafter maintain a system to monitor and review the advertisements of each licensee, as specified below in Subparagraphs 1 and 2, to ensure compliance with Provisions I, II, and III of this Order. The system must be implemented as follows:
 - 1. No later than 30 days after the issuance date of this Order, and on an annual basis thereafter, Respondents must identify the licensees who ordered, purchased, or otherwise obtained the

specified amount of covered product as scheduled below:

- a. In the first 5 years after the issuance date of this Order, \$20,000 or more of any covered product within the last 12 months;
- b. After 5 years and until 10 years from the issuance date of this Order, \$30,000 or more of any covered product within the last 12 months;
- c. After 10 years and until 15 years from the issuance date of this Order, \$40,000 or more of any covered product within the last 12 months; and
- d. After 15 years from the issuance date of this Order and until this Order is terminated in accordance with Provision XVI of this Order, \$50,000 or more of any covered product within the last 12 months.
- 2. Respondents must monitor and review a representative sample of advertisements, including online advertising, social media postings, or brochures or pamphlets, of each licensee identified in accordance with Paragraph C(1) of this Provision.

Provided however, Respondents are not required to monitor and review any representations by a licensee about the potential safety, health benefits, performance, efficacy, or side effects of a covered product when, in connection with a licensee-patient Relationship, a licensee is consulting privately with one patient about such covered product.

Provided further, Respondents are not required to monitor and review any representations by a licensee about the potential safety, health benefits, performance, efficacy, or side effects of a covered

product when: 1) the licensee has purchased a covered product solely for incorporation into the licensee's own product; and 2) Respondents are not involved in the advertising, marketing, promoting, or sale of that licensee's product.

D. Suspend any licensee, regardless of time, within 10 days after any Respondent becomes aware that a licensee has made any representation prohibited by Provisions I, II, or III of this Order in connection with the advertising, promotion, or sale of any covered product after receipt of the notice required by Paragraph A of this Provision.

Respondents must provide a suspended licensee with a notice of noncompliance and may provide an opportunity to cure the noncompliance within 10 days after any Respondent becomes aware of Respondents must inform any noncompliance. licensee to whom they have provided a notice of noncompliance that any continued or subsequent noncompliance will result in immediate termination. Respondents may reinstate a licensee who has cured the noncompliance. However, Respondents must terminate immediately any licensee who has received previously a notice of noncompliance under Paragraph D of this Provision and has any continued or subsequent noncompliance.

XV. Notice to Customers

IT IS FURTHER ORDERED that Respondents must send, within 30 days after the issuance date of this Order, all customers who purchased directly from them TA-65MD® or TA-65® for Skin: 1) within one year prior to the issuance of this Order; or 2) through a currently active enrollment in a continuity or autoship program, by first-class mail, postage paid, or by courier service with signature proof of delivery, an exact copy of the notice attached hereto as Appendix C, showing the date of mailing. This mailing must not include any other documents or enclosures.

XVI. Order Effective Dates

IT IS FURTHER ORDERED that this Order is final and effective upon the date of its publication on the Commission's website (ftc.gov) as a final order. This Order will terminate on April 18, 2038, or 20 years from the most recent date that the United States or the Commission files a complaint (with or without an accompanying settlement) in federal court alleging any violation of this Order, whichever comes later; *provided*, *however*, that the filing of such a complaint will not affect the duration of:

- A. Any Provision in this Order that terminates in less than 20 years;
- B. This Order's application to any Respondent that is not named as a defendant in such complaint; and
- C. This Order if such complaint is filed after the Order has terminated pursuant to this Provision.

Provided, further, that if such complaint is dismissed or a federal court rules that the Respondent did not violate any provision of the Order, and the dismissal or ruling is either not appealed or upheld on appeal, then the Order will terminate according to this Provision as though the complaint had never been filed, except that the Order will not terminate between the date such complaint is filed and the later of the deadline for appealing such dismissal or ruling and the date such dismissal or ruling is upheld on appeal.

By the Commission.

Appendix A

APPENDIX A

[On Telomerase Activation Sciences, Inc. Letterhead]

Date

[insert addressee name] [insert addressee address]

Dear [name of licensee]:

The Federal Trade Commission (FTC) has investigated and sued our company, Telomerase Activation Sciences (TAS) alleging that TAS made false and deceptive advertising claims for TA-65MD and TA-65 for Skin. Without admitting wrongdoing, TAS settled the case with the FTC and agreed to send this notification to our licensees.

According to the FTC, our claim that TA-65MD and TA-65 for Skin reverse aging was misleading. The FTC also says other specific claims about the products were misleading. The FTC says we claimed that TA-65MD:

- a. prevents and repairs DNA damage;
- b. restores aging immune systems;
- c. increases bone density;
- d. reverses the effects of aging, including improving skin elasticity, increasing energy and endurance, and improving vision;
- e. prevents or reduces the risk of cancer; and
- f. is clinically or scientifically proven to reverse aging, prevent and repair DNA damage, restore aging immune systems, and increase bone density.

According to the FTC, we also claimed that TA-65 for Skin reverses the effects of aging, including improving skin elasticity, and decreases recovery time of the skin after medical procedures. Although we disagree, the FTC says we do not have adequate scientific evidence that the above claims are true.

Under our settlement with the I	FTC, TAS has agreed not to make any claims about
disease, health, or safety unless we have	ve scientific evidence that supports them. You should
review any advertising and marketing	materials for TA-65 products and stop using any materials
that make the above claims. In the futu	ire, TAS will monitor licensees' advertising and marketing
of TA-65 products, including on websi	ites and social media postings, and could terminate
licensees for noncompliance. Please si	gn and date the enclosed acknowledgement form and
return it to TAS at	within 20 days of receiving this notice.

Very truly yours,

Name, Title Telomerase Activation Sciences, Inc.

Enclosures

FEDERAL TRADE COMMISSION DECISIONS VOLUME 165

Decision and Order

ACKNOWLEDGMENT FORM

I have received the notice dated [insert date of notice], accompanied by [a Federal Trade Commission administrative/an United States federal court] order, from Telomerase Activation Sciences. I agree to comply with the notice.		
Name		
Signature		
Date		

Appendix B

APPENDIX B

[On Telomerase Activation Sciences, Inc. Letterhead]

Date

[insert addressee name] [insert addressee address]

Dear [name of future licensee]:

The Federal Trade Commission (FTC) previously settled a lawsuit with our company, Telomerase Activation Sciences (TAS) about allegedly false and deceptive advertising claims for TA-65MD and TA-65 for Skin. Without admitting wrongdoing, TAS settled the case with the FTC and agreed to send this notification to our licensees.

According to the FTC, our claim that TA-65MD and TA-65 for Skin reverse aging was misleading. The FTC also says other specific claims about the products were misleading. The FTC says we claimed that TA-65MD:

- a. prevents and repairs DNA damage;
- b. restores aging immune systems;
- c. increases bone density;
- d. reverses the effects of aging, including improving skin elasticity, increasing energy and endurance, and improving vision;
- e. prevents or reduces the risk of cancer; and
- f. is clinically or scientifically proven to reverse aging, prevent and repair DNA damage, restore aging immune systems, and increase bone density.

According to the FTC, we also claimed that TA-65 for Skin reverses the effects of aging, including improving skin elasticity, and decreases recovery time of the skin after medical procedures. Although we disagree, the FTC says we do not have adequate scientific evidence that the above claims are true.

Under our settlement with the	FTC, TAS has agreed not to make any claims about
disease, health, or safety unless we ha	ve scientific evidence that supports them. You should
review any advertising and marketing	materials for TA-65 products and stop using any materials
that make the above claims. In the futi	are, TAS will monitor licensees' advertising and marketing
of TA-65 products, including on webs	ites and social media postings, and could terminate
licensees for noncompliance. Please si	ign and date the enclosed acknowledgement form and
return it to TAS at	within 20 days of receiving this notice.

Very truly yours,

Name, Title Telomerase Activation Sciences, Inc.

Enclosures

FEDERAL TRADE COMMISSION DECISIONS VOLUME 165

Decision and Order

ACKNOWLEDGMENT FORM

	e notice dated [insert date of notice], accompanied by [a Federal Trade inistrative/an United States federal court] order, from Telomerase Activation
	o comply with the notice.
Name	
Signature	
Date	

Appendix C

APPENDIX C

[On Telomerase Activation Sciences, Inc. Letterhead]

Date

[insert addressee name] [insert addressee address]

Dear [name of customer]:

Our records show that you have bought TA-65MD and/or TA-65 for Skin from our company, Telomerase Activation Sciences (TAS). The Federal Trade Commission (FTC) has investigated and sued TAS alleging that TAS made false and deceptive advertising claims for TA-65MD and TA-65 for Skin. Without admitting wrongdoing, TAS settled the case with the FTC and agreed to send this notification to our customers.

According to the FTC, our claim that TA-65MD and TA-65 for Skin reverse aging was misleading. The FTC also says other specific claims about the products were misleading. The FTC says we claimed that TA-65MD:

- a. prevents and repairs DNA damage;
- b. restores aging immune systems;
- increases bone density;
- d. reverses the effects of aging, including improving skin elasticity, increasing energy and endurance, and improving vision;
- e. prevents or reduces the risk of cancer; and
- f. is clinically or scientifically proven to reverse aging, prevent and repair DNA damage, restore aging immune systems, and increase bone density.

According to the FTC, we also claimed that TA-65 for Skin reverses the effects of aging, including improving skin elasticity, and decreases recovery time of the skin after medical procedures. Although we disagree, the FTC says we do not have adequate scientific evidence that the above claims are true. TAS has agreed not to make any claims about disease, health, or safety unless we have scientific evidence that supports them.

If you have questions about TA-65MD and TA-65 for Skin, talk to your doctor or health
care provider. If you currently purchase the products through our autoship or continuity program
and would like to cancel or have any questions, please contact TAS at

Very truly yours,

Name, Title Telomerase Activation Sciences, Inc.

ANALYSIS OF CONSENT ORDER TO AID PUBLIC COMMENT

The Federal Trade Commission ("FTC" or "Commission") has accepted, subject to final approval, an agreement containing a consent order as to Telomerase Activation Sciences, Inc. and Noel Thomas Patton (collectively "respondents").

The proposed consent order ("order") has been placed on the public record for 30 days for receipt of comments by interested persons. Comments received during this period will become part of the public record. After 30 days, the Commission will again review the agreement and the comments received, and will decide whether it should withdraw from the agreement or make final the agreement's order.

This matter involves respondents' advertising for TA-65MD, a product that comes in capsule and powder forms, and TA-65 for Skin ("TA-65 Skin"), a topical cream product. The complaint alleges that respondents violated Sections 5(a) and 12 of the FTC Act by making false or unsubstantiated health or performance claims that: TA-65MD and TA-65 Skin reverse aging; TA-65MD prevents and repairs DNA damage; TA-65MD restores aging immune systems; TA-65MD increases bone density; TA-65MD reverses the effects of aging, including improving skin elasticity, increasing energy and endurance, and improving vision; TA-65MD prevents or reduces the risk of cancer; TA-65 Skin reverses the effects of aging, including improving skin elasticity; and TA-65 Skin decreases recovery time of the skin after medical procedures. The complaint also alleges that respondents claimed that some of the above performance claims were clinically or scientifically proven.

The complaint further alleges that respondents misrepresented that a 2012 paid-for segment on *The Suzanne Show* featuring TA-65MD was independent, educational programming and not paid commercial advertising. Additionally, the complaint alleges that respondents deceptively represented that consumers appearing in advertisements were independent users of TA-65MD, expressing their impartial views of satisfaction. According to the complaint, respondents failed to disclose that these consumer endorsers

received compensation, including free TA-65MD. Finally, the complaint alleges that by providing promotional materials that had false or unsubstantiated health or performance claims to marketers of other products containing TA-65MD, respondents provided these other marketers the means and instrumentalities to engage in deceptive acts and practices.

The order includes injunctive relief that prohibits these alleged violations and fences in similar and related violations. The order applies to marketing claims for any covered product, defined as TA-65MD and TA-65 Skin or any other drug, food, dietary supplement, or cosmetic. As additional fencing-in relief, the order requires respondents to provide a notice to all of its licensees authorized to advertise, market, or sell any covered product, monitor certain high-selling licensees, and follow appropriate recordkeeping, compliance reporting, and document preservation requirements.

Provision I prohibits any representation that a covered product reverses human aging; prevents or repairs DNA damage; restores aging immune systems; increases bone density; reverses the effects of aging, including improving skin elasticity, increasing energy and endurance, and improving vision; decreases recovery time of the skin after medical procedures; prevents or reduces the risk of cancer; or cures, mitigates, or treats any disease unless the representation is non-misleading and respondents possess and rely upon competent and reliable scientific evidence that substantiates that the representation is true. The definition of competent and reliable scientific evidence in Provision I specifies human clinical testing and requires that the testing be sufficient in quality and quantity, based on standards generally accepted by experts in the relevant disease, condition, or function to which the representation relates, when considered in light of the entire body of relevant and reliable scientific evidence, to substantiate that the representation is true. Such testing must (1) be randomized, double-blind, and placebocontrolled; and (2) be conducted by researchers qualified by training and experience to conduct such testing. In addition, respondents must maintain all underlying or supporting data and documents generally accepted by experts in the field as relevant to an assessment of such testing.

Provision II prohibits representations regarding the health benefits, performance, efficacy, safety, or side effects of any covered product unless the representation is non-misleading and respondents possess and rely upon competent and reliable scientific evidence to substantiate that the representation is true. Provision II defines competent and reliable scientific evidence as tests, analyses, research, or studies: (1) that have been conducted and evaluated in an objective manner by experts in the relevant disease, condition, or function to which the representation relates; (2) that are generally accepted by such experts to yield accurate and reliable results; and (3) that are randomized, double-blind, and placebo-controlled human clinical testing of the covered product, when such experts would generally require such human clinical testing to substantiate that the representation is true. When such tests or studies are human clinical tests or studies, respondents must maintain all underlying or supporting data and documents generally accepted by experts in the field as relevant to an assessment of such testing.

Provision III prohibits misrepresentations that any covered product is clinically or scientifically proven to reverse human aging, prevent or repair DNA damage, restore aging immune systems, or increase bone density. Provision III also prohibits any misrepresentation that the performance or benefits of any product are scientifically or clinically proven or about the existence, contents, validity, results, conclusions, or interpretations of any test, study, or research.

Provision IV is a provision for FDA-approved claims.

Provision V prohibits misrepresentations in connection with the marketing, advertising, or promoting of any product, service, or program that paid commercial advertising is independent programming.

Provision VI prohibits any representation about any user, consumer, or endorser of a covered product without disclosing, clearly and conspicuously, and in close proximity to that representation, any unexpected material connection between such endorser and (1) any respondent; or (2) any other individual or entity affiliated with the product. "Unexpected material

connection" means any relationship that might materially affect the weight or credibility of the testimonial or endorsement and that would not reasonably be expected by consumers.

Provision VII prohibits misrepresentations regarding the status of any endorser or person providing a review of a product, including a misrepresentation that the endorser or reviewer is an independent or ordinary user of the product.

Provision VIII prohibits respondents from providing the means and instrumentalities to make any false or misleading statement of material fact, including the representations prohibited by Provisions I to III. "Means and instrumentalities" mean any information, document, or article referring or relating to any covered product, including any advertising, labeling, promotional, or purported substantiation materials, for use by a licensee to market or sell any covered product.

Provision IX, triggered when the human clinical testing requirement in Provisions I or II applies, requires that respondents secure and preserve all underlying or supporting data and documents generally accepted by experts in the field as relevant to an assessment of the test, such as protocols, instructions, participant-specific data, statistical analyses, and contracts with the test's researchers. There is an exception for a reliably reported test (defined as a test that is published in a peer-reviewed journal) that was not conducted, controlled, or sponsored by, with, or on behalf of any respondent or by any supplier or manufacturer of the product. Also, the published report must provide sufficient information about the test for experts in the relevant field to assess the reliability of the results.

Provision X mandates that respondents acknowledge receipt of the order, distribute the order to principals, officers, and certain employees and agents, and obtain signed acknowledgments from them.

Provision XI requires that respondents submit compliance reports to the FTC 60 days after the order's issuance and submit notifications when certain events occur for 10 years.

Provision XII requires that respondents create and retain certain records for 10 years.

Provision XIII provides for the FTC's continued compliance monitoring of respondents' activities during the order's effective dates.

Provision XIV requires that respondents notify their licensees, monitor their highest-selling licensees' advertising to ensure compliance with Provisions I through III, and suspend any licensee who makes any prohibited claims. Respondents must terminate any licensee who continues to make prohibited claims. There are two limited exceptions to the monitoring requirement: (1) representations during private consultations between a licensee and one of the licensee's patients about the potential safety, health benefits, performance, efficacy, or side effects of a covered product; and (2) representations about the potential safety, health benefits, performance, efficacy, or side effects of a covered product by a licensee who has purchased a covered product solely for incorporation into the licensee's own product and markets that product without any involvement by respondents.

Provision XV requires that respondents send a notice to all customers who purchased directly from them TA-65MD or TA-65 Skin within one year prior to the issuance of the order or through a currently active enrollment in a continuity or autoship program.

Provision XVI provides that, with exceptions, the order will terminate in 20 years.

The purpose of this analysis is to facilitate public comment on the order, and it is not intended to constitute an official interpretation of the complaint or order, or to modify the order's terms in any way.